

ORCHID CANCER APPEAL

England & Wales · Charity number 1080540

Details

Other names	ORCHID
Status	Registered
Legal form	Charitable company
Company number	03963360
Registered	2000-05-03
Register	View on the Charity Commission register

Contact

Address	60 Gray's Inn Road London WC1X8AQ
Phone	02037457310
Email	info@orchid-cancer.org.uk
Website	www.orchid-cancer.org.uk

Activities

Objects: THE PROMOTION OF RESEARCH INTO AND EDUCATION ABOUT THE DIAGNOSIS AND TREATMENT OF GENITAL CANCER AND RELATED CONDITIONS

Activities: Every year over 58,000 men will be diagnosed with prostate, testicular or penile cancer in the UK. Orchid Cancer Appeal supports anyone affected by or interested in male specific cancers through a range of support services led by Male Cancer Information Nurse Specialists, awareness campaigns such as the Orchid Male Cancer Awareness Week, education and training programmes and world class research.

Classification

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-09-30	£767,210	£1,047,335	£357,014	7
2023-09-30	£730,024	£634,721	£637,139	7
2022-09-30	£841,808	£740,252	£541,836	7
2021-09-30	£530,278	£673,004	£440,280	7
2020-09-30	£401,181	£756,577	-	-

Trustees

Name	Role	Appointed
DAVID BADENOCH		2006-06-12
Jeremy Shedden		2023-12-07
WARREN COHEN		2016-05-16

ORCHID CANCER APPEAL

England & Wales - Charity number 1080540

Accounts

ORCHID CANCER APPEAL
*Annual report and financial
statements 2023–2024*

**Orchid:
here for
those who
need us
most.**

ORCHID CANCER APPEAL

Annual report and financial statements 2023–2024

Board of Trustees

Mr D Badenoch	
Mr W Cohen, Treasurer	
Mr J Shedden	(appointed 7 December 2023)
Mr CS Osborne, Chair	(resigned 14 April 2025)
Mr B Ayres	(resigned 14 April 2025)
Mr PG Bracher	(resigned 14 April 2025)
Mr M Bryan-Brown	(appointed 4 December 2024, resigned 14 April 2025)
Mr S Harris	(resigned 14 April 2025)
Mr M Kibblewhite	(resigned 11 September 2024)
Professor RTD Oliver	(resigned 24 January 2025)
Professor P Rajan	(appointed 7 December 2023, resigned 13 April 2025)
Dr J Reddy	(appointed 4 December 2024, resigned 14 April 2025)

Chief Executive

Mr A Orhan

Independent Examiner

Moore Kingston Smith LLP
6th Floor, 9 Appold Street,
London EC2A 2AP

Accountants

JS2 Limited
1 Crown Square, Woking,
Surrey GU21 6HR

Legal advisors

Farrer & Co
66 Lincoln’s Inn Fields,
London WC2A 3LH

Bankers

HSBC Plc
20 Electric Parade,
George Lane,
South Woodford,
London E18 2LX

Registered Office

60 Gray’s Inn Road,
London WC1X 8AQ

Tel 020 3745 7310
www.orchid-cancer.co.uk

Registered in England with the
Charity Commission No.1080540

Company Limited by Guarantee
Registered in England
No. 3963360

Welcome from Colin Osborne MBE, Honorary President

I am pleased to share the significant strides our charity has made in the financial year 2023-2024 in the fight against prostate, testicular and penile cancers.

Data released in January 2025 showed that early cancer diagnosis relating to 13 of the most common cancers in England had reached the highest ever level. This reflects the ongoing efforts by healthcare professionals, and the targeted campaigns delivered by charities including Orchid, which have helped achieve this positive outcome.

To help men avoid late diagnoses with poorer outcomes, one major priority last year was to educate people about male cancers, helping them understand who is at risk and to recognise potential signs and symptoms. In response to rising male cancer cases in the UK, Orchid’s Nurse led services were promoted widely. For the first time, our Freephone Male Cancer Helpline was available 5 days a week, offering confidential support and information to callers, as well as signposting to other Orchid services.

Orchid’s roots are in research and last year we were delighted to support two different research areas. One was the Robert Lane Tissue Bank, and the other work explored whether bacteria could be used to predict who will develop aggressive or recurring prostate cancer.

Orchid was so proud when, out of over 500 applications, our charity was announced as one of ten winners of a 2024 GSK Impact Award in March. The awards are run in partnership with The King’s Fund and recognise and reward charities doing outstanding work to improve people’s health and wellbeing. This award provides Orchid with an important quality mark.

Ali Orhan continued to lead the charity throughout the year. His was a dual role of CEO and Director of the Overcoming the Barriers to Engaging with Prostate Cancer programme for the first part of the year, and then from August, Director of the Active Participation in Male Cancer Awareness in Prisons programme. We are grateful to the National Lottery Community Fund for their support for these two innovative pieces of work.

Orchid was so proud when, out of over 500 applications, our charity was announced as one of ten winners of a 2024 GSK Impact Award

Governance matters

We were delighted to welcome two new Trustees during the year: Professor Prabhakar Rajan and Jerry Shedden in December 2023. Mark Kibblewhite stepped down during the year, and I would like to recognise his tremendous contribution, including as an active member of the Finance Committee.

It was with great sadness that we heard in July of the death of former Trustee Lord Robert Fellowes, who had served as Queen Elizabeth II’s private secretary. Lord Fellowes’ steadfast commitment, wisdom, and leadership were instrumental in advancing our mission to fight male cancers and support those affected by these devastating diseases.

The composition of the Board was discussed throughout the year. This led to a governance audit in Spring 2025 using the template of the Charity Governance Code and the Charity Commission’s governance recommendations. As a result of this exercise, a decision was made to reduce the size of the Board. From April 2025 a consolidated and focussed group of Trustees became responsible for the good governance of our charity.

Having stepped down as a Trustee and Chair of the Board of Trustees, I was delighted to accept the invitation to continue to play a role in Orchid as an Honorary President. Professor Tim Oliver also became an Honorary President in recognition of his significant contribution to the charity.

I would like to thank all the Trustees who served from the beginning of the reporting year onwards and who participated in the governance review and then stepped down in April. We remain very grateful for their offers of support and best wishes for the future.

As we move forward, we remain committed to saving men’s lives from prostate, testicular and penile cancer. This will only be possible with the help of our many supporters and volunteers who champion our work. Thank you to you all.

Colin Osborne MBE

Orchid – here today, giving hope for the future

As CEO of the Orchid Cancer Appeal, it is my honour to reflect on the remarkable progress we have achieved together over the past year, from October 2023 to September 2024. This period has been one of growth, innovation, and dedication as we continued our mission to combat male-specific cancers.

We have made significant strides in raising awareness, expanding support services, and advancing research. Key achievements during this time include:

- **Community outreach:** 2024 saw the completion of the Overcoming the Barriers to Engaging with Prostate Cancer programme. Through this a dedicated team of Volunteer Community Champions worked tirelessly for 3 years across ten cities outside London, reaching an incredible 33,977 individuals with vital information about prostate cancer.
- **Penile Cancer Programme:** With the securing of new funding, we initiated the Four Nations Penile Cancer Programme. This effort is aimed at raising awareness and enhancing support for those affected by this rare but impactful condition.
- **Support services:** Our Freephone Confidential Helpline has remained a lifeline for those affected by male-specific cancers. Additionally, a specialised telephone counselling service was made available to support those navigating penile and testicular cancer diagnoses.
- **Male Cancer Awareness Week:** September 2024’s digital campaign which reached over 400,000 people had a nostalgic feel with a “Focus on Facts.” The Week saw a series of posts about prostate, testicular and penile cancer, and the support Orchid can offer.
- **Research advancements:** In our commitment to advancing scientific understanding, we increased our investment in research, awarding grants for innovative prostate cancer studies. The Robert Lane Tissue Bank, a vital international resource for research into male-specific cancers, continues to be at the forefront of our efforts.

The year’s accomplishments are a testament to the unwavering dedication of our donors, fundraisers, volunteers, staff, and trustees. In a challenging year for our fundraising, your support has been the cornerstone of our success, and we are deeply grateful for your commitment to this critical cause.

We were privileged to have one of our Trustees join the staff team to lead a strategic planning day, a pivotal step in shaping our future direction and developing operational plans. This collaborative effort reflects our shared commitment to tackling male-specific cancers with renewed focus and purpose.

With your support, Orchid remains strong, committed, and ready to face the future. As we look ahead, we do so with optimism, determination, and an unyielding dedication to our mission. Together, we will continue to save lives, support families, and drive forward in the fight against male cancers. Thank you for standing with us.

With gratitude
Ali Orhan
CEO, Orchid Cancer Appeal

We have made significant strides in raising awareness, expanding support services, and advancing research

The year in review

1 October 2023 – 30 September 2024



LEFT: The Orchid team accepting the award at the 2024 GSK IMPACT Awards

The incidence of prostate, testicular and penile cancer has been increasing, and there is currently an annual combined total of over 58,000 new cases each year in the UK. These cancers can be aggressive, life-changing, and devastating to families. Furthermore, they can strike at any age and in any walk of life. While medical advancements have improved outcomes, many men are still diagnosed too late and over 12,000 lives are lost to these cancers each year in the UK.

In response to the rising numbers of people diagnosed, and the impact of a diagnosis, Orchid worked throughout the year to support anyone affected through our Nurse-led services. We also worked across the four nations to help people learn about risk factors, potential signs and symptoms, and the benefits of an early diagnosis. Additionally, the charity invested in research to benefit both current and future generations of men, supporting two areas of work in the year.

Mark of Excellence

It was a huge honour that Orchid’s work was recognised when the charity was announced as one of ten winners of a 2024 GSK IMPACT Award (run in partnership with The King’s Fund). These awards recognise charities doing outstanding work to improve people’s health and wellbeing. The award name ‘IMPACT’ comes from: Innovation, Management, Partnership, Achievement, Community focus and Targeting need, and we were proud that assessment showed our work and charity to meet those demanding criteria.

Double the reach

Orchid increased our reach during the year. For example, the number of male cancer leaflets, booklets and posters distributed through awareness activities such as Roadshows, our Volunteer Community Champions, talk and presentations was more than double that of the year before.

Helpline increase

The hours of the Orchid Male Cancer Helpline increased, and for the first time since it was set up ten

years ago, our two part-time Male Cancer Nurse Specialists were on hand to support callers from 9am to 5.30pm Monday to Friday. Accurate information about penile cancer is hard to find, and during the year, around 50% of calls related to this rare cancer.

Calling the Helpline makes a difference and in 2023-2024, 80% of people said calling the Helpline and speaking to an Orchid Male Cancer Nurse Specialist helped them with their query, and 90% of healthcare professionals felt it helped them with a patient.

Positive feedback, unique service

Orchid continued to offer our telephone counselling service for those diagnosed with the rare testicular or penile cancer. Nurses on the Helpline assessed callers’ needs, and where relevant, men were referred to this unique service.

Evaluation is positive, and in the words of one man who benefited during the year: “I was supported, listened to and guided in a way that helped me adjust to the new me, be prepared for the what ifs of surgery and treatment, realise that no matter the outcome, I could still find joy in my body.” To complement and supplement existing services, a new offer of mentoring for men who have been diagnosed with testicular cancer was introduced.

On the road again

Cancers found early are often the easiest to treat with the best prognosis, and therefore male cancer education remained a priority. Day long Male Cancer Information Roadshows were delivered in the heart of targeted communities and provided 7,703 people with the opportunity to learn about male cancers and talk about any concerns. Our reach through our Health at Work talks increased, as our Male Cancer Nurse Specialists delivered informative talks both in person and virtually with the latter bringing a wider geographical reach.

Focusing on facts

Social media and digital activity continued to play a huge role in educating people about male cancers and the bespoke support services Orchid can offer. One



‘Focus on Facts’ during Male Cancer Awareness Week took inspiration from mechanics’ manual to set out the facts and figures associated with each of the male cancers.

example was Orchid’s Male Cancer Awareness Week in 2024 ‘A Focus on Facts’ which highlighted information about each of the male cancers and how Orchid can help, and we are grateful to our partners for sharing these important messages. Another successful social media campaign was ‘Warn a Brother’ which highlighted the increased incidence of prostate cancer in Black African and Black Caribbean men.

Barriers overcome

Alongside our core activities, Orchid delivered targeted projects and activities throughout the year. Overcoming the barriers to engaging with prostate cancer, our three-year project funded by the National Lottery Community Fund ended in the Spring. Through this we trained Volunteer Community Champions to cascade prostate cancer messaging in ten locations in England.

HMP Orchid

We were delighted when further three-year funding was granted by the National Lottery Community Fund to deliver Active participation in male cancer awareness in prisons, which incorporates some learnings from the previous Lottery funded work. This new programme began in August.

Four nations, one programme

Despite being the rarest of the three male-specific cancers, penile cancer will often cause the most severe physical and psychological side effects, yet awareness of penile cancer is low even amongst healthcare professionals. Orchid’s Four Nations Penile Cancer Programme was launched at the beginning of the year to address these issues and to help men cope with the isolation of a diagnosis and the difficulties they face in managing the physical and psychological impact of the disease.

National conference

At the heart of our charity is diversity and inclusion. Orchid was proud to work with Cancer Equality to deliver a National Prostate Cancer Awareness Conference to launch Ethnic Minority Cancer Awareness Month in July. This was attended by

patients, healthcare professionals and service providers and explored the experience of Black African and Black Caribbean men diagnosed with prostate cancer.

Diverse communities

In response to the increased incidence within this community Orchid delivered a Prostate Cancer and Faith project in Birmingham and London through which we delivered talks in faith settings with a predominantly Black African and Black Caribbean congregation. Our work to reach trans women at risk of prostate cancer continued including via a social media campaign, and a new project began to raise awareness of male cancers within the Deaf community with Orchid speakers supported by a British Sign Language interpreter.

Download here

Orchid information in the form of leaflets, booklets, and short films/videos and the charity’s website (where resources can be downloaded) is subject to regular reviews to ensure it contains the most up-to-date, accurate and accessible information to meet the needs of men. Some was updated during the year and a new short film Living with Advance Prostate Cancer was added to the portfolio.

On the European stage

Orchid’s position as a key patient advocacy organisation within the European urological landscape was further strengthened during the year through its continued role in collaboration with the European Association of Urology (EAU) and the European Reference Network for Rare Urogenital Diseases (eUROGEN). As the only male cancer charity in Europe with membership of these influential networks, we are proud that Orchid continued to help shape the future of care for the rare penile and testicular cancers.

Forecourt and foyer

At the year-end funding was received to deliver a prostate cancer awareness campaign in petrol stations entitled Every last Drop, and a community play in Nottingham called Prostate not Prostate working with a local partner.

Thank you

Orchid’s work can only happen thanks to the generosity of our supporters. We could not deliver our Nurse-led services, targeted programmes or fund research without donations and grants from individuals, community and faith groups, the National Lottery Community Fund, Trusts and Foundations and our corporate supporters. We offer our heartfelt thanks to you all.

Fundraising

Orchid is committed to generating funds from diverse income streams to balance risk and to provide sustainable income to ensure we can continue to deliver our education and awareness programme and Nurse-led services, as well as to fund innovative male cancer research. We thank each and every one of our most wonderful supporters who raised funds or gave us donations in the year, be they individuals, community groups, sports clubs, schools, Companies, Charitable Trusts or Foundations, or The National Lottery Community Fund.

Many Orchid supporters have a connection to our cause, perhaps because they, or someone they know, have been touched by male cancer. People also pay tribute to loved ones by giving in their memory. Individuals contributing through Payroll giving schemes continued to provide a valuable source of unrestricted income.

We are truly humbled by the dedication of our fundraisers and supporters, which is why our small team were there to cheer on runners at events such as the London Marathon and the London Landmarks Half Marathon. Where we could not be there in person, we helped and encouraged individuals and groups across the UK. Examples of some of the wonderful fundraising events in the last year include cake sales and tea parties; fundraising events in schools; challenge and sporting events from walks, a cricket match and bike rides, to mountain climbs, tough mudders, a 24 Charity Race and the Southern Scale Trail; and the annual Twyford Beer Festival.

Grants from Charitable Trusts and Companies enabled Orchid to provide male cancer information in different formats and settings, support those affected via nurse-led services, and to deliver innovative awareness activities. We were delighted to receive news of new three-year funding from The National Lottery Community Fund to deliver a new programme entitled “Active Male Cancer Awareness in Prisons” which started in August and will roll out to all prisons in England. We enjoy reporting back to funders to show the impact of their funding.

A total of £767,210 was raised during the year which was a slight increase on the previous year’s income.

Under the leadership of a part time Head of Fundraising, the small fundraising team continued to review our activities using both our own learnings and that of the wider fundraising sector, and sought to identify new opportunities to ensure we retain a diverse and cost-effective fundraising base to balance risk in the years ahead.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies. Orchid operates a clear and stringent complaints handling procedure that is reported to senior management and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves.

During the year we received three complaints in relation to our fundraising activities which were resolved swiftly in line with our procedures. We remain committed to improving our practice, learning from supporter feedback.

Focus on: FUNDRAISERS

Pedal for Pride, Fight for Life!

After a routine bike ride that turned serious when he discovered a worrying symptom, Jadem knows the importance of early diagnosis, and wanted to use his experience as a powerful reminder to listen to your body and seek help and support at the earliest possible stage. LDN RIDERS knew they wanted to celebrate Jadem’s triumph over testicular cancer and empower others facing cancer with confidence.

Forty LDN RIDERS came together to take on a London to Manchester cycle – a gruelling 360 kilometres with over 3,600 meters of elevation – that’s more than three times the height of Mount Snowdon!

They chose Orchid as we provide invaluable support to those facing male cancers, just like Jadem – the LDN Riders are passionately supporting our life-saving research, support services, and public awareness initiatives.

Their dedication shone through, not only in completing the physical challenge, but in their tireless fundraising: they finished with a fantastic total of £5,318.



Forty LDN RIDERS rode a gruelling 360 kilometres and raised a total of £5,318 to support Orchid’s life-saving work.

“A huge shoutout to our amazing riders who cycled 360km from London to Manchester, and to everyone who donated. Your support means the world to us and will make a real difference in the lives of those affected by cancer”

Orchid’s collaborative role in European urological initiatives

Orchid’s position as a key patient advocacy organisation within the European urological landscape was further strengthened during the year through its continued role in collaboration with the European Association of Urology (EAU) and the European Reference Network for Rare Urogenital Diseases (eUROGEN).

As the only male cancer charity in Europe with membership of these influential networks, Orchid continued to help shape the future of care for the rare penile and testicular cancers during the reporting year. This work was driven by Orchid’s Male Cancer Information Nurse Specialist, Rob Cornes.

European Association of Urology
EAU Testicular Cancer Guidelines panel

As an active patient advocate member of the European Association of Urology (see box, right) Testicular Cancer Guidelines panel, Rob’s involvement has ensured that patient quality of life and unmet needs are considered at the forefront of new treatment guidelines. Future initiatives may involve the creation of patient-friendly resources revolving around shared decision-making to improve communication between clinicians and patients.

EAU Patient Advocacy Group

Orchid is currently also a member of the EAU Patient Advocacy Group (EPAG), an initiative created by the EAU Patient Office. Rob is a patient advocate for both penile and testicular cancer within this group. The EPAG consists of organisations, charities and disease coalitions from all over Europe who work with the Patient Office to ensure that patient advocacy is promoted wherever possible. This involves the creation of information and resources designed to help patients understand and manage conditions which are used throughout Europe.

Orchid’s involvement has helped to create vital resources and deliver patient-centric talks across Europe. This collaboration has led to initiatives such as a Penile Cancer Roundtable at the EAU Congress 2024, which Rob facilitated, involving patients and clinicians. It also led to the creation of the EAU penile cancer animation which Rob helped script in 2023 which includes an overview of treatment and importance of

European Association of Urology

The European Association of Urology (EAU) is the biggest urological association in the world with a network of 19,000 urologists throughout Europe. It undertakes the teaching and education of urologists, research projects and initiatives to treat urological disease. These projects and information are disseminated via an annual European Congress.

In addition, the EAU creates guidelines for the treatment of every urological condition. Although the UK has NICE Guidelines for prostate cancer, there are none for penile or testicular cancer. Recommendations for treatment of these diseases is currently derived from the European Association of Urology (EAU) Guidelines. These guidelines are compiled by individual expert panels, made up of urologists, oncologists, histopathologists and radiologists as well as patient advocates.

psychological support for patients which was instigated by Rob. Two versions of this video were created (English and Spanish) with a combined total of 78,000 worldwide views so far.

As a member of the EPAG Rob will be involved in future initiatives to improve patient outcomes and experience for prostate, testicular and penile cancer.

European Reference Network for Rare Urogenital Diseases ERN (eUROGEN)

Orchid’s collaboration with eUROGEN (see box, right) further solidifies its role in advocating for the rare urological diseases, and Orchid is a member of Workstream 3. Rob is the official patient advocate for both penile and testicular cancer within this group, along with two penile cancer advocates who were introduced through Orchid’s support.

Rob has given several talks at the EAU Congress discussing the unmet needs of testicular and penile cancer patients and working with the other advocates has helped create a Patient Pathway for penile cancer. He has also taken part in three international webinars discussing the needs of testicular and penile cancer patients and has contributed to the recent eUROGEN publication Rare and Complex Urology. eUROGEN also provided the funding for the EAU penile cancer animation mentioned above, as well as advocate Richard Stamp’s video Ignore It, dedicated to raising awareness of penile cancer.

Future initiatives will involve the creation of more in-depth documentation of patient journeys for clinical reference.

What this collaboration means for patients

Orchid has been particularly impactful through Rob’s advocacy. Rob and the advocates introduced by Orchid are playing a pivotal role in shaping clinical pathways and patient journeys.

Orchid is set to continue leading patient advocacy initiatives by bringing our insight and experience to initiatives and projects created by clinicians who will ultimately be responsible for shaping future care and patient outcomes throughout Europe and the UK.

These collaborations will ensure that the needs of penile and testicular cancer patients are recognised, and outcomes improved.

European Reference Network for Rare Urogenital Diseases ERN (eUROGEN)

This is a European organisation which works alongside the European Commission to provide equitable care throughout Europe to patients with rare urological disease including penile and testicular cancer. It is split into various workstreams which are made up of urologists, oncologists and patient advocates.

BELOW: At his EAU24 presentation, Orchid Nurse Rob Cornes described how virtual support groups can help problems associated with testicular cancer treatment and recovery, by transcending physical barriers and bringing those affected together with healthcare professionals.



Thank you to our incredible Orchid volunteers!

Volunteers are the heart and soul of Orchid. As a small charity, we rely on the dedication and generosity of those who give their time to support our mission.

Whether it’s raising awareness, cheering on our runners at events, or helping to raise much-needed funds, every volunteer plays a vital role in the fight against male cancers.

One of our most passionate and dedicated volunteers, Trevor, has been an extraordinary force in educating thousands about prostate, testicular, and penile cancer. His commitment to spreading awareness has made a tangible difference in communities across Hillingdon, Harrow, Ruislip, and Ealing.

Over the past year alone, Trevor delivered an astounding 88 awareness activities, reaching people in gyms, libraries, supermarkets, shopping centres, faith groups, and other community settings. His efforts have helped ensure that more men recognise the risks, symptoms, and understand the importance of early detection.

Trevor’s impact is remarkable: in just twelve months, he has distributed over 18,332 male cancer resources, empowering individuals with knowledge about their health and when to seek medical advice if concerned. His dedication has not only raised awareness but has undoubtedly saved lives.

Trevor, your passion, hard work, and unwavering enthusiasm have made a real and lasting difference. From all of us at Orchid, thank you for being such an incredible part of our mission. We are truly grateful for everything you do.

To all our volunteers – thank you for standing with us in the fight against male cancers. We couldn’t do this without you!

Volunteer spotlight | TREVOR



Orchid wins top UK health award



Following a rigorous selection and assessment process, Orchid was proud to be chosen from more than 500 charities across the UK as one of the 10 winners of the 2024 GSK IMPACT Awards which are delivered in partnership with The King's Fund.

Now in its 27th year, the awards are a mark of excellence in the charity sector, designed to recognise the outstanding work of small and medium-sized charities working to improve people's health and wellbeing in the UK.

The award judges commented positively about the wide-ranging work Orchid does to raise awareness amongst members of the public as well as healthcare professionals; our determination to target communities most in need; our services; and our ability to build strong partnerships across the health and charity sectors to amplify our reach.

The award judges also praised the charity's work to improve understanding of male-specific cancers including possible causes, potential new treatments and ways of enhancing care, mentioning the research carried out in the Robert Lane Tissue Bank.

Lisa Weeks, Senior Associate at The King's Fund, said: "Through its creative and inclusive approach, Orchid Cancer Appeal has developed a unique way of reaching those who are more likely to be diagnosed with male specific cancers and is working hard to reduce the gap in poor health outcomes across different communities. It spreads awareness of signs and symptoms, supports those who are diagnosed with these often-devastating diseases, and funds research into the causes and treatment of cancer. For a small charity with very few staff, through their tireless campaigning and

research driven focus, they have a substantial reach and impact to support the cancer community."

As an award winner, Orchid received £40,000 in unrestricted funding as well as both an 'explainer' film about our work and social media assets which have been helping us showcase our work to supporters and potential partners.

Another element of the award Orchid benefited from is expert support and leadership development provided by leading health and care charity, The King's Fund. Orchid attended the three-day GSK IMPACT Awards Development Programme which is tailored to the needs of each year's award winners.

Orchid is now a member of the GSK IMPACT Awards Network, which connects past award winners, both online and at meetings. The aim of the Network is to develop charity leaders on an ongoing basis, providing them with the skills to respond to the challenges of their environment and to share experiences and expertise. It also provides an opportunity to build the recognition of their significant and vital contribution to the health and social care system.

Orchid is particularly grateful to Patrick Meehan who shared his penile cancer journey and the support he received via our Helpline and penile cancer counselling service as part of our film. We were absolutely delighted that he joined Orchid CEO Ali Orhan on stage at the awards ceremony to collect our award.

Orchid would like to thank GSK and The King's Fund for recognising our contribution to improving the health of people across the Four Nations. This award will help take the charity forward with the ultimate goal of reaching more people at risk of prostate, testicular or penile cancer and better supporting those living with a diagnosis.

‘Through its creative and inclusive approach, Orchid has developed a unique way of reaching those who are more likely to be diagnosed with male specific cancers’

*Lisa Weeks, Senior Associate,
The King's Fund*



69,528 male cancer leaflets, booklets and posters were distributed through awareness activities such as Roadshows, our Volunteer Community Champions, talks and presentations. This was more than double the amount in the previous year.

Through the awareness interventions of Orchid Community Champions and experienced volunteers, 21,744 people were able to learn about prostate cancer.

On the road with Orchid’s Male Cancer Roadshows

Orchid’s Male Cancer Information Roadshows are informative and engaging. They are delivered in busy locations in the heart of local communities by our experienced Community Engagement Team.

Roadshows provide an opportunity for local people to find out about male cancers in a familiar environment and can act as a sounding board for people to discuss male cancer concerns.

We particularly target locations in areas of deprivation to reach people who may miss mainstream health education and who might not be able to prioritise their health.

In the year, our team delivered 21 Roadshows giving 7,703 people the opportunity to learn about prostate, testicular and penile cancers.

“It’s so important to know these things and I agree that men are awful at this health thing. I’ve moved and still haven’t even registered with my new GP... couldn’t even tell you where it was! I’ll go and get signed up now and be wary of these things in the future.”


“I didn’t even know you could be more at risk for being Black! I’ll definitely have a read of this booklet now. Thanks mate.”

“I’m usually embarrassed about it but you’re so helpful.”

“To be honest with you, I didn’t even know what a prostate is and I’m scared to google it to see what comes up!”

“Oh we didn’t know all of those symptoms, we just thought those were parts of getting older!”

“Yeah, it’s about time I started looking into my health, I’ve used and abused my body so far without so much as a check-up, so it’s well overdue!”



Social media: a vital tool for changing lives

“Over the past year, we’ve seen strong engagement with educational posts, personal stories, and awareness campaigns, highlighting the need for continued digital outreach.”

Social media has been a vital tool for Orchid throughout the last reporting year, allowing us to raise awareness, share lifesaving information, and engage directly with those affected by male cancers. From 1 October 2023 to 30 September 2024, Orchid reached a total of 235,446 accounts through our Facebook, X, Instagram, TikTok and LinkedIn platforms. Our social media channels have helped us reach wider audiences, break down stigmas, and drive people to essential resources. Over the past year, we’ve seen strong engagement with educational posts, personal stories, and awareness campaigns, highlighting the need for continued digital outreach. Moving forward, expanding our reach through targeted content, collaborations, and interactive campaigns will be key to strengthening our impact and ensuring more men have access to the information they need.

Focus on: **SOCIAL MEDIA**


Warn-a-Brother

Diversity and inclusion run throughout Orchid, and we strive to sustainably and consistently reach people who do not have equal access to awareness and support in their cancer journeys. This is why that as well as using our own platforms, we also use paid advertising on social media to increase our reach and target our campaigns. One example is our successful and impactful *Warn-a-Brother* campaign which was delivered in March 2024 using striking images and words. The campaign was delivered in response to the fact that Black African and Black Caribbean men are at increased risk of prostate cancer. Data shows they are more likely to be diagnosed younger and at a later stage than other men, and with a more aggressive type of disease. The term ‘brother’ is commonly used in the Black community, and so the campaign was based on this play on words. Alongside that, the images used in the campaign focused on mouths to symbolise speaking up – speaking to your brother, father, friend, and telling them about prostate cancer.

The *Warn-a-Brother* campaign used social media to target Black communities in London and Birmingham to raise awareness around their risk of prostate cancer. Its aim was to change the way in which Black African and Black Caribbean men understand, respond, and promote information about what is now the most common cancer in the UK, and to encourage them to seek early

intervention. It complemented other Orchid awareness initiatives. We were delighted to achieve a reach of over 100,000 Black men with total clicks of over 2,000 through Facebook and Instagram. As one user posted: “This campaign has made me stop and think about what I should be doing to help raise prostate cancer awareness amongst my community.”

“A powerful and very positive campaign. Thank you for seeing us.”



Overcoming the Barriers to Engaging with Prostate Cancer

“That knowledge is there, in the back of your mind. It doesn’t leave you and is there to feed into your work and life. Even if formally you are not working as a champion, you still are in principle and practice. I will not forget what I’ve learnt and will look for opportunities to share it with those around me.”

Volunteer Community Champion

In March 2021, Orchid was awarded funding from the National Lottery Community Fund to deliver a three-year programme in ten identified areas of England, aimed at overcoming the barriers to engaging with prostate cancer.

The programme was developed in response to the rising number of cases of prostate cancer; low awareness of risk factors, signs and symptoms even amongst those at increased risk; the high number of late diagnoses; and the negative impact this has on treatment options and outcomes.

The aim of the programme was to develop a regional network of Volunteer Community Champions who would deliver awareness raising and information sharing, especially among high-risk groups (for example marginalised communities) for whom barriers to engaging with the issue are greatest.

Overcoming the Barriers to Engaging with Prostate Cancer launched on 4 May 2021 and ran until 3 May 2024. It was delivered in the following ten locations: Birmingham, Bradford, Bristol, Dudley, Leeds, Liverpool, Manchester, Newcastle, Nottingham, and Wolverhampton.

Orchid is proud of what the programme achieved, and independent evaluation of the programme can be found on the Orchid website.

Over the three years a total of 168 Volunteer Community Champions were recruited, trained and supported by the Orchid team. Champions brought a wide range of skills and experience, and our team of Champions was made up of community members including people with lived experience, members of partner organisations, healthcare professionals, and prison residents. What they all had in common however, is that they were passionate about getting people in their communities talking about prostate cancer.

Champions were empowered to use their own networks and ideas to book activities and to reach members of their local communities. For example, some Champions ran information stalls in markets, libraries and at festivals, and others attended men’s groups, gave talks, or disseminated information at food banks. 37 men in prisons cascaded information to other prison residents.

Whilst Champions may have delivered different activities, they all only did so after structured training by the Orchid team. Each Champion was issued with an Orchid prostate cancer tool kit full of easy-to-follow information and pictures to help them convey information in an accurate manner, and to ensure they had the answers to commonly asked questions. Refresher training was also available to Champions, as well as opportunities to meet others for ongoing learning and peer support.



Through their chosen activities, Champions disseminated prostate cancer fact sheets which were accessible and engaging for the programme’s target audience. This leaflet, which some Champions had helped develop, included details of Orchid’s website and Freephone Male Cancer Helpline for more information. It was complemented by regionalised signposting leaflets which were distributed by the Community Champions as part of their engagement activity.

Through the efforts of our Community Champions over the 36 months, 34,577 people engaged with the programme to learn about prostate cancer. Furthermore, Champions disseminated 22,000 prostate cancer factsheets and over 8,000 signposting leaflets.

Measuring impact was an important part of the programme both in relation to the Champions themselves as well as the beneficiaries. Being a Community Champion provided meaningful opportunities for people with lived experience to pursue a subject of importance to them and develop their own awareness, knowledge and skills, as well as improving Champions’ self-esteem and confidence.

People who engaged with the programme identified positive impacts of their engagement, including increased awareness and knowledge relating to prostate cancer and increased confidence to access healthcare services.

One example that a Community Champion from a partner healthcare organisation fed back to Orchid is: “One woman came to us and was worried about her husband who she noticed was going to the toilet more during the night. She spoke with us and we gave her a leaflet. This gave her the tools to speak with her

ABOVE: Attendees at the conference held to mark the end of the three programme


husband and I know that she encouraged him to go to the doctors. She got back in touch to say that they had detected it early and he is OK now.” This example also shows the important role that women can play in the health of men in their lives.

Orchid would like to thank The National Lottery Community Fund for their grant which enabled us to train 168 wonderful Community Champions who reached 34,577 people with prostate cancer information. In turn we would like to thank the Champions who gave their time and passion freely and helped Orchid deliver such a successful programme.

We would also like to thank the ten members of a Task Force recruited at the beginning of the programme, and which included senior and strategic level representation from organisations across England. Members helped shape the programme, provided access to networks and groups to support volunteer recruitment and to cascade information, and gave invaluable input into the design of resources.

The programme left a lasting legacy of a pool of knowledge, training and resources with which Community Champions can continue promoting awareness of prostate cancer, whether that be formally or informally in their everyday lives.





There were 77,000 page views on the Orchid website and 11,386 views on Orchid's testicular cancer microsite Your Privates.

We reached a total of 235,446 accounts through Orchid's five social media platforms.

‘Orchid was proud to work with Cancer Equality to deliver a conference dedicated to exploring the experience of Black African and Black Caribbean men diagnosed with prostate cancer.’

Prostate cancer

Prostate cancer is the most common cancer in men in the UK with an annual incidence of over 55,000. Sadly around 12,000 men will die from the disease each year, a level which has remained stable over the last five years suggesting an improvement in overall mortality. However, up to 25% of men are diagnosed with late-stage disease.

The incidence for men of Black African and Black Caribbean descent remains twice that of Caucasian men along with family history in a first degree relative and a family history of the BRCA gene responsible for genetic breast cancer.

Orchid continues to engage with men from these high-risk communities. Debate around UK screening programmes continues, and various trials/research initiatives have been launched to identify the most relevant way forward although it is still likely to be a few years before agreement is reached.

Active surveillance continues to be the preferred option for men with low grade prostate cancer while different approaches to more advanced but curable disease are being evaluated for less invasive (focal) treatments.

With over 110 prostate cancer support groups now existing in the UK, face to face and virtual peer support for those diagnosed continues to grow, while many celebrities who have been affected by the disease, talk freely about their experience which serves to promote awareness of the disease.

National Prostate Cancer Awareness Conference

July is Ethnic Minority Cancer Awareness Month which is driven by the charity Cancer Equality to shine a light on the issues affecting Minority Ethnic Communities and cancer.

This year Orchid was proud to work with Cancer Equality to

deliver a National Prostate Cancer Awareness Conference at the Royal College of Nursing in London to celebrate the beginning of the Month. It was attended by patients, healthcare professionals and service providers.

The conference was dedicated to exploring the experience of Black African and Black Caribbean men diagnosed with prostate cancer. It was an excellent chance for those in attendance to learn first-hand from healthcare professionals and patients the problems and inequalities associated with raising awareness of prostate cancer and supporting men within this community.

Speakers included Klark Mullen, Government Affairs Lead at Astellas Pharma, who discussed inequalities, Dr Eva McGrowder (Institute of Cancer Research) who gave an overview of the PROFILE study and Rebecca Todd (UCH) who presented information on the TRANSFORM study. Personal experience was provided by Sally Green (see case study on following page) and Maurice Blake while Marcella Turner, CEO of Manchester based charity Can-Survive UK, discussed the need for the development of culturally appropriate information.

Feedback was extremely positive, and it provided opportunities for improved partnership working. From 2025 Orchid will now be the lead charity on Ethnic Minority Cancer Awareness Month.

RIGHT: The National Prostate Cancer Awareness Conference at the Royal College of Nursing in London was attended by patients, healthcare professionals and service providers.

EMCAM24

Ethnic Minority Cancer Awareness Month – JULY 2024

NATIONAL PROSTATE CANCER AWARENESS CONFERENCE

Monday 01 July 2024
10am – 3pm
Royal College of Nursing
20 Cavendish Square
London W1G 0RN

Places are limited. To register your FREE place,
email: admin@orchid-cancer.org.uk

 + 

ORCHID and CANCER EQUALITY working together to raise awareness of prostate cancer among Black African and Black Caribbean men

Sally’s story

“We have lost so many of us worshippers to prostate cancer. This knowledge will help us to be aware of the signs and symptoms and, most importantly, seek medical help soon.”



Sally’s unwavering passion for raising awareness about prostate cancer, especially among Black African and Black Caribbean men, stems from a deeply personal loss. In 2021, her husband, John, succumbed to this disease, leaving behind not just a grieving family but also a powerful legacy of education and support.

John found solace and camaraderie as a regular member of an Orchid support group, where he shared stories, found strength, and even laughter with other men affected by cancer. For Sally and her family, these support networks became a beacon of hope during difficult times. They expressed heartfelt gratitude for the invaluable assistance Orchid provided during their journey. Inspired by John’s experiences, Sally collaborated with Orchid to share his story in one of three impactful films aimed at raising awareness of male cancers. These films have since reached and touched countless lives.

Orchid recognises Sally’s incredible contributions, particularly her moving speech at the National Prostate Cancer Awareness Conference, which stood out as a highlight of the event. Her words resonated deeply, inspiring action, and fostering understanding about the importance of early detection and support.

At the core of Sally’s advocacy is her faith, which became the driving force behind Orchid’s groundbreaking Prostate Cancer and Faith Project. With Sally’s encouragement, Orchid delivered

talks in churches across London and Birmingham, engaging predominantly Black congregations. These efforts aimed to dismantle stigmas and create safe spaces to discuss prostate cancer openly.

Through Sally’s dedication, over 2,750 individuals gained crucial knowledge about prostate cancer risk factors and early warning signs. In these familiar and supportive environments, attendees were equipped to share this vital information with others. As one congregation member put it: “We have lost so many of us worshippers to prostate cancer. This knowledge will help us to be aware of the signs and symptoms and, most importantly, seek medical help soon.”

Sally’s tireless commitment continues to transform lives, spreading awareness, fostering community engagement, and honouring John’s memory in the most impactful way possible. Her story is a testament to the power of love, faith, and resilience in the face of loss.

5,245 men, women and healthcare professionals had in-depth support or information directly from an Orchid Nurse or Orchid Male Cancer Information Manager.

7,703 people had the opportunity to learn about male cancer by attending an Orchid Roadshow, an increase of over 2,000 on the previous year.

4,696 people had a one-to-one interaction with a trained Orchid Community Champion or an experienced volunteer.

‘Orchid is currently supporting one of the few testicular cancer support groups in the UK. It has an online Facebook group with around 350 members’

Testicular cancer

Testicular cancer in the UK affects around 2,400 men a year.


Approximately 70% of these men will be between the ages of 15-45, although it can occur at any age.

The incidence and mortality (around 65 men die each year), have remained stable and constant over the last five years in the UK.

Testicular cancer also remains the most treatable and potentially curable cancer with 95% of men, including those with metastatic disease, surviving for 10 years. However, it is important to recognise that to achieve cure men may need to undergo gruelling chemotherapy treatment which will have long term survival implications.

Chemotherapy increases the risk of physical illness such as cardiovascular disease, can reduce testosterone levels which may contribute to metabolic syndrome, and can cause temporary, but sometimes permanent side effects, such as poor cognitive function, peripheral neuropathy, and reduced lung function. In addition, the psychological impact of the disease on a predominantly young, less mature age group can often result in severe coping difficulties.

Orchid now provides a unique telephone counselling service which allows men to undergo counselling with a degree of anonymity at a convenient time and at any point in their treatment journey. In addition, Orchid is currently supporting one of the few testicular cancer support groups in the UK. This group meets physically in London and virtually. It has an online closed Facebook group with around 350 members. Orchid Male Cancer Information Nurse Specialist, Rob Cornes, acts as an administrator for the group.



Simon’s story: A journey of strength, resilience, and purpose

Simon Feldman’s story is one of extraordinary courage, perseverance, and hope. He has survived testicular cancer not once, not twice, but three times. Now, he shares his experience to inspire conversations, support others, and bring awareness to this journey of resilience.

The battle begins

Simon was first diagnosed with testicular cancer at the age of 20 while living as an international student in Australia. In his words, he was “having the time of his life” when his world was suddenly turned upside down. The memory of calling his parents to share the devastating news still stays with him.

Following treatment, a scan revealed that the cancer had spread to his stomach, requiring him to return to London for further treatment. Over the course of several months, he endured three rounds of chemotherapy. It was a gruelling process, but he fought through and slowly began to rebuild his life.

A second battle

Four years later, Simon received another devastating diagnosis – testicular cancer had returned. Facing cancer a second time was incredibly difficult, but with surgery and treatment, he once again overcame the disease. Determined not to let cancer define him, Simon set a bold new goal – completing the New York Marathon. Just one year after his

second diagnosis, he crossed the finish line, proving his resilience and strength.

A third fight

Four more years passed. Simon was busy with work, life, and planning his wedding when he was once again blindsided – his third diagnosis of this rare cancer. Another operation followed, but amidst the challenge, Simon and his wife were able to celebrate the wedding of their dreams.

One heartbreaking reality, however, weighed heavily on him: he would not be able to father children naturally. The journey to parenthood was filled with challenges, but Simon and his wife refused to give up. On their fifth and final attempt at IVF, they received the news they had longed for – a positive pregnancy test. Today, they are the proud parents of a beautiful daughter.

Turning pain into purpose: Coaching and giving back

Simon is now a qualified coach, dedicating his life to helping others transform their own journeys. Through his generosity and commitment, Orchid was able to offer free coaching to men diagnosed with testicular cancer.

Working alongside these men, Simon helped them redefine who they were and supported them in becoming the person they always wanted to be. His experience, empathy, and strength make him

‘Through it all, I have learned something invaluable: the person who has been there for me every step of the way is me.’

an invaluable mentor and source of inspiration for others facing adversity.

His passion shines through in his words:

“I know how difficult it is to remain strong when you feel weak. To hold on when you want to let go. But through it all, I have learned something invaluable: the person who has been there for me every step of the way is me.

“I have discovered a strength, determination, and resilience I never gave myself credit for. Now, I am using that strength to change the way I see myself and to help others transform their lives.

“I share my story, so you know this: You are not alone.

“That person staring back at you in the mirror – that’s you. You show up every day, battling through with courage, conviction, and power, even if you don’t see it yet.

“Recognise your strength. Hold on. It will carry you forward through even the hardest days.

“With grit, belief, and the love of those around you, you can keep going. You can keep fighting. And no matter how dark the storm, it will pass.

“You can. And you will.”

Simon’s story is a testament to resilience, the power of the human spirit, and the ability to turn adversity into purpose. Through his journey, he continues to inspire countless others, proving that even in the face of unimaginable challenges, strength, hope, and determination can lead to incredible triumphs.

80% of callers to the Helpline felt better able to deal with their enquiry after speaking to an Orchid Male Cancer Nurse Specialist.

90% of healthcare professionals who called the Helpline said it would help them meet the needs of their patients.

‘Despite being the rarest of all male-specific cancers, penile cancer will often cause the most severe physical and psychological side effects’

Penile cancer

Penile cancer will affect 36,000 men globally each year with a risk of 1 in 100,000. In the UK it affects around 760 men each year. In the last few years this means that the incidence has increased by just under 10%.

Despite being the rarest of all male-specific cancers, it will often cause the most severe physical and psychological side effects because all curative treatment will involve some form of surgery to the penis itself.

One of the biggest problems is lack of awareness amongst the public and some healthcare professionals. This can result in inappropriate treatment and therefore a delay in diagnosis increasing the risk of more invasive surgery.

Although men diagnosed with penile cancer are treated at regional specialist centres there remains an inconsistency in support.

Orchid’s 4 Nations Penile Cancer Programme is addressing these issues. Many men may feel isolated and face difficulty in managing the physical and psychological impact of the disease.

Orchid’s website now includes practical information on how to deal with some of these issues, while our telephone counselling service is offering a unique and invaluable service for many men.

Over the next year this service will be extended to partners and will include a more in-depth specialist counselling approach where applicable using psychosexual therapy. We have developed a robust referral pathway and protocols.

Orchid is gaining recognition on a European level for the initiatives we are leading and the support that we are offering. For more information on this, see pages 12-14.

Orchid’s 4 Nations Penile Cancer Programme

This new programme launched in October 2023 and is led by Urology Cancer Nurse, Sinéad Collins. She has a special interest in this rare cancer and is experienced in the clinical management of this patient group.

The aims of the programme are to raise awareness and the profile of penile cancer throughout the four nations by engaging with the general public, primary care and Allied Health Professionals; to work with supranetworks and specialist treatment centres; to create opportunities for sustainable peer support; and to develop a one stop penile cancer information hub.

Plans for Year 2 include presenting to GPs, practice managers and primary care network leads at the ‘Best Practice’ conference in October, addressing urology nurses at the annual British Association of Urology Nurses’ conference in November, and continuing to support patients and healthcare professionals across the four nations.



Urology Cancer Nurse, Sinéad Collins joined the programme in October 2023

4 Nations Penile Cancer Programme: Achievements in the year

- Attendance at busy community events such as the Belfast Mela and the Lambeth Country Show to talk about the risk factors, signs and symptoms and to disseminate information created for the programme.
- The availability of posters bespoke to each of the four nations to display in, for example, GP practices, pharmacies and community settings.
- The development of first of its kind written information for all Health Care Professionals which can be downloaded or printed as preferred.
- Multimedia resources and information are now available on the penile cancer hub which signposts to our virtual and in-person support.
- The creation of a Four Nation Nurse Forum attended by Clinical Nurse Specialists and which is facilitated by Orchid. This new group provides a platform for peer support as well as improving parity by sharing best practice.
- The establishment of an online “Wives, Husbands and Partners” peer support group which is providing powerful first-hand testimony as to the reality of the impact of penile cancer on intimate relationships.
- A Four Nations Penile Cancer Conference was held in Manchester to mark International Penile Cancer Awareness Day on September 20th. Oncology surgeons, Nurse Specialists, patients and their loved ones attended from across the four nations. Together the delegates collated ideas and thoughts to create an ideal penile cancer service. Feedback from the day was overwhelmingly positive.

Case study | PENILE CANCER

Patrick’s story

“Two years on I am mentally ten times stronger, ten times more resilient. I have a grasp on life. You have an army of support from Orchid who are going to back you up and get you through it the best way you can.”



We are so very grateful to Patrick for sharing his story to raise awareness of this rare cancer and to help others.

In early 2021, Patrick Meehan was 32, fit, healthy, and busy enjoying his social and working life when he noticed a rash on his penis.

Like so many others during lockdown, he was unable to arrange a face-to-face appointment with his GP. After a telephone consultation, he was referred to a sexual health clinic where he was given a steroid cream to treat what they thought was an infection. It was not until much later in the year after he developed other symptoms, that Patrick was sent for a biopsy which led to a diagnosis of penile cancer.

When diagnosed, Patrick felt shocked, annoyed and angry. Just before his operation, he called the Orchid Helpline saying, “I don’t know why I am calling you”. Speaking to Orchid Male Cancer Information Nurse Rob Cornes, whom he later described as “his guardian angel”, made Patrick feel safe and supported.

After treatment he felt he needed to talk. Orchid’s Telephone Counselling gave Patrick an understanding of what had happened to him, as well as giving him the building blocks and head space to move forward. Without counselling, he does not think he would have been able to do that.

By being involved with Orchid, he now feels he is part of or a community which really understands his experience, and where he can be totally open and vulnerable: “Two years on I am mentally ten times stronger, ten times more resilient. I have a grasp on life. You have an army of support from Orchid who are going to back you up and get you through it the best way you can.”

35,840 male cancer leaflets, booklets and posters were ordered or requested by individuals, companies, educators, and healthcare professionals. This is an increase of more than 3,000 compared with the previous year.



Research

The Robert Lane Tissue Bank

Orchid was pleased to continue to support the work of the Robert Lane Tissue Bank during the year. The Robert Lane Tissue Bank is led by Professor Dan Berney who is one of the world’s leading genito-urinary pathologists. The Tissue Bank carries out translational work which aims to link molecular and pathological data with clinical trials. The aim of the team is to curate a bespoke Tissue Bank concentrating on the three male cancers. They were delighted to renew their ethical approval for the bank in 2024 which will run for another five years. In summary, it:

- holds over 9,000 male-specific cancer tissue samples to facilitate understanding of prostate, testicular and penile cancers, from the potential causes, through to how they are diagnosed, treated, and possibly prevented.
- houses one of the largest collections of penile cancer tissues in Europe, is one of the largest testicular tissue banks in the world and is custodian of the largest series of untreated prostate cancers globally.
- collaborates with research on an international scale, as well as conducting its own pathological and molecular research into penile, prostate, and testicular cancer.
- works in collaboration with other Orchid funded research projects.
- is committed to the ethical collection, processing, and storage of samples.

The aim of the team is to curate a bespoke Tissue Bank concentrating on the three male cancers. So they were delighted to renew their ethical approval for the bank for further five years.

- has major external collaborations with prestigious research bodies such as The Institute of Cancer Research, The Rigshospitalet in Denmark, University College London, Memorial Sloan Kettering Hospital, Indiana University Hospital, The Cleveland Clinic, and The Karolinska Institute.
- is a valuable source of information for students and specialist researchers wanting to learn more about male cancers; as well as being accessible to lay visitors.
- focuses on samples where outcome data is available from clinical trials. Advances in technology increasingly allow high quality sequencing and molecular work in these media.

Professor Dan Berney
Professor Berney is Editor in Chief of *Histopathology*, a leading journal in the field. He is Past Secretary of the International Society of Urological Pathologists (ISUP), Past Secretary and President of the British Society of Urological Pathologists (BAUP) and Past International Secretary of the British Division of the International Academy of pathologists (BDIAP).
He is the expert pathology lead on testis for the European Association of Urology and helping with their clinical guidance.
He has received from the International Society of Urological Pathology, The Gleason Medal, and

from the British Division of the International Association of Pathology, he received the Cunningham Medal in November 2023.
Professor Berney was co-editor of the 5th edition of the classification of GU-tumours and led on the testis classification for the World Health Organisation and is invited author for .
He has a strong social media presence being one of a select number of uro-pathologists with over 3,000 followers.
He has lectured throughout the world, especially in the USA and also Africa, to improve prostate cancer diagnosis.
He is Visiting Professor at Manipal Medical College in India and was invited to be Visiting Professor at the Cleveland Clinic in Ohio.
Professor Berney has over 320 peer reviewed publications and numerous book chapters on urological pathology. He has an H score of 87 (ie. he has published 87 articles each of which has been cited at least seven times) and his work has been cited over 136,000 times.
Professor Yong-Jie Lu
Professor Yong-Jie Lu whose work Orchid has previously supported is the scientific lead on the Robert Lane Tissue Bank Governance Committee and has supervised the day-to-day running/maintenance in the past year, while running his research team on prostate cancer circulating biomarker development.


Highlights of the year

12 papers were published from the group in the year. Many of these relate to work done on tissue from the Robert Lane Tissue Bank in the past and donated over 10 years ago yet still in clinical use. Professor Berney now has over 320 papers.

Prostate cancer
With Professor G Attard at University College London we continue to work on the STAMPEDE clinical trial which aims to assess new treatment approaches for people affected by high-risk prostate cancer. Ms Larissa Mendez had her first abstract accepted on this work to present in Boston in 2025.
Further work continues to be published from the Trans-Atlantic prostate group cohort into early-stage prostate cancer, a longer term follow up is planned as well as a planned project funded by Myriad genetics looking at the use of AI in this cohort to predict outcome.
A collaboration with the Institute of Cancer Research to collect further samples of prostate cancer from recent clinical trials. This supports Orchid work and will focus (among others) on the PACE-B trial which found that men undergoing treatment for prostate cancer could be safely given far less radiotherapy. Tissue has started to be collected and will continue for another two years to 2026.

Testis cancer
The main success of the year continues in the field of testis cancer with the publication of the second and third collaboration with Denmark into risk factors to

predict whether testis cancer will come back and whether chemotherapy is needed. These papers will directly affect the decisions on who gets chemotherapy after removal of the cancer in surgery.
Professor Berney is lead for the testis International Collaboration on Cancer reporting. This work ensures that pathology reports on testis cancer are standardised worldwide.
With the support of both the Genito-Urinary Pathology Society (GUPS) and the International Society of Urological Pathologists (ISUP), Professor Berney has set up a new group to examine the ‘sex cord stromal tumours’ of the testis. These rare tumours are not well understood, may be malignant and are resistant to treatment. He was the lead on an international meeting in Baltimore in 2024 about these tumours and hopes to make advances in this challenging area.
The logo for this group can be seen below.
This group has one paper in press for 2025 and one in preparation and plan to expand this important work for the treatment of rare testis tumours.
Another paper published in January 2025 looks at the rare spermatocytic tumours’ and showed in novel work, which of these usually rare tumours can occasionally behave in an aggressive manner.



Research Identifying urine biomarkers for non-invasive prostate cancer surveillance

Characterisation of the anaerobic microbiome and genomic methylation status of prostate cancer patients experiencing active Vitamin D and K2 deficiency: prevention, risk stratification, diagnosis and treatment potential

Orchid was pleased to support this new research project led by Dr Belinda Nedjai who is an Associate Professor (Reader) specialising in Cancer Biomarkers and Epigenetics.

Summary of the project

Prostate cancer is one of the most common cancers among men but many people with slow-growing prostate cancer die with it – not of it. A blood test called the prostate-specific antigen blood test (PSA) is how patients are screened for prostate cancer. If test results are abnormal, further testing is done with a prostate biopsy, which involves obtaining a small sample of prostate tissue. This process is painful and not always predictive of prostate cancer aggressiveness.

A non-invasive solution would greatly benefit the patients and also

the healthcare profession providing a tool for patients’ management. Prostate MRI can also be used, which has been shown to help detect prostate cancers that are likely to be aggressive. So, if this study shows that we can use bacteria to predict who will develop aggressive or recurring prostate cancer, it could potentially help to save lives.

Right now, however, it’s a ‘chicken or the egg’ scenario: does the presence of these bacteria cause cancer? Or does cancer allow these bacteria to flourish? In recent results (Phase 1) Dr Nedjai’s work has demonstrated that obligate anaerobes are associated with an increase of PSA and prostate cancer risk.

Using a urine test could be another great – and non-invasive way – to detect aggressive prostate cancers. 90% of bacterial species in every human can only grow

Right now, it’s a ‘chicken or the egg’ scenario: does the presence of these bacteria cause cancer? Or does cancer allow these bacteria to flourish?

without oxygen, ie. obligate anaerobes. Scar tissue after injury or infection can often have reduced blood supply. Bacteria colonising such scarred gastric tissue cause stomach cancer, an idea which was initially ridiculed. Antibacterial treatment now forms the basis of therapy in cancer prevention. Recent research suggests the same may be true for prostate cancer.

Research using genomic methylation studies (these measure switching on and off of genes) has demonstrated chronic inflammation from bacteria affects the methylation status of genes responsible for Vitamin D’s role in controlling bacteria, and prevents Vitamin D working with Vitamin K2 to enhance control of cancer as demonstrated in animal studies.

This research proposal is the first to test this issue in humans. Work demonstrating the health benefits

of fermenting foods from the ZOE project in King’s College, is making this project more important as Vitamin K2 is produced by food fermentation. At the end of this study, the team hope to not only identify the obligate anaerobes responsible for prostate cancer progression, but they will also understand better the link between obligate anaerobes and vitamin K and D.

This work could pave the way to the design of new clinical trials for cancer prevention (by treating Vitamin D and K deficiency), early detection (by detecting obligate anaerobes) and treatment (by identifying new prostate cancer progression genes with methylation).

The main objective has been to develop prognostic models for individuals using obligate anaerobes and DNA methylation with early lesions, using blood, urine and biopsy material and risk factors to personalise management of screen-detected cancers or precancerous lesions to identify those at high-risk, needing more intensive investigations such as MRI scans and molecular studies. Additionally, the aim has to identify those at low-risk, who may benefit from minimal or even no treatment or further screening.

Dr Nedjai has been exploring three questions over the year. These were:

- **Do certain obligate anaerobes drive a specific methylation signature?**
- **Could she and her colleagues identify a non-invasive urine biomarker combining microbiome and DNA methylation to improve the management of patients with indolent cancer on active surveillance?**
- **Can they design a chemo preventive trial to improve the outcome of prostate cancer patients under active surveillance?**

A key question for Dr Nedjai and her colleagues: can they design a chemo preventive trial to improve the outcome of prostate cancer patients under active surveillance?

Progress made

Dr Nedjai and her colleagues have now completed and published a full analysis on the microbiome of urine samples from the PROVENT study. This is a study to see if aspirin with or without vitamin D can delay the progression of prostate cancer in men on active surveillance.

We are delighted to report that this work demonstrates that certain Obligates anaerobes bacteria are associated with high levels of PSA and could perhaps contribute to prostate cancer progression.

January 2025 saw the research published in a paper in Cancers which is an esteemed peer reviewed Journal. A summary of the findings will be included in Orchid’s Annual Report for 2024-2025, or can be requested from Orchid.



Dr Belinda Nedjai

Dr Belinda Nedjai is an Associate Professor (Reader) specialising in Cancer Biomarkers and Epigenetics. She also serves as the Director of the Molecular Epidemiology Laboratory within the Wolfson Institute of Population Health (WIPH).

Dr Nedjai earned her Ph.D. in Functional Genomics from Queen Mary, Bart’s, and the London School of Medicine and Dentistry in London, UK. Her academic journey includes a Master’s degree

in Cellular and Molecular Physiopathology from the University of Sciences, Pierre et Marie Curie, Paris VI, France, and another Master’s degree in Biochemistry with a focus on Immunology and Genetics from the University of Science, Aix Marseille II Luminy, France.

She conducted research for eight years at Imperial College London as post-doctoral researcher and then research Fellow. Her extensive experience spans over 20 years in identifying and validating biomarkers using advanced Next generation sequencing techniques. Her primary research focus is the application of novel quantitative technologies for discovery and validation of DNA methylation biomarkers.

One of Dr Nedjai’s notable achievements is the development and validation of DNA methylation assays for triaging women infected with papillomavirus, such as the S5 classifier, which combines DNA methylation of HPV and human genes. This method has been substantially validated in studies worldwide and is considered a gold standard in the field of HPV-related cancers. Dr Nedjai is currently involved in numerous studies focussing on the development of screening and triage molecular tools and algorithms to detect HPV related precancer lesions and cancer early.

She is dedicated to unravelling genetic and epigenetic pathways in HPV related cancers and working on the development of biomarkers for early cancer detection, accurate diagnosis, and effective cancer management.

Dr Nedjai’s laboratory collaborates closely with clinicians, epidemiologists, and statisticians on various clinical trials, exploring innovative screening, diagnostic, and treatment approaches.

The year ahead

As we head into the new financial year, work will be delivered in line with the four pillars in our organisational Strategy 2024 -2028, namely Support, Awareness , Educate and Research. Fundraising will underpin everything we do.

Support

In line with our strategy, we will continue to offer personal support for patients, families and healthcare professionals, promoting how we can help widely to encourage people from across the four nations to access Orchid’s Nurse-led services. Any service development in the coming year will take on board what we hear from patients, their loved ones, and the healthcare professionals working in the field.

Our Male Cancer Nurse Specialists will be available five days a week to provide information and support to anyone calling Orchid’s Freephone Male Cancer Helpline. Callers to our Helpline may also be signposted to other services, such as Orchid’s telephone counselling service for those diagnosed with penile or testicular cancer, or peer support opportunities.

Plans are in place to use learnings to review our testicular and penile cancer counselling service including the existing protocols, the referral pathway and how its impact is evaluated. Based on feedback from wives and partners of penile cancer patients, we will also be extending this service to them. We will continue to support existing peer support groups, both online and in person. Men continue to tell us there is a lack of support for penile cancer patients, and more is needed. In response, we plan to set up a virtual group which will meet in the evening to be as inclusive as possible, allowing those who work to attend. We will continue to grow the online Wives, Husbands and Partners penile cancer support group in response to need.

The Four Nations Penile Cancer Programme led by Orchid Nurse Sinéad Collins entered its second year in October. During 2024-2025 we will build on the solid foundations and relationships now in place to further raise the profile of penile cancer and improve support for anyone who has been affected by the disease, increasing equity across the UK.

Supported by penile cancer patient advocates, Orchid Nurse Rob Cornes, who is a member of the European Association of Urology Patient Advocacy Group and the European Reference Network eUROGEN European Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid, will continue to work to improve the patient experience for those affected.

Awareness

Knowing that cancers found early are often the easiest to treat, we will raise awareness of male cancers, especially in diverse and vulnerable groups to reduce inequality and to reach those who may not feel able to prioritise their health or who miss mainstream health messaging.

Male Cancer Information Roadshows remain an established part of our community outreach, through which we take information right into the heart of communities, mainly in areas of deprivation. These will be delivered in targeted communities as funding becomes available. We will also continue to offer male cancer talks and presentations to community groups and via our Health at Work programme. As the new year started, talks were being booked in Deaf Clubs to be supported by a British Sign Language interpreter. Bookings were also being made to give talks in Churches with mainly Black African and Black Caribbean congregations in response to Black men’s increased risk of prostate cancer.

An exciting new three-year programme called “Active Participation in Male Cancer Awareness in Prisons” started in August 2024. This is funded by the National Lottery Community Fund and Orchid will deliver talks in prisons across England, attend health days, train residents as Male Cancer Community Champions, and offer support for those diagnosed.

Another innovative development in the year ahead is our new Every Last Drop prostate cancer awareness campaign. This is scheduled to go live in petrol stations in the Brighton area and on the Isle of Man soon after the new year starts. This will be delivered with thanks to sponsorship funding from Astellas, a grant from Takeda and the support of the Isle of Man Anti-Cancer Association.

Digital activity will continue to be important as we use our social media platforms to reach both existing and new audiences with male cancer messaging and information about the support Orchid can offer. Campaigns in the pipeline for delivery in the first half of the year include one targeting Deaf people using images and videos of Deaf people and using British Sign Language, one using a young man who was diagnosed with testicular cancer to raise awareness

amongst young men, and another to reach trans women at risk of prostate cancer.

Orchid’s Male Cancer Awareness Week will take place between 15-21 September 2025 with engaging messaging, with International Penile Cancer Awareness Day on 20 September 2025.

Educate

During the year our Nurses will review Orchid information about diagnosis, treatment and care to ensure that it is up to date.

Our Nurses will also continue to promote our resources to, and work with, healthcare professionals to improve the patient journey for those affected by male cancer. We will work to build closer relationships with healthcare professionals such as urologists and pharmacists to disseminate information, as well as with targeted corporate partners to spread male cancer messaging.

Furthermore, we will keep working across the four nations to equip people with knowledge about the signs, symptoms, treatment and care options, targeting the most vulnerable and at-risk groups.

Research

Research is vital to understand why men develop prostate, testicular or penile cancer and to improve diagnosis and treatment. There will be two areas of research funded by Orchid grants in the new financial year.

We are delighted to have committed a grant towards the continuation of the important work led by Professor Dan Berney in the Robert Lane Tissue Bank from 1 October 2024 to 30 September 2025. In addition, work will be continuing for the first few months of the year on the research funded by a grant from the Research Innovation Project which is led by Dr Belinda Nedjai.

Environmental Policy

At Orchid, we are committed to reducing our carbon footprint and minimising our environmental impact. As part of our ongoing efforts, we continuously monitor our activities to align with our Environmental Policy. One key initiative is optimising how we share resources. Encouraging digital downloads over printed materials will help us reduce paper waste, lower postage costs, and minimise our overall environmental impact, all while ensuring that individuals still have easy access to the vital information and support they need.

Fundraising

Orchid’s work is only possible because of the generosity of our supporters, and we will look after them in every way we can. We will review our supporter care processes to ensure people have an excellent experience whilst fundraising for us. We will continue to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and all the individuals and community groups who support us with donations and fundraise on our behalf. Our fundraising strategy for the year will be to generate income from diverse income streams at the best possible return on investment to ensure the charity has sufficient funding in place to deliver our plans for the coming years. We will explore new income generating opportunities in all areas of fundraising. Applications will be submitted to warm Charitable Trusts and Foundations on a rolling basis, carrying out research to identify new potential supporters. We will develop mutually beneficial partnerships with our corporate supporters to meet their needs as well as Orchid’s. As the current financial year has progressed, securing unrestricted income has become increasingly challenging, while operational costs continue to rise. In response, Orchid Trustees have been reviewing all areas of the charity’s work and exploring a range of options to help increase income and reduce expenditure, whilst ensuring the charity remains effective and sustainable.

Thank you

We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead. As the year began, a wonderful group of young men in the Sixth Form at Warminster School were busy fundraising ahead of October’s Bournemouth Half Marathon, as were our magnificent team of runners in the Royal Parks Half Marathon. We are looking forward to supporting more wonderful fundraisers as the year progresses.

Governance

Orchid’s aim is to provide greater knowledge and awareness about male specific cancers by funding scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK.

Objects, operating context and activities

Objects

The number of people being diagnosed with prostate, testicular or penile cancer in the UK has been increasing. There are now over 58,000 new cases of these cancers each year. Orchid’s aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid’s aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our

Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Orchid recognises that an effective Board of Trustees with a balanced composition is essential if the charity is to be effective in achieving its objects, and a new Trustee Recruitment and Training Policy was agreed during the year. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. Trustees acknowledge the need to increase diversity on the Board and continue to explore the best ways to do this.

A governance audit has been agreed. It will use the template of the Charity Governance Code and the Charity Commission’s governance recommendations and will be complemented by a skills audit.

The Board met four times during the year, and most meetings were held virtually during 2023-2024. At the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from office in rotation, in order of longevity of appointment and are eligible to be reappointed.

Trustee training and induction

New Trustees are offered an induction programme. All new Trustees receive a copy of Orchid’s governing documentation, the most recent Annual Report, and the Charity Commission’s The essential trustee: what you need to know, what you need to do (CC3). New Trustees are also offered a meeting with the lead programme researchers and a visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Opportunities for ongoing governance training are highlighted in the monthly updates the CEO provides for Trustees. Trustees can elect to attend courses which interest them or which they feel will benefit them in their role as an Orchid Trustee.

Delegation and decision-making

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid’s direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance

remains a key requirement.

- The Finance Committee is responsible for the financial oversight of the Charity including budgeting, financial planning and monitoring as well as financial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at 30 September 2024, it comprised the Honorary Treasurer, Mr W Cohen, Mr C Osborne and Mr S Harris.
- At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept appraised of personnel, awareness, research programme and budgetary issues.

Public benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission’s general guidance on public benefit including (PB2 Public Benefit: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation’s strategy and

objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the verification of outcomes, a Scientific Advisory Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identifies risks under the following headings:

- Governance and compliance
- Operational
- Financial
- Research
- Environmental/external
- Quality assurance

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed annually and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified. These are as follows:

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to

- Mitigation
- An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and financial, are covered by suitably qualified professionals
 - Training and support for Board of Trustees and Finance Committee
 - Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
 - Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Operational

Attracting, developing and retaining talented staff in a competitive employment market

- Mitigation
- Annual salary review to include benchmarking of compensation and benefits
 - Staff development, training and succession planning programmes
 - Communication programme to ensure staff are involved in the development of and progress towards Orchid’s strategy and annual workplan

Financial

Economic pressures, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

- Mitigation
- Annual budgeting and ongoing management, reporting and monitoring of financial performance
 - Diversification of income streams
 - Ongoing consideration of market and consumer trends and regulations including GDPR

Research

Orchid’s Research Programme fails to deliver results

- Mitigation
- Scrutiny and approval of research funding applications by an expert Scientific Advisory Board
 - Annual review of progress

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid’s work

- Mitigation
- Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
 - Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
 - Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

- Mitigation
- Services developed, delivered and evaluated in line with agreed protocol and standards
 - Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)
 - All information materials and content regularly reviewed and updated
 - High-quality training for staff

Financial review

Results for the year

Income for the year ended 30 September 2024 totalled £767,210 (2023: £730,024). After total expenditure of £1,047,335 (2023: £634,721), the year’s activities show a net deficit of £280,125 (2023: surplus of £95,303). Total reserves at the end of the year amounted to £357,014 (2023: £637,139).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or ‘designated’ for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity’s core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity’s planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available free reserves net of tangible and intangible fixed assets are £79,367 (2023: £157,287). It is the Charity’s policy to maintain free reserves of approximately 3–4 months of operating costs. At current levels of expenditure this equates to £155,000–£212,000.

Formal statements

Statement of Trustees’ responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiner’s information

So far as each of the directors at the time the Trustees’ report is approved is aware:

- a) there is no relevant information of which the examiner is unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees



W Cohen, Treasurer
18/06/25

Independent Examiner’s Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2024.

Responsibilities and basis of report

As the charity’s trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (“the 2006 Act”).

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (“the 2011 Act”). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145 (5) (b) of the 2011 Act.

Independent examiner’s statement

Since the Company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

- 1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
- 2. the accounts do not accord with those records; or
- 3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Moore Kingston Smith LLP

Adam Fullerton FCA DChA

Date: 26 June 2025

For and on behalf of
Moore Kingston Smith LLP
Chartered Accountants
6th Floor, 9 Appold Street,
London
EC2A 2AP

Statement of financial activities

(incorporating an income and expenditure account)
For the year ended 30 September 2024

	Note	Unrestricted Total £	Restricted Total £	Year ended 30 September 2024 £	Year ended 30 September 2023 £
Income from:					
Donations and Legacies	2	467,901	156,644	624,545	567,782
Charitable Activities	4	-	140,344	140,344	160,850
Trading Activities		419	-	419	272
Investment income		1,902	-	1,902	1,120
Total income		470,222	296,988	767,210	730,024
Expenditure on:					
Raising funds Fundraising (donations and grants)	5	196,759	-	196,759	163,449
Charitable Activities Education and Awareness	5	332,846	284,001	616,847	420,021
Research	5	22,694	211,035	233,729	51,251
Total expenditure		552,299	495,036	1,047,335	634,721
Net income / (expenditure) and net movement in funds	5,6	(82,077)	(198,048)	(280,125)	95,303
Reconciliation of funds					
Total funds brought forward		298,601	338,538	637,139	541,836
Total funds carried forward		216,524	140,490	357,014	637,139

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 14 to the financial statements.

Balance sheet

As at 30 September 2024

		30 September 2024	30 September 2023
	Note	£	£
Fixed Assets			
Tangible Assets	10	3,225	3,340
Intangible fixed assets	11	12,125	16,166
Current Assets			
Cash at bank and in hand		526,386	630,903
Debtors	12	157,187	67,957
		683,573	698,860
CREDITORS			
Amounts due within one year	13	(341,909)	(81,227)
Net Current Assets			
		341,664	617,633
Total Assets less Current Liabilities			
	14	357,014	637,139
NET ASSETS			
		357,014	637,139
Represented by:			
	15		
General Unrestricted Funds		94,717	176,793
Designated Funds		121,808	121,808
		216,525	298,601
Restricted funds		140,489	338,538
		357,014	637,139

The company is limited by guarantee.

For the year ending 30 September 2024 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 18/06/25 and signed on its behalf by:



Mr W Cohen
Company number 3963360

Statement of cash flows

For the year ended 30 September 2024

	2024 £	2023 £
Cash flows from operating activities:		
Net (expenditure)/income for the year	(280,125)	95,303
Adjustments for:		
Depreciation charges	5,655	5,338
Interest	(1,902)	(1,120)
Decrease / (increase) in debtors	(89,230)	40,849
(Decrease) / increase in creditors	260,682	(89,282)
Net cash (used in)/provided by operating activities		
	(104,920)	51,088
Cash flows from investing activities:		
Interest	1,902	1,120
Purchase of fixed asset	(1,499)	(11,749)
Net cash (used in) investing activities		
	403	(10,629)
Change in cash and cash equivalents in the year	(104,517)	40,459
Cash and cash equivalents at the beginning of the year	630,903	590,444
Cash and cash equivalents at the end of the year	526,386	630,903
Analysis of cash and cash equivalents		
Cash at bank and in hand	526,386	630,903
	526,386	630,903

Notes to the financial statements

1. Accounting policies

For the year ended 30 September 2024

Basis of Preparation

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements. In particular the trustees have considered the charities forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2024/25 however that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing its financial statements.

The trustees confirm that there are no material uncertainties about the

ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its financial statements.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment - 33 1/3% on written down value.

Intangible fixed assets and Amortisation

Intangible fixed assets are included in the balance sheet at original cost less accumulated amortisation. Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the number of years of expected use. Assets are amortised at the following rate:

Website - 20% on straight line value

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity's objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity's objects.

Governance costs are those incurred in connection with the management of the Charity's assets, organisational

administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension Scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee's services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

2. Donations

Current year	Year ended 30 September 2024			Year ended 30 September 2023
	Restricted	Unrestricted	Total	Total
	£	£	£	£
Individuals	1,360	155,961	157,321	58,012
Legacies	-	-	-	19,147
Corporates	-	91,226	91,226	76,601
Trusts and Foundations	155,284	49,850	205,134	264,628
Fundraising Events	-	170,864	170,864	149,394
Total	156,644	467,901	624,545	567,782
Prior year	Year ended 30 September 2023			
	Restricted	Unrestricted	Total	
	£	£	£	
Individuals	500	57,512	58,012	
Legacies	-	19,147	19,147	
Corporates	-	76,601	76,601	
Trusts and Foundations	256,650	7,978	264,628	
Fundraising Events	-	149,394	149,394	
Total	257,150	310,632	567,782	

3. Fundraising events

Current year	Year ended 30 September 2024			Year ended 30 September 2023
	Restricted	Unrestricted	Total	Total
	£	£	£	£
Cycling events	-	9,253	9,253	2,296
Running events	-	57,014	57,014	68,852
Third party organised events	-	99,324	99,324	63,886
Trek	-	-	-	92
Other	-	5,273	5,273	14,268
Total	-	170,864	170,864	149,394
Prior year	Year ended 30 September 2023			
	Restricted	Unrestricted	Total	
	£	£	£	
Cycling events	-	2,296	2,296	
Running events	-	68,852	68,852	
Third party organised events	-	63,886	63,886	
Trek	-	92	92	
Other	-	14,268	14,268	
Total	-	149,394	149,394	

4. Charitable activities

Current year	Year ended 30 September 2024			Year ended 30 September 2023
	Restricted	Unrestricted	Total	Total
	£	£	£	£
National Lottery Community Fund	140,344	-	140,344	160,850
Total	140,344	-	140,344	160,850
Prior year	Year ended 30 September 2023			
	Restricted	Unrestricted	Total	
	£	£	£	
National Lottery Community Fund	160,850	-	160,850	
Total	160,850	-	160,850	

5. Total expenditure

	Cost of raising funds	Education and Awareness	Research	Year ended 30 September 2024 Total	Year ended 30 September 2023 Total
	£	£	£	£	£
Grants	-	-	205,428	205,428	18,519
Staff costs	91,218	192,408	18,983	302,609	264,654
Fundraising expenses	60,767	-	-	60,767	39,663
Information materials	-	293,692	-	293,692	126,256
Direct costs	-	27,196	-	27,196	33,511
	151,985	513,296	224,411	889,692	482,603
Support costs					
Depreciation	1,590	3,734	331	5,655	5,338
Other	34,130	80,121	7,103	121,354	117,930
Governance - staff costs	6,551	13,820	1,363	21,734	22,099
Governance - independent examiners	2,503	5,876	521	8,900	6,751
	44,774	103,551	9,318	157,643	152,118
Total expenditure	196,759	616,847	233,729	1,047,335	634,721
Prior year	163,449	420,021	51,251	634,721	

6. Grants awarded

	Year ended 30 September 2024 Total	Year ended 30 September 2023 Total
	£	£
Grant commitments brought forward	35,646	126,617
Institutional grants for medical research awarded during year/period		
– Orchid Study and Travel Awards (2024: 2 individuals, 2023: 2 individuals)	1,128	1,000
– Barts and London School of Medicine	54,398	35,646
– Write off	149,902	(18,128)
Payments made during period/year	(4,182)	(108,489)
Grant commitments carried forward	236,892	36,646
Payable less than one year	236,892	36,646
Payable two to five years	-	-

7. Net expenditure for the period

	Year ended 30 September 2024 Total	Year ended 30 September 2023 Total
	£	£
This is stated after charging:		
Depreciation	1,613	1,297
Independent examiners’ remuneration:		
Independent examination	5,700	5,435
Trustees’ remuneration	-	-

8. Staff costs and numbers

	Year ended 30 September 2024 Total	Year ended 30 September 2023 Total
	£	£
Staff costs were as follows:		
Salaries and wages	269,204	235,955
Social security costs	22,772	18,666
Pension contributions	3,307	2,122
	295,283	256,743
Consultant costs	29,060	30,010
Total cost	324,343	286,753

During the year ended 30 September 2024, one employee earned more than £60,000 (Year to 30 September 2023: 1). The pension contribution paid in respect of this employee totalled £Nil (2023: £Nil)

The key management personnel of the charity comprise the trustees and the chief executive. The charity trustees do not receive remuneration.

The total remuneration of the chief executive was £86,324 (year ended 30 September 2023: £83,579).

The number of employees whose emoluments amounted to over £60,000 in the year (exclusive of employer pensions and employer National Insurance contributions) was as follows:

	2024 No.	2023 No.
£70,000–£79,999	1	1

The average number of employees during the year was 7.4 (2023: 7.4)

The average number of employees during the year on a headcount basis was as follows:

	2024 No.	2023 No.
Fundraising	1.7	1.7
Education and Awareness	5.4	5.4
Grant support	0.3	0.3
Overall average	7.4	7.4

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Tangible fixed assets

	Computer and office equipment Total £	30 September 2024 Total £
Cost		
At the start of the period	10,924	10,924
Additions	1,499	1,499
At the end of the period	12,423	12,423
Depreciation		
At the start of the period	7,584	7,584
Charge for Period	1,614	1,614
At the end of the period	9,198	9,198
Net book value		
At the end of the period	3,225	3,225
At the start of the period	3,341	3,341

11. Intangible fixed assets

	Website development Total £	30 September 2024 Total £
Cost		
At the start of the period	20,208	20,208
Additions	-	-
At the end of the period	20,208	20,208
Amortisation		
At the start of the period	4,042	4,042
Charge for Period	4,041	4,041
At the end of the period	8,083	8,083
Net book value		
At the end of the period	12,125	12,125
At the start of the period	16,166	16,166

12. Debtors

	Year ended 30 September 2024 Total £	Year ended 30 September 2023 Total £
Prepayments	69,476	7,439
Other debtors and accrued income	87,711	60,518
	157,187	67,957

13. Creditors: amounts due within one year

	Year ended 30 September 2024 Total £	Year ended 30 September 2023 Total £
Grants Payable	236,892	35,646
Trade and Other Creditors	62,976	11,424
Accruals	42,041	-
	341,909	47,070

14. Movements in funds

	Brought forward £	Income £	Expenditure £	Carried forward £
Unrestricted				
General	176,793	470,222	(552,299)	94,716
Designated – Development	121,808	-	-	121,808
Total unrestricted	298,601	470,222	(552,299)	216,524
Restricted				
Counselling	-	10,000	(5,500)	4,500
The National Lottery Community Fund: – Overcoming the Barriers	29,030	81,629	(110,659)	-
The National Lottery Community Fund: – Active Participation in Male Cancer Awareness in Prisons	-	58,715	(7,630)	-
The Innovation Research Project	156,137	500	(156,637)	-
Penile Cancer Peer Support	1,565	2,484	(3,244)	805
Education and Awareness	4,000	22,500	(25,500)	1,000
Student Study and Travel Scholarships	3,729	-	(1,000)	2,729
Roadshows	-	50,160	(49,300)	860
Robert Lane Tissue Bank	13,054	49,500	(54,398)	8,156
Nurse Led Services	2,000	31,500	(17,000)	16,500
Four nations penile cancer programme	129,023	-	(69,668)	59,355
Total restricted	338,538	296,988	(495,036)	140,490
Total funds	637,139	767,210	(1,047,335)	357,014

14. Movements in funds (continued)

Prior year movements in funds	Brought forward	Income	Expenditure	Carried forward
	£	£	£	£
Unrestricted				
General	175,208	312,024	(310,439)	176,793
Designated – Development	121,808	-	-	-
Total unrestricted	297,016	312,024	(310,439)	298,601
Restricted				
The National Lottery Community Fund				
- RC England-wide	32,445	166,673	(158,322)	29,030
Male Cancer Nurse Information Specialist				
- other funders	8,252	12,100	(16,752)	0
The Innovation Research Project	92,800	68,700	(7,320)	156,137
Penile Cancer Peer Support	-	8,500	(7,500)	1,565
Education and Awareness	5,000	58,950	(30,295)	4,000
Student Study and Travel Scholarships	6,729	-	(2,000)	3,729
Roadshows	2,860	42,871	(38,871)	0
Robert Lane Tissue Bank	-	48,700	(35,646)	13,054
Nurse Led Services	-	2,000	-	2,000
Four nations penile cancer programme	-	130,000	(977)	129,023
Total restricted	244,820	418,000	(324,282)	338,538
Total funds	541,836	730,024	(634,721)	637,139

General funds are unrestricted funds available for use at the Trustees’ discretion in furtherance of the general activities of the charity and which have not been designated for other purpose

Designated Development funds represent monies set aside at the Trustees’ discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

15. Analysis of net assets between funds

	Unrestricted funds	Restricted funds	Total funds at 30 September 2024
	£	£	£
Fixed Assets	3,225	-	3,225
Current Assets	555,207	140,490	695,697
Creditors due within one year	(341,908)	-	(341,908)
Net assets at 30 September 2024	216,524	140,490	357,014
Prior year analysis of net assets between funds			
	Unrestricted funds	Restricted funds	Total funds at 30 September 2023
	£	£	£
Fixed Assets	3,340	-	3,340
Current Assets	376,490	338,538	715,028
Creditors due within one year	(81,229)	-	(81,229)
Net assets at 30 September 2023	298,601	338,538	637,139

16. Related party transactions

Aggregate donations of £50,000 were received from trustees in the year ended 30 September 2024. (Year to 30 September 2023: £500).

17. Financial commitments

For the year ended 30 September 2024, the charity was committed to making the following future payments under non cancellable operating leases.

	Year ended 30 September 2024	Year ended 30 September 2023
	Total	Total
	£	£
Land and buildings		
Expiring within one year	15,637	15,637
Expiring within two to five years	-	-
	15,637	15,637

18. Capital commitments

At the year ended 30 September 2024, the charity had no capital commitments.

ORCHID CANCER APPEAL

England & Wales - Charity number 1080540

Accounts

Orchid Cancer Appeal
**Annual Report and
Financial Statements
2022–2023**

**OUR
IMPACT**

ORCHID 
FIGHTING MALE CANCER

Orchid Cancer Appeal

Annual report and financial statements 2022-2023

Board of Trustees

Mr CS Osborne Chair
Mr W Cohen Treasurer
Mr D Badenoch
Mr PG Bracher
Mr S Harris
Mr M Kibblewhite
Professor RTD Oliver
Mr P Norman
(resigned 21 May 2023)
Mr B Ayres
Professor P Rajan
(appointed 7 December 2023)
Mr J Shedden
(appointed 7 December 2023)

Chief Executive

Mr A Orhan

Independent Examiner

Moore Kingston Smith LLP
6th Floor, 9 Appold Street,
London EC2A 2AP

Accountants

JS2 Limited
1 Crown Square, Woking,
Surrey GU21 6HR

Legal advisors

Farrer & Co
66 Lincoln's Inn Fields,
London WC2A 3LH

Bankers

HSBC Plc
20 Electric Parade,
George Lane,
South Woodford,
London E18 2LX

Registered Office

60 Gray's Inn Road,
London WC1X 8AQ

Tel 020 3745 7310
www.orchid-cancer.co.uk

Registered in England with the
Charity Commission No.1080540

Company Limited by Guarantee
Registered in England
No. 3963360

Inside this report:

Letter from the Chair	6
CEO's letter	7
The year in review	10
Fundraising	14
Our impact	22
Prostate cancer	22
Testicular cancer	26
Penile cancer	30
Research	32
The year ahead	36
Governance	40
Financial review	44
Formal statements	44
Independent Examiner's information	44
Independent Examiner's Report	45
Statement of financial activities	47
Balance sheet	48
Statement of cash flows	49
Notes to the financial statements	50

Letter from the Chair

Orchid has now been a charity for 26 years. We exist to save men's lives – sadly over 12,000 men in the UK lose their lives to male-specific cancers (testicular, prostate and penile) each year – yet it's a testament to our donors, fundraisers, volunteers and staff that many more are saved through awareness and early interventions.

Every year over 55,000 people are diagnosed with prostate, testicular or penile cancer and this number continues to increase.

Despite this:

- there is low awareness amongst men even those at most risk
- too many are diagnosed too late which reduces treatment options
- there are health inequalities – Black African and Black Caribbean men have an increased risk of prostate cancer
- men don't know where to turn for support on diagnosis

And so, Orchid continues to educate people about male cancers, creating understanding about who is at risk and the signs and symptoms to look out for, so as many men as possible get an early diagnosis if they need one.

Orchid's roots are in research and the research we have funded to date has helped to identify new ways to treat male cancers and improved our understanding of how male-specific cancers behave.

We continue our support for the Robert Lane Tissue Bank which is an internationally important resource for research into penile, testicular, and prostate cancer, and is led by Professor Dan Berney who is an internationally recognised pathology expert in the three male

genito-urinary cancers. We were delighted when he was chosen to deliver the Kristin Henry Lecture at the Liverpool Pathology conference in June 2023 and again when he was presented with the Cunningham Medal by the British Division of the International Academy of Pathology in November 2023.

We congratulate Professor Berney and are immensely proud to have him with us, as we are to have all our staff and supporters – the individuals who donate or participate or volunteer; the Charitable Trusts and Foundations, the National Lottery Community Fund and companies who fund our projects; our project partners who help us deliver results; our Trustees, giving their time to make sure Orchid keeps on with its mission and of course all our staff.

And finally, I would like to mention Peter Norman who stepped down as a Trustee during the year and thank him for his most wonderful service and contribution to what we have achieved.

My sincere thanks to you all

Colin Osborne MBE, Chair

Letter from the CEO

It has been another busy and productive year for Orchid. While our overall aim remains to develop innovative ways of meeting the needs of those at risk of and affected by prostate, testicular and penile cancer, we also recognise that some people face additional challenges to accessing services such as diagnosis and treatment. We aim to meet these needs by working collaboratively and thinking creatively to reach wider and new audiences, regardless of who they are, so they receive the information and support they need.

Highlights this year included:

- Male Cancer Awareness Week in September 2023, which focused on Small Change, Big Difference, helping men understand the changes in their bodies which could be a sign of male cancer.
- Our team of 85 Volunteer Community Champions did a fabulous job cascading prostate cancer messages across 10 cities outside of London.
- Funding was received to deliver a new Four Nations Penile Cancer Programme to raise the profile of penile cancer in the UK and improve support for anyone affected.
- We worked collaboratively with partners across the UK to reach marginalised communities to make sure they did not miss out on messaging about prostate, testicular and penile cancer.
- Orchid's Freephone Confidential Helpline continued to provide a lifeline to those affected by any of the cancers we cover.
- Our unique telephone counselling service enabled those affected by penile and testicular cancer to deal with the challenges of a diagnosis and treatment undergone.
- We launched Take 3 – a series of short documentary drama films introduced by the case studies themselves.
- We increased investment in research with a grant awarded for a new area of prostate cancer research.

The dedication of our staff, trustees, volunteers, patient advocates, partners and those who shared their stories enabled the charity to achieve so much.

I would like to take this opportunity to thank everyone who helped us in any way and highlight our wonderful donors. We could not have reached and supported so many people without both existing loyal and new donors whose support we really value. Thank you to each and every supporter.

Ali Orhan, CEO




33,977 people learnt about prostate cancer through the awareness interventions of Orchid Community Champions and experienced volunteers



The year in review

More than 55,000 men are diagnosed each year in the UK with prostate, testicular or penile cancer, and sadly around 12,000 die. Thankfully, however, many more will recover. To save lives, Orchid worked tirelessly throughout the year to help people better understand male cancer risk factors, potential signs and symptoms, as well as the benefits of an early diagnosis.



We were excited to launch *Take 3*, a new series of films based on real patient experiences

Through our Nurse-led services we supported those living with a diagnosis, and we continued to invest in world-class male cancer research to benefit both current and future generations.

Orchid's Male Cancer Information Nurse Specialists gave personal support and guidance about concerns, the diagnostic pathway and treatment to those who called our confidential Freephone Male Cancer Helpline. This offers a joined-up service with some callers signposted to our unique testicular and penile cancer telephone service which offers a degree of anonymity to encourage men affected by these diseases to talk openly about their fears with a professional cancer counsellor. Peer support opportunities were delivered both virtually and in person.

As cancers found early are often the easiest to treat, education and awareness was a priority, especially as male cancer awareness remains low. We had a particular focus on reaching people from marginalised communities who may miss mainstream health messaging. 5,511 people had an opportunity to learn about male cancer by attending a Male Cancer Information Roadshow delivered in settings such as shopping centres and markets and in locations from Glasgow to Hastings, and Wakefield to Slough. Others had a chance to better understand their risk and what to look out for by attending talks and question and answer sessions in community groups or via our Health at Work programme.

Trans women are also at risk of prostate cancer, and we used the learnings from a focus group we ran with a group of trans women to inform a targeted series of social media posts. We also updated our website to make it more inclusive with the support of a charity trusted by the community.



The learnings from a focus group with trans women helped inform a targeted series of social media posts


We are grateful for the support we receive from volunteers who help us spread the word about male cancers. A London based volunteer reached 7,675 people with information during the year, and 26,302 people in ten different locations in England received prostate cancer information from our Volunteer Community Champions who were trained as part of our *Overcoming the Barriers to Engaging with Prostate Cancer* project. Our Champions include those with lived experience, healthcare professionals, residents in prisons and those who simply want to help.

Reaching people digitally has become increasingly effective and 2023's Male Cancer Awareness Week with its message of *Small Change, Big Difference*, and International Penile Cancer Awareness Day, were both driven by social media. In addition to the organic reach of social media during Male Cancer Awareness Week, paid advertising on Facebook enabled 236,970 people to see our message highlighting that responding to a concern about a change to your body quickly can make a big difference if cancer is detected.

Orchid's awareness activities are supported by a portfolio of online, paper based and film resources. December saw the launch of a new Orchid website to

provide more accessible information to men and their loved ones as well as to healthcare professionals. Demand for information on both the Orchid website and our Your Privates testicular cancer microsite remained high throughout the year.

We were excited to launch a new series of films called *Take 3* based on three real patient experiences to help inform men of all ages about the signs, symptoms and risk factors of prostate, penile and testicular cancers, and the need to seek help from a healthcare professional promptly if concerned. This was complemented by a new booklet describing nine real life encounters designed to get people thinking – and talking – about these male-specific cancers. Orchid had an advisory role in a short film called *Ignore It* which was produced by penile cancer survivor Mr Richard Stamp and funded by eUROGEN.



[A new booklet describing nine real life encounters was designed to get people thinking – and talking – about male-specific cancers](#)

Orchid works closely with eUROGEN a European organisation which is dedicated to improving the outcomes for rare urological conditions by enabling equitable access to diagnosis, treatment, and care for patients across Europe. Two penile cancer advocates supported by Orchid were involved in updating the current EAU Guidelines for penile cancer, a huge achievement, providing a much better recognition of the long-term issues which men may experience as a result of treatment and the need to expand the support which is currently available.


Orchid collaborated throughout the year with health and social care professionals, policy makers and other cancer charities to bring about positive change for men and their families. Examples include helping recruit Black African and Black Caribbean men to share their experience of prostate cancer on Prostate Cancer Research's new Infopool, and as part of our collaboration with the Testicular Cancer Network, Orchid Nurse Rob Cornes attended the National Germ Cell Meeting in Glasgow attended by around 130 clinicians and specialist nurses where he helped chair a session on how members are working together to save lives.

Funding research is vital to help understand why men develop male cancers and to improve the way in which they are diagnosed and treated. Orchid continued support for the Robert Lane Tissue Bank which is led by Professor Dan Berney whose work is focused on the pathology and natural history of prostate, testicular and penile cancer, translating basic research into practical treatments for patients with novel tests and bespoke predictive treatments. A grant was also agreed for new prostate cancer research to be funded by donations to the Innovation Research Project and which will begin in the new financial year.



December saw the launch of Orchid's new website to provide more accessible information to men and their loved ones as well as to healthcare professionals





350,906 accounts were reached
through Orchid's five social
media platforms

Fundraising

Orchid is committed to fundraising from diverse income streams to ensure adequate income is received to fund our work to save lives from prostate, testicular and penile cancers. A total of £730,024 was raised during the year, and we thank each and every one of our wonderful supporters who gave during the financial year, be they individuals, community groups, sports clubs, schools, companies, charitable trusts and foundations or The National Lottery Community Fund.



A new fundraising leaflet was developed to encourage donations

So many people supported Orchid during the year because they have been touched by male cancer themselves, or they raised funds in memory of loved ones. Payroll giving and both new and regular donors provided a valuable source of unrestricted income, as did the gifts given in Wills. A new fundraising leaflet was developed to encourage donations.

It is quite humbling to view people's dedication to our cause. This is why the Orchid team were there to cheer participants on at major events such as the London Marathon and Landmarks Half Marathon, as well as at Orchid's own events including our first Willy Waddle in Edinburgh and one in London. Our small fundraising team also helped and encouraged our many supporters from right across the UK who organised so many different fundraising activities such as cake sales, the Twyford



Orchid team were there to cheer on participants at major events such as the London Marathon and Landmarks Half Marathon

Beer Festival, a large beard competition, a new 'Bollox and Boots' event, a classic car event, or who challenged themselves via cycling, walking, climbing, or running events. Each person helped Orchid to make a difference.

There were some significant grants received during the year from Charitable Trusts and Companies towards delivering Nurse-led services to support those affected, to raise awareness through Male Cancer Information Roadshows in the heart of local communities, in faith settings and via social media, to develop new films, and to fund a new Four Nations Penile Cancer Programme to start in the new financial year. Funding was also received to fund male cancer research.

Incorporating learnings is important across the charity. Throughout the year Orchid staff and Trustees continued to review our fundraising activities and sought to identify new opportunities to ensure we retain as diverse and cost-effective fundraising base as possible to balance risk in the years ahead.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and putting supporters at the heart of all we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies. Orchid operates a clear and stringent complaints handling procedure that is reported to the Chief Executive and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to

help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves.

During the year we did not receive any complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

Small Change, Big Difference

Orchid's Male Cancer Awareness Week successfully raises the profile of prostate, testicular and penile cancer each year. In 2023 it was launched by Orchid Patron Steve Davis OBE, and included a fundraising ask for the first time.

The Week was themed *Small Change, Big Difference* and was delivered mainly digitally. Posts about each male-specific cancer across all social media platforms throughout the Week highlighted the small changes to men's bodies which could be a symptom of that cancer.

As well as highlighting the difference an early diagnosis can make, the posts also showed the difference making a donation or giving your small change to Orchid would make, linking donations to the Nurse-led services and the male cancer research the charity funds.

It also provided an opportunity for supporters to fundraise under the umbrella of Small Change, Big Difference.





Prostate Cancer
hesitancy 52,000 cases
urgency weak flow
frequency

Small change

Big difference
information
funding vital research
awareness
education
helpline
counselling

ORCHID
FIGHTING MALE CANCER

Make a big difference by donating this awareness week


 Registered with
THE FCA
REGULATOR
Registered in England No. 1000240
Company Registered in England No. 3963360

orchid-cancer.org.uk

Male Cancer Awareness week
11th - 17th September 2023

Orchid's Male Cancer Awareness Week provided an opportunity for supporters to fundraise under the umbrella theme of *Small Change, Big Difference*



A blurred background image showing a person in a blue sweater holding a white booklet or pamphlet. The person is seated at a table with a glass of water. The background is out of focus, showing other people and an indoor setting.

32,691 male cancer leaflets, booklets and posters were ordered or requested by individuals, companies, educators, and healthcare professionals

Our impact:

Prostate cancer

Over 52,000 people are diagnosed with prostate cancer in the UK annually, that's more than 140 every day. Sadly, there are 11,855 deaths from prostate cancer each year with 10-year survival at around 78%. According to CRUK, 1 in 6 UK males (born in the 1960s) will be diagnosed with prostate cancer in their lifetime, although the most commonly accepted statistic for general risk remains 1 in 8.

With more and more men being diagnosed with prostate cancer it is becoming more essential to correctly identify those who may be at risk of disease progression and those with mild or inactive disease. One of the interesting directions that this may take is so called liquid biopsies – the sampling of circulating cancer cells within the blood. Orchid has helped fund research into circulating tumour cells or CTCs and this method along with a more frequent use of MRI scans to identify potential areas of prostate cancer may improve medical assessment dramatically and reduce the side effects men may experience from cancer treatment.

In addition, those men with minimal risk of disease progression are likely to be managed by active surveillance. This is an option that is likely to increase dramatically over the next few years and one which Orchid has already created information about. Some men who are put on active surveillance may take 6-months or more to adjust to the fact that their cancer does not require immediate treatment and Orchid has responded to the need for information and support to help them.

One of the greatest challenges around prostate cancer remains the unequal risk of this cancer among Black African and Black Caribbean men who are twice as likely to develop prostate cancer than Caucasian men. Creating awareness in this community and helping support Black men diagnosed with prostate cancer is crucial. Although there are more than a hundred prostate cancer support groups in the UK, the Black community remains underrepresented.

A need also exists to reach trans women and non-binary people assigned male at birth with prostate cancer messaging, as they too can be diagnosed with this cancer.



Spotlight on Let's Talk Prostate Cancer Campaign

One in four Black African and Black Caribbean men will get prostate cancer in their lifetime, compared to one in eight Caucasian men, and tackling health inequalities is at the heart of Orchid's work.

Orchid was therefore proud to be invited by Astellas Pharma Limited to host a parliamentary workshop to hear from Black African and Black Caribbean men who are living with prostate cancer about their personal experiences of care.

The voices of these men informed the writing of the report *'1 in 4 Black men. Turning the tide on health inequalities in prostate cancer care'* with its important recommendations which are being considered by national parliamentarians and policy makers.

The workshop took place in March 2023 and all men present spoke with great passion about their prostate cancer journeys. Whilst there were many different experiences expressed, there was complete consensus that health inequalities associated with prostate cancer are not adequately prioritised or given the attention they should be.

Attendees felt men from diverse backgrounds could not easily engage with public prostate cancer messaging, and that they were not involved in their development. They found that the 1 in 4 statistic is not

sufficiently prominent. Messaging does not feature Black African and Black Caribbean men in images and it lacks cultural awareness / sensitivity. Furthermore, the men felt that the stigma around prostate cancer diagnosis and the use of a Digital Rectal Examination, and the potential side effects of treatment, which could both be barriers to engaging, have not been adequately addressed. Also expressed were the difficulties encountered asking GPs for a PSA test, which were often only offered based on age even when men highlighted their increased risk / family history.

Men also shared that there is a lack of easy to understand and culturally appropriate information at the point of diagnosis. This led to a lack of understanding about their treatment pathway and any potential side effects of treatment, and when they expressed a treatment preference, they felt their views were not always listened to and felt under pressure to have certain treatment.

The report, written taking the view of these men into account along with research of the prostate cancer policy landscape, sets out key recommendations to help push prostate cancer and the unequal risk of Black men up the agenda. The report has been well received and the recommendations are currently being discussed with parliamentarians and policy makers.

A photograph of a Black man with a warm smile, wearing a dark blue quilted puffer jacket. He is standing outdoors, with a blurred background showing a body of water and some structures. The lighting is natural, suggesting daytime. A blue rectangular box is overlaid on the bottom left of the image, containing white text.

7,041 people had a one-to-one
interaction with Orchid Community
Champion or volunteer



Our impact:

Penile cancer

Penile cancer is exceptionally rare in the UK with around 700 men being diagnosed each year. Around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.

Out of the three male-specific cancers, penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexual function.

Due to its intimate nature up to 50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics.

Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease - many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its rarity therefore missing out on invaluable peer support.

In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral. Orchid has therefore focused on the development of a telephone

counselling service to support men and wherever possible has created events to offer peer support, as well as supporting and encouraging allied healthcare professionals in the creation of regional support groups.

With 83 cases a year, there is a higher incidence of penile cancer in Scotland in comparison to the rest of the UK, and those affected by penile cancer in Scotland are also being diagnosed at a younger age. A penile cancer diagnosis can be psychologically devastating, and treatment can be challenging especially if the diagnosis has been made at a late stage. Orchid has significant experience of educating people about the signs and symptoms of penile cancer, as well as understanding the complex issues involved in supporting penile cancer patients.

Whilst we do not as yet know why Scotland has a higher incidence proportionally than the rest of the UK, we do know that many people have not heard of penile cancer, let alone know what potential symptoms might be. This is why Orchid identified the need to deliver a project to put penile cancer on the agenda in Scotland, and whilst delivery of this specific piece of work is complete, many of the elements have now been brought into Orchid's core services.

We are delighted that funding has been received to deliver the Four Nations Penile Cancer programme from October 2023. The aim of this Nurse-led initiative is to raise the profile of penile cancer in the UK and improve support for anyone who has been affected by the disease.



Spotlight on Penile cancer animation for EAU

Over the last few years, Orchid Nurse Rob Cornes has been working collaboratively with both the European Reference Network for Rare Urogenital Disease (ERN eUROGEN) and the European Association of Urology Patient Advocacy Group (EAU EPAG), part of the EAU Patient Office initiative.

The Patient Office is dedicated to promoting advocacy for patients being treated for urological conditions. Rob is a patient advocate for testicular and penile cancer for both these groups.

Last year with the help of Orchid, the EAU Patient Office received funding from eUROGEN to create an informative animated video discussing penile cancer to complement the EAU video library of urology.

A script was written by Orchid Nurse Rob which was then reviewed by three urology consultants specialising in penile cancer treatment. Once the script had been finalised it was also reviewed by a lay person panel and then put into production.

The aim was to include both an informative and honest overview of penile cancer diagnosis and treatment, as well as information about potential side effects in lay person's terms. It describes the most common approach to diagnosing and treating penile cancer.

Rob was particularly delighted to be able to include a section which promotes the need for men diagnosed with penile cancer to obtain psychological support.

As part of the funding a Spanish language version was also created.

Both animations have proved extremely popular with a combined viewing of around 20,000 views, as well as over 50 positive comments from both urologists and patients who have viewed it.



5,511 people had the opportunity to learn about male cancer by attending an Orchid Male Cancer Information Roadshow.



Our impact:


Testicular cancer

Testicular cancer is rare with around 2,300-2,400 diagnoses each year in the UK. Around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of those diagnosed between the ages of 15-45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life. Treatment occurs quickly with men often being diagnosed and treated within a few weeks. As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects, chemotherapy can increase the risk of cardiovascular disease in later life.

Challenges around testicular cancer involve supporting men in adjustment to life following treatment. Many men will only realise the full implication of their cancer journey when treatment ends and may not be able to access either peer support or psychological support.

Orchid has consistently supported the biggest testicular cancer support group in the UK, which is coordinated by several Specialist Nurses in London, both physically and virtually. In addition, the creation of Orchid's telephone counselling service allows men to access psychological support without the necessity of waiting for extended periods of time. Orchid also continues to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the UK.



Spotlight on The Know Your Body Project

Partnership working is important for Orchid to ensure we reach as many people as possible at risk of testicular cancer. The charity was therefore proud to work collaboratively with Ansar Projects and CoppaFeel! to create a series of accessible resources about testicular and breast cancer for people with learning disabilities.

49% of all deaths in people with a learning disability are deemed to be avoidable and 8% of these deaths were caused by cancer (The London King's College Learning from Lives and Deaths – People with a learning disability and autistic people LeDeR 2021 report).

The 'Know Your Body' resources were launched in October 2022 and are the first of their kind. These new resources were developed in response to the need for information for people with a learning disability to know their body and to seek medical advice when they notice changes at an earlier stage.

They include accessible testicular and breast cancer information packs, self-checking cards, testicular and breast cancer symptom guides, self-checking social stories and information on what to expect if you notice a change.

The 'Know Your Body' accessible resources were shortlisted as a finalist in the Breaking Down Barriers award at the 2023 National Learning Disabilities and Autism Awards.

We were also pleased that the resources were referenced in the *Learning from lives and deaths – People with a learning disability and autistic people (LeDeR) Action from learning report 2022/23*, taking the resources to a wider audience.

Our impact:

Research

Orchid was pleased to continue to support the work of the Robert Lane Tissue Bank during the year.

Highlights of the year

Over 30 papers were published from the group in the year. Many of these relate to work done on tissue from the Robert Lane Tissue Bank in the past and donated over 10 years ago yet still in clinical use. Professor Berney now has over 300 papers.

Prostate cancer

In collaboration with Professor G Attard at University College London the team have processed 700 cases from the groundbreaking STAMPEDE clinical trial which aims to assess new treatment approaches for people affected by high-risk prostate cancer. Ms Larissa Mendez who is a histopathologist passed her PhD in September 2023 on this cohort and numerous publications are planned.

Further work continues to be published from the Trans-Atlantic prostate group cohort into early-stage prostate cancer, with a publication on how best to measure the size of prostate cancer in biopsies that will affect management.

The team are delighted to announce a collaboration with the Institute of Cancer Research to collect further samples of prostate cancer from recent clinical trials. This will support Orchid work and will focus (among others) on the PACE-B trial which found that men undergoing treatment for prostate cancer could be safely given far less radiotherapy.

Testis cancer

The main success of the year in the field of testis cancer was the publication of the first paper from the collaboration with a team at the University of Copenhagen in Denmark into risk factors to predict whether testis cancer will come back and whether chemotherapy should be offered in seminoma (a common type of testis cancer). This paper was published in September 2023 in the highly prestigious Journal of Clinical Oncology. This work will directly affect the decisions on who gets chemotherapy after removal of the cancer in surgery. This figure from the paper shows how testicular seminoma can be stratified into separate groups. The low-risk groups can be treated expectantly while the high risk groups might consider chemotherapy.

Professor Berney is lead for the testis International Collaboration on cancer reporting. This work ensures that pathology reports on testis cancer are standardised worldwide.

With the support of both the Genito-Urinary Pathology Society (GUPS) and the International Society of Urological Pathologists (ISUP), Professor Berney has set up a new group to examine the 'sex cord stromal tumours' of the testis. These rare tumours are not well understood, may be malignant and are resistant to treatment. He is the lead on an international meeting in Baltimore in 2024 about these tumours and hopes to make advances in this challenging area.

The Robert Lane Tissue Bank is led by Professor Dan Berney who is one of the world's leading genito-urinary pathologists. The Tissue Bank carries out translational work which aims to link molecular and pathological data with clinical trials. The aim of the team is to curate a bespoke Tissue Bank concentrating on the three male cancers. In summary, it:

- holds over 9,000 male-specific cancer tissue samples to facilitate understanding of prostate, testicular and penile cancers, from the potential causes, through to how they are diagnosed, treated, and possibly prevented.
- houses one of the largest collections of penile cancer tissues in Europe, one of the largest testicular tissue banks in the world, and is custodian of the largest series of untreated prostate cancers globally.
- collaborates with research on an international scale, as well as conducting its own pathological and molecular research into penile, prostate, and testicular cancer.
- works in collaboration with other Orchid funded research projects.
- is committed to the ethical collection, processing, and storage of samples. Renewal of their research ethics is due in 2024.
- has major external collaborations with prestigious research bodies such as The Institute of Cancer Research, The Rigshospitalet in Denmark, University College London, Memorial Sloan Kettering Hospital, Indiana University Hospital, The Cleveland Clinic, and The Karolinska Institute.
- is a valuable source of information for students and specialist researchers wanting to learn more about male cancers; as well as being accessible to lay visitors.
- focuses on samples where outcome data is available from clinical trials. Advances in technology increasingly allow high quality sequencing and molecular work in these media.

Professor Dan Berney

- Professor Berney is Editor in Chief of Histopathology, a leading journal in the field. He is Past Secretary of the International Society of Urological Pathologists (ISUP), Past Secretary and President of the British Society of Urological Pathologists (BAUP) and Past International Secretary of the British Division of the International Academy of pathologists (BDIAP).
- He is the expert pathology lead on testis for the European Association of Urology and helping with their clinical guidance.
- He has received from the International Society of Urological Pathology, The Gleason Medal, and from the British Division of the International Association of Pathology, he received the Cunningham Medal in November 2023.
- Professor Berney was co-editor of the 5th edition of the classification of GU-tumours and led on the testis classification for the World Health Organisation.
- He has a strong social media presence being one of a select number of uro-pathologists with over 3,000 followers @daniel_berney. He has lectured throughout the world, especially in the USA and also Africa, to improve prostate cancer diagnosis.
- He is Visiting Professor at Manipal Medical College in India and has been invited to be Visiting Professor at the Cleveland Clinic in Ohio.
- Professor Berney has over 300 peer reviewed publications and numerous book chapters on urological pathology. He has an H score of 84 (i.e. he has published 84 articles each of which has been cited at least 84 times) and his work has been cited over 15,000 times. Furthermore, he had 23 publications in the last 18 months.

Professor Yong-Jie Lu

- Professor Yong-Jie Lu whose work Orchid has previously supported is the scientific lead on the Robert Lane Tissue Bank Governance Committee.
- He has supervised the day-to-day running and maintenance in the past year, while running his research team on prostate cancer circulating biomarker development.





33,100 male cancer leaflets, booklets and posters were distributed through awareness activities such as Roadshows, Volunteer Community Champion community outreach, talks and presentations

The year ahead

Cancers diagnosed at an early stage are more likely to be treated successfully which means that raising awareness of the risk factors, signs and symptoms and the benefits of an early diagnosis remained a priority as we entered the new financial year. All work will be delivered in line with our organisational Strategy October 2022 to September 2026. Funding has been received and plans are in place to deliver several new and transformational initiatives, and to further develop existing work.

Keeping the faith

We will be working with faith leaders in London to raise awareness of prostate cancer amongst the Black African and Black Caribbean men in their congregations who are at increased risk of this cancer and we will equip them to better support those living with a diagnosis. We are also planning a social media campaign around the theme of “Warn a Brother” to encourage Black African and Black Caribbean men to share information about prostate cancer with their friends and family.

Orchid on film

Films are in development to highlight prostate cancer and to get people talking about this cancer which affects over 52,000 people each year. We will also increase our outreach to trans women to make sure they gain a better understanding of their prostate cancer risk and know the support and information available to them including from Orchid.

On the road again

Male Cancer Information Roadshows are an established part of our community outreach, through which we take information right into the heart of communities. These will be delivered in targeted communities as funding becomes available. We will continue to offer male cancer talks and presentations to community groups and one priority for the year will be to deliver talks to the Deaf community supported by a British Sign Language interpreter to reduce inequality.

We are the champions

We will also continue to recruit, train and support Volunteer Community Champions as part of the National Lottery Community Fund project “Overcoming the Barriers to Engaging with Prostate Cancer”. Our Champions cascade important messages in their own

communities and workplaces, and we will explore how this work can be sustainable after funding for the project ends in May 2024, including upskilling Champions further about testicular and penile cancer alongside their knowledge of prostate cancer. Independent evaluation has been running throughout the project, and learnings will be shared with stakeholders and interested parties via a report after the project ends.

A week and a day

Orchid’s Male Cancer Awareness Week will take place between 16-22 September 2024, with International Penile Cancer Awareness Day on 20 September 2024.

Helpline focus

Supporting those affected by male cancer is also a high priority for the coming year. We are exploring increasing the hours of our Freephone National Male Cancer Helpline with the aim of missing fewer calls. Our commitment to delivering and co-facilitating peer support opportunities both in person and virtually remains, and we will continue to offer a telephone counselling service to those affected by penile or testicular cancer.

Four Nations

A new Four Nations Penile Cancer Programme started at the beginning of October led by Sinéad Collins who joined Orchid as a Male Cancer Information Nurse Specialist – Penile Cancer. Through this programme we will raise the profile of penile cancer in the UK and improve support for anyone who has been affected by the disease.

Improved patient journey

Orchid Nurse Rob Cornes will continue to work with healthcare professionals both in the UK and beyond to improve the patient journey for those affected by male

cancer. Orchid resources and services will be promoted throughout the year to healthcare professionals working in the relevant fields throughout the UK. Rob Cornes plans to work with the Testicular Cancer Network to produce an evidence-based guideline for testicular self-examination in the coming year.

Supported by penile cancer patient advocates, Rob Cornes, who is a member of the European Association of Urology Patient Advocacy Group and the European Reference Network eUROGEN European Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid, will continue to work to improve the patient experience for those affected by these two rare cancers. This work will include being involved in the updating of the European Association of Urology Testicular Cancer Guidelines as a patient advocate.

More social

Social media will be used to relay male cancer messages, promote our educational films, to drive followers to the Orchid website / Your Privates testicular cancer microsite, to view, order or download resources and to help promote fundraising activities. The number of followers on all platforms has increased, and we aim to grow this further. Activity is planned incorporating learnings of the last year where we saw most reaction in response to personal stories and awareness.

Rooted in research

Orchid's roots are in male cancer research, and we will continue to invest in innovative research. Trustees have agreed new funding for the year for the Robert Lane Tissue Bank, led by Professor Dan Berney MB B Chir, MA, FRCPath which is an internationally important resource for research into penile, testicular, and prostate cancer. Funding has also been agreed for new research into the characterisation of the anaerobic microbiome

and genomic methylation status of prostate cancer patients experiencing active Vitamin D and K2 deficiency: prevention, risk stratification, diagnosis, and treatment potential, led by Dr Belinda Nedjai.

Measuring up

In the coming year we will be working to improve the way in which we measure activities and their impact so we can better evidence the difference our work makes.

Orchid recognises its responsibility to reduce its carbon and environmental footprint and will continue to monitor its activities in relation to our Environmental Policy.

Diverse income streams

Led by a new Head of Fundraising, our fundraising strategy for 2023-2024 will focus on generating income from diverse income streams to secure adequate funding at the best possible return on investment to ensure we can deliver plans for the years ahead. We will also explore new income generating opportunities and encourage people to take part in our unique Willy Waddles planned for Edinburgh and London in the summer months. Applications will be submitted to Charitable Trusts and Foundations on a rolling basis, carrying out research to identify new potential supporters. We will work in partnership with our corporate supporters to meet their needs as well as Orchid's.

Orchid's work is only possible because of the generosity of our supporters, and we will look after them in every way we can. We will continue to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and all the individuals and community groups who support us with donations and fundraise on our behalf. We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead.



2,893 men, women and healthcare professionals had in-depth support or information directly from an Orchid Nurse / Male Cancer Information Manager



Governance

Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK.

Objects, operating context and activities

Objects

Over 55,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly this number is increasing. Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and

information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair's aim to maintain a balanced composition. Trustees acknowledge the need to increase diversity on the Board and are exploring the best ways to do this. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from office in rotation, in order of longevity of appointment and are eligible to be reappointed.

Trustees continued to meet virtually for most meetings held during 2022-2023.

Trustee training and induction

On appointment, Trustees are offered a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Delegation and decision-making

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance Committee is responsible for the financial oversight of the Charity including budgeting, financial planning and monitoring as well as financial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at 30 September 2023, it comprised the Honorary Treasurer, Mr W Cohen,

Mr C Osborne, Mr M Kibblewhite, Mr S Seymour and Mr S Harris.

- At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept apprised of personnel, awareness, research programme and budgetary issues.

Public benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit including (PB2 Public Benefit: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation's strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the verification of outcomes, a Scientific Advisory Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identifies risks under the following headings:

Governance and compliance

Operational

Financial

Research

Environmental/external

Quality assurance

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not

less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified. These are as follows:

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to

Mitigation

- An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and financial, are covered by suitably qualified professionals
- Training and support for Board of Trustees and Finance Committee
- Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
- Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

- Annual salary review to include benchmarking of compensation and benefits
- Staff development, training and succession planning programmes
- Communication programme to ensure staff are involved in the development of and progress towards Orchid's strategy and annual workplan

Financial

Economic pressures, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

Mitigation

- Annual budgeting and ongoing management, reporting and monitoring of financial performance
- Diversification of income streams
- Ongoing consideration of market and consumer trends and regulations including GDPR

Research

Orchid's Research Programme fails to deliver results

Mitigation

- Scrutiny and approval of research funding applications by an expert Scientific Advisory Board
- Annual review of progress

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid's work

Mitigation

- Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
- Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
- Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid's strategy

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

- Services developed, delivered and evaluated in line with agreed protocol and standards
- Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)
- All information materials and content regularly reviewed and updated
- High-quality training for staff

Financial review

Results for the year

Income for the year ended 30 September 2023 totalled £730,024 (2022: £841,808). After total expenditure of £634,721 (2022: £740,252), the year's activities show a net surplus of £95,303 (2022: surplus of £101,556). Total reserves at the end of the year amounted to £637,139 (2022: £541,836).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity's core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available free reserves net of tangible and intangible fixed assets are £157,287 (2022: £162,113). It is the Charity's policy to maintain free reserves of approximately 3–4 months of operating costs. At current levels of expenditure this equates to £155,000–£212,000.

Formal statements Statement of Trustees' responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiner's information

So far as each of the directors at the time the Trustees' report is approved is aware:

- a) there is no relevant information of which the examiner is unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees



C S Osborne
Chairman of Trustees
12/06/24

Independent Examiner's Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2023.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ("the 2011 Act"). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145 (5) (b) of the 2011 Act.

Independent examiner's statement

Since the Company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Adam Fullerton FCA DChA

Date: **19 June 2024**

For and on behalf of
Moore Kingston Smith LLP
Chartered Accountants
6th Floor, 9 Appold Street,
London
EC2A 2AP

Statement of financial activities

(incorporating an income and expenditure account)

For the year ended 30 September 2023

	Note	Unrestricted Total £	Restricted Total £	Year ended 30 September 2023 £	Year ended 30 September 2022 £
Income from:					
Donations and Legacies	2	310,632	257,150	567,782	674,700
Charitable Activities	4	-	160,850	160,850	166,673
Trading Activities		272	-	272	309
Investment income		1,120	-	1,120	126
Total income		<u>312,024</u>	<u>418,000</u>	<u>730,024</u>	<u>841,808</u>
Expenditure on:					
Raising funds					
Fundraising (donations and grants)	5	163,449	-	163,449	185,431
Charitable Activities					
Education and Awareness	5	131,385	288,636	420,021	376,842
Research	5	15,605	35,646	51,251	177,979
Total expenditure		<u>310,439</u>	<u>324,282</u>	<u>634,721</u>	<u>740,252</u>
Net income / (expenditure) and net movement in funds	5,6	1,585	93,718	95,303	101,556
Reconciliation of funds					
Total funds brought forward		<u>297,016</u>	<u>244,820</u>	<u>541,836</u>	<u>440,280</u>
Total funds carried forward		<u>298,601</u>	<u>338,538</u>	<u>637,139</u>	<u>541,836</u>

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 14 to the financial statements.

Balance sheet

As at 30 September 2023

	Note	£	30 September 2023 £	£	30 September 2022 £
Fixed Assets					
Tangible Assets	10		3,340		3,891
Intangible fixed assets	11		16,166		9,204
Current Assets					
Cash at bank and in hand		630,903		590,444	
Debtors	12	67,957		108,806	
		698,860		699,250	
CREDITORS					
Amounts due within one year	13	(81,227)		(170,509)	
Net Current Assets			617,633		528,741
Total Assets less Current Liabilities	14		637,139		541,836
NET ASSETS			637,139		541,836
Represented by:					
General Unrestricted Funds		176,793		175,208	
Designated Funds		121,808		121,808	
			298,601		297,016
Restricted funds			338,538		244,820
			637,139		541,836

The company is limited by guarantee.

For the year ending 30 September 2023 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 12/06/24 and signed on its behalf by:



Mr C S Osborne
Company number 3963360

Statement of cash flows

For the year ended 30 September 2023

	2023 £	£	2022 £	£
Cash flows from operating activities:				
Net income for the year	95,303		101,556	
Adjustments for:				
Depreciation charges	5,338		1,944	
Interest	(1,120)		(126)	
Decrease / (increase) in debtors	40,849		(31,481)	
(Decrease) / increase in creditors	(89,282)		21,639	
Net cash provided by operating activities	51,088		93,532	
Cash flows from investing activities:				
Interest	1,120		126	
Purchase of fixed asset	(11,749)		(12,068)	
Net cash (used in) investing activities		(10,629)		(11,942)
Change in cash and cash equivalents in the year		40,459		81,590
Cash and cash equivalents at the beginning of the year		590,444		508,854
Cash and cash equivalents at the end of the year		630,903		590,444
Analysis of cash and cash equivalents				
Cash at bank and in hand		630,903		590,444
		630,903		590,444

Notes to the financial statements

1. Accounting policies

For the year ended 30 September 2023

Basis of Preparation

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements. In particular the trustees have considered the charities forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2023/24 however that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing its financial statements.

The trustees confirm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its financial statements.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment - 33 $\frac{1}{3}$ % on written down value.

Intangible fixed assets and Amortisation

Intangible fixed assets and Amortisation
Intangible fixed assets are included in the balance sheet at original cost less accumulated amortisation.

Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the number of years of expected use. Assets are amortised at the following rate:

Website - 20% on straight line value

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity's objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity's objects.

Governance costs are those incurred in connection with the management of the Charity's assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been

allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension Scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee's services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

2. Donations

Current year			Year ended 30 September 2023	Year ended 30 September 2022
	Restricted £	Unrestricted £	Total £	Total £
Individuals	500	57,512	58,012	186,887
Legacies	-	19,147	19,147	100,000
Corporates	-	76,601	76,601	36,814
Trusts and Foundations	256,650	7,978	264,628	209,721
Fundraising Events	-	149,394	149,394	141,278
Total	257,150	310,632	567,782	674,700
Prior year			Year ended 30 September 2022	
	Restricted £	Unrestricted £	Total £	
Individuals	68,800	118,087	186,887	
Legacies	-	100,000	100,000	
Corporates	-	36,814	36,814	
Trusts and Foundations	165,121	44,600	209,721	
Fundraising Events	-	141,278	141,278	
Total	233,921	440,779	674,700	

3. Fundraising events

Current year	Year ended 30 September 2023			Year ended 30 September 2022	
	Restricted £	Unrestricted £	Total £	Total £	
Cycling events	-	2,296	2,296	658	
Running events	-	68,852	68,852	68,646	
Third party organised events	-	63,886	63,886	62,806	
Trek	-	92	92	-	
Other	-	14,268	14,268	9,168	
Total	-	149,394	149,394	141,278	

Prior year	Year ended 30 September 2022			Year ended 30 September 2021	
	Restricted £	Unrestricted £	Total £	Total £	
Cycling events	-	658	658	-	
Running events	-	68,646	68,646	68,646	
Third party organised events	-	62,806	62,806	62,806	
Other	-	9,168	9,168	9,168	
Total	-	141,278	141,278	141,278	

4. Charitable activities

Current year	Year ended 30 September 2023			Year ended 30 September 2022	
	Restricted £	Unrestricted £	Total £	Total £	
The National Lottery Community Fund RC England-wide	160,850	-	160,850	166,673	
Total	160,850	-	160,850	166,673	

Prior year	Year ended 30 September 2022			Year ended 30 September 2021	
	Restricted £	Unrestricted £	Total £	Total £	
The National Lottery Community Fund RC England-wide	166,673	-	166,673	166,673	
Total	166,673	-	166,673	166,673	

5. Total expenditure

	Cost of raising funds £	Education and Awareness £	Research £	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Grants	-	-	18,519	18,519	149,222
Staff costs	80,542	162,814	21,298	264,654	240,059
Fundraising expenses	39,663	-	-	39,663	68,941
Information materials	-	126,256	-	126,256	98,605
Direct costs	-	33,511	-	33,511	38,393
	120,205	322,581	39,817	482,603	595,220
<i>Support costs</i>					
Depreciation	1,499	3,443	396	5,338	1,944
Other	33,124	76,047	8,759	117,930	117,654
Governance - staff costs	6,725	13,596	1,778	22,099	18,936
Governance - examiners fees	1,896	4,354	501	6,751	6,498
	43,244	97,440	11,434	152,118	145,032
Total expenditure	163,449	420,021	51,251	634,721	740,252
Prior year	185,431	376,842	177,979	740,252	

6. Grants awarded

	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Grant commitments brought forward	126,617	87,576
Institutional grants for medical research awarded during year/period		
Orchid Study and Travel Awards (2023: 2 individuals, 2022: 2 individuals)	1,000	2,000
Barts and London School of Medicine	35,646	144,652
Write off	(18,128)	
Payments made during period/year	(108,489)	(107,611)
Grant commitments carried forward	36,646	126,617
Payable less than one year	36,646	126,617
Payable two to five years	-	-

7. Net expenditure for the period

This is stated after charging:	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Depreciation	2,400	1,944
Independent examiners' remuneration:		
Independent examination	5,435	5,415
Trustees' remuneration	Nil	Nil

8. Staff costs and numbers

Staff costs were as follows:	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Salaries and wages	235,955	205,290
Social security costs	18,666	16,414
Pension contributions	2,122	1,616
	256,743	223,320
Consultant costs	30,010	35,675
Total cost	286,753	258,995

During the year ended 30 September 2023, 1 employee earned more than £60,000 (Year to 30 September 2022: 1). The pension contribution paid in respect of this employee totalled £Nil (2022: £Nil).

The key management personnel of the charity comprise the trustees and the chief executive.

The charity trustees do not receive remuneration. The total remuneration of the chief executive was £83,579 (year ended 30 September 2022: £78,802).

The number of employees whose emoluments amounted to over £60,000 in the year (exclusive of employer pensions and employer National Insurance contributions) was as follows:

	2023 No.	2022 No.
£60,000–£69,999	-	1
£70,000–£79,999	1	-

The average number of employees during the year was 7.4 (2022: 7.5)

The average number of employees during the year on a headcount basis was as follows:

	2023 No.	2022 No.
Fundraising	1.7	1.7
Education and Awareness	5.4	5.5
Grant support	0.3	0.3
Overall average	7.4	7.5

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Tangible fixed assets

	Computer and office equipment	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Cost			
At the start of the period	10,179	10,179	7,315
Additions	745	745	2,864
At the end of the period	10,924	10,924	10,179
Depreciation			
At the start of the period	6,288	6,288	4,344
Charge for Period	1,296	1,296	1,944
At the end of the period	7,584	7,584	6,288
Net book value			
At the end of the period	3,340	3,340	3,891
At the start of the period	3,891	3,891	2,971

11. Intangible fixed assets

	Website development	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Cost			
At the start of the period	9,204	9,204	-
Additions	11,004	11,004	9,204
At the end of the period	20,208	20,208	9,204
Amortisation			
At the start of the period	-	-	-
Charge for Period	4,042	4,042	-
At the end of the period	4,042	4,042	-
Net book value			
At the end of the period	16,166	16,166	9,204
At the start of the period	9,204	9,204	-

12. Debtors

	Year ended 30 September 2023	Year ended 30 September 2022
	Total	Total
	£	£
Prepayments	7,439	10,071
Other debtors and accrued income	60,518	98,735
	67,957	108,806

13. Creditors: amounts due within one year

	Year ended 30 September 2023	Year ended 30 September 2022
	Total	Total
	£	£
Grants Payable	35,646	126,617
Trade and Other Creditors	11,424	11,113
Accruals	34,157	32,779
	81,227	170,509

14. Movements in funds

	Brought forward	Income	Expenditure	Carried forward
	£	£	£	£
Unrestricted				
General	175,208	312,024	(310,439)	176,793
Designated – Development	121,808	-	-	121,808
Total unrestricted	297,016	312,024	(310,439)	298,601
Restricted				
The National Lottery Community Fund - Overcoming the Barriers	40,796	160,850	(172,616)	29,030
Male Cancer Nurse Information Specialist	3,600	16,000	(19,600)	-
The Innovation Research Project	154,180	1,957	-	156,137
Penile Cancer Peer Support	1,000	760	(195)	1,565
Education and Awareness	33,655	19,858	(49,513)	4,000
Student Study and Travel Scholarships	4,729	-	(1,000)	3,729
Roadshows	6,860	37,875	(44,735)	-
Robert Lane Tissue Bank	-	48,700	(35,646)	13,054
Nurse Led Services	-	2,000	-	2,000
Four nations penile cancer programme	-	130,000	(977)	129,023
Total restricted	244,820	418,000	(324,282)	338,538
Total funds	541,836	730,024	(634,721)	637,139

14. Movements in funds (continued)

Prior year movements in funds	Brought forward £	Income £	Expenditure £	Carried forward £
Unrestricted				
General	157,158	441,214	(423,164)	175,208
Designated – Development	121,808	-	-	121,808
Total unrestricted	278,966	441,214	(423,164)	297,016
Restricted				
The National Lottery Community Fund - RC England-wide	32,445	166,673	(158,322)	40,796
Male Cancer Nurse Information Specialist - other funders	8,252	12,100	(16,752)	3,600
The Innovation Research Project	92,800	68,700	(7,320)	154,180
Penile Cancer Peer Support	-	8,500	(7,500)	1,000
Education and Awareness	5,000	58,950	(30,295)	33,655
Student Study and Travel Scholarships	6,729	-	(2,000)	4,729
Roadshows	2,860	42,871	(38,871)	6,860
Robert Lane Tissue Bank	-	42,800	(42,800)	-
Young Person's Testicular Cancer Project	3,228	-	(3,228)	-
City of London Corporation	10,000	-	(10,000)	-
Total restricted	161,314	400,594	(317,088)	244,820
Total funds	440,280	841,808	(740,252)	541,836

General funds are unrestricted funds available for use at the Trustees' discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

15. Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total funds at 30 September 2023 £
Fixed Assets	3,340	-	3,340
Current Assets	376,490	338,538	715,028
Creditors due within one year	(81,229)	-	(81,229)
Net assets at 30 September 2023	298,601	338,538	637,139
Prior year analysis of net assets between funds			
Fixed Assets	13,095	-	13,095
Current Assets	454,430	244,820	699,250
Creditors due within one year	(170,509)	-	(170,509)
Net assets at 30 September 2022	297,016	244,820	541,836

16. Related party transactions

Aggregate donations of £500 were received from trustees in the year ended 30 September 2023.
(Year to 30 September 2022: £52,500).

17. Financial commitments

For the year ended 30 September 2023, the charity was committed to making the following future payments under non cancellable operating leases.

	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
<i>Land and buildings</i>		
Expiring within one year	15,637	14,184
Expiring within two to five years	-	-
	15,637	14,184

18. Capital commitments

At the year ended 30 September 2023, the charity had no capital commitments (2022: £9,204).

ORCHID CANCER APPEAL

England & Wales - Charity number 1080540

Accounts

Fighting male cancer

Orchid Cancer Appeal

Annual report and
financial statements
2021-2022

Orchid Cancer Appeal

Annual report and
financial statements
2021-2022

Board of Trustees

Mr CS Osborne Chair
 Mr W Cohen Treasurer
 Mr D Badenoch
 Mr PG Bracher
 Mr S Harris
 Mr M Kibblewhite
 Professor RTD Oliver
 Mr P Norman
 Mr S Seymour
 (resigned 1 January 2022)
 Mr N Watkin
 (resigned 7 December 2021)
 Mr B Ayres
 (appointed 22 June 2022)

Chief Executive

Mr A Orhan

Independent Examiner

Moore Kingston Smith LLP
 6th Floor, 9 Appold Street,
 London EC2A 2AP

Accountants

JS2 Limited
 1 Crown Square, Woking,
 Surrey GU21 6HR

Legal advisors

Farrer & Co
 66 Lincoln's Inn Fields,
 London WC2A 3LH

Bankers

HSBC Plc
 20 Electric Parade,
 George Lane,
 South Woodford,
 London E18 2LX

Registered Office

60 Gray's Inn Road,
 London WC1X 8AQ

Tel 020 3745 7310
www.orchid-cancer.co.uk

Registered in England with the
 Charity Commission No.1080540

Company Limited by Guarantee
 Registered in England
 No. 3963360

Inside this report:

	Welcome	CEO's letter	The year in review	Fundraising	Our impact	The year ahead	Governance	Financial review
--	---------	--------------	--------------------	-------------	------------	----------------	------------	------------------

Welcome	6
CEO's letter	7
1. The year in review	8
2. Fundraising	16
3. Our impact	20
Prostate cancer	22
Testicular cancer	24
Penile cancer	26
Research	28
4. The year ahead	30
5. Governance	36
Objects, operating context and activities	38
Structure, Governance and Management	38
6. Financial review	42
Formal statements	44
Independent Examiner's information	45
Independent Examiner's Report	46
Statement of financial activities	47
Balance sheet	48
Statement of cash flows	49
Notes to the financial statements	50

Welcome from our Chair

Orchid has again worked tirelessly throughout the year, to support those affected by prostate, testicular or penile cancer. As well as to help people understand the risk factors of male cancers and to prevent the worst prognoses in the future.

To this end, we have continued to invest in world-class male cancer research to benefit both current and future generations of men. Orchid's roots are in male cancer research, our past studies have significantly advanced the understanding of male cancers. Building on this, the Trustees and I agreed further funding for the Robert Lane Tissue Bank. Led by Professor Dan Berney MB B Chir, MA, FRCPath, the work focusses on translating research into practical interventions for patients via novel tests and bespoke predictive treatments.

Led by our CEO Ali Orhan, in his capacity as Director. Orchid has made excellent progress on our three-year programme: 'Overcoming the Barriers to Engaging with Prostate Cancer', funded by the National Lottery Community Fund. Through this substantial piece of work, Orchid will be reaching men at high risk and in some of the most deprived areas of the country.

Work is ongoing to increase the number of peer support opportunities in collaboration with a variety of other organisations. This is as an effective and personal way to provide information and support to those affected by a male specific cancer. Orchid's collaborative working approach means that Orchid not only shares its expertise, but reaches more men and relevant healthcare professionals, with our information and advice. One highlight next year will be our Specialist Nurse Rob

Cornes, presenting a session at the European Association of Urology (EAU) conference in Milan in 2023, together with Orchid's patient advocates.

Securing funding in these tricky times has become more of a challenge, and we expect this to continue. However, I am delighted to report that Orchid increased its fundraising effort as per our strategy and gained a significant increase in income, which puts us on secure ground to continue our work.

Orchid's work is only possible because of the dedication of our staff, the commitment of our volunteers and the generosity of our supporters. The trustees and I are incredibly grateful to everyone who contributed towards our efforts in the last year, and offer a warm welcome to those who will support us in the year ahead.

Colin Osborne MBE

CEO's letter

It was a successful year of delivering against our objectives. As we emerged from COVID-19 restrictions, we were able to reach those at risk, especially people from marginalised communities, by delivering our Male Cancer Information Roadshows in the heart of local communities, reaching over 8,000 people with information and support.

We were able to maintain increased operational hours for Orchid's confidential Male Cancer Helpline and therefore sent a greater number of referrals to the penile and testicular cancer telephone counselling service. The Overcoming the Barriers to Engaging with Prostate Cancer project is fully underway and almost 4,500 people received prostate cancer information from Orchid's trained Volunteer Community Champions. We are extremely grateful to the Task-Force members who help to drive this project. Orchid also identified the need to reach out to trans women who may be at risk of prostate cancer, and we thank the National Lottery Awards for All England for their grant to begin this work.

We worked in many collaborative partnerships this year such as with breast cancer charity CoppaFeel! to produce posters for schools to raise awareness of breast and testicular cancer. We also inputted into a series of four new videos about testicular health by the British Fertility Society.

As we look forward, Orchid will be aiming for excellence in its health information and the team will be reviewing our information assets to ensure that it is the most up to date

and that it achieves the PIF TICK quality mark for UK health information.

We want to ensure that information about the three male-specific cancers, our resources and Nurse-led support services reaches more people via the development of a new Orchid website and our social media platforms. We already use online and digital platforms to good effect to disseminate male cancer messages, promote educational films, encourage people to view and download information, inspire people to donate and also access further services and support, and we want to build further on this.

As we face an uncertain economic climate in the UK, Orchid will continue to keep a diversified fundraising strategy by including individuals as well as Corporate and Charitable Trust supporters.

I am extremely grateful to those who have made our successes possible – not only our dedicated staff, trustees, volunteers, and patient advocates, but also our donors, Corporate partners, new and existing loyal supporters, organisations with which we collaborate to help reach new audiences, and people who have shared their personal stories to help us raise awareness of prostate, testicular and penile cancer.

Ali Orhan, CEO

1.

The year in review

Increased helpline hours maintained

Roadshow programme reaches targeted communities

Penile cancer advocate performs at Edinburgh Fringe

New resources launched

Supporting research for practical treatments

There are more than 55,000 new cases of prostate, testicular and penile cancer each year in the UK. Sadly around 12,000 people will die from these diseases, but thankfully, many will also recover. In response, Orchid has worked throughout the year to support those affected, as well as to help people understand the risk factors, changes to look out for, and the need to get help as soon as possible if concerned. The charity has also continued to invest in world-class male cancer research to benefit both current and future generations of men.

Orchid's Freephone confidential Male Cancer Helpline has remained at the heart of the charity's Nurse-led services, and the increased hours introduced in response to the COVID-19 pandemic continued.

The number of calls taken by our Nurse was in line with the previous year, but an increased number of referrals to the penile and testicular cancer counselling service were made. The peer support sessions which Orchid help facilitate were delivered both virtually and in person, and Orchid Nurse Rob Cornes continued to support the St Bartholomew's Testicular Cancer Support Group.

Reaching those at risk was a priority, especially people from marginalised communities who may not engage with mainstream health messaging. Orchid was active delivering Male Cancer Information Roadshows in the heart of local communities in targeted locations from Aberdeen to Lancaster, and Derby to Hackney. Orchid met over 8,000 people via the Roadshow programme, with others learning about male cancer via the Health at Work programme and awareness talks. In addition, almost 4,500 people received prostate cancer information from the Orchid Volunteer Community Champion team via the Overcoming the Barriers

to Engaging with Prostate Cancer project. Orchid has also identified the need to reach out to trans women who may also be at risk of prostate cancer, and a grant was received from the National Lottery Awards for All England to begin this work.

In August 2022 Orchid supported comedian Mr Richard Stamp, a penile cancer survivor and advocate, who performed his one man show about his experience of penile cancer at the Edinburgh Fringe Festival for three weeks. This show is a hard-hitting journey through his diagnosis and treatment and won critical local acclaim. Orchid organised and supported a support meeting

following one of these shows for other survivors and health care professionals working in the field of penile cancer.

In recent years reaching people digitally has become increasingly effective and both Male Cancer Awareness Week and International Penile Cancer Awareness Day were driven by social media. Social media content over the year has also been used to share male cancer information as well as links to direct people to the Orchid website, and to the portfolio of paper based and online resources such as our PSHE Association accredited lesson plan and the Your Privates testicular cancer microsite.



A new poster series included one for each male cancer, one about all three, and one on how to access Orchid's support and information



A number of new resources were developed and launched in the year to support our awareness activities. These include a fold out 3 in 1 leaflet about all three male-specific cancers called "Prostate, Testicular and Penile Cancer. Get to know the facts and how to spot them," as well as a series of five posters. The poster series has one about each male cancer, one

about all three, and one about the support Orchid can offer. Orchid was pleased to contribute to an initiative created by breast cancer charity CoppaFeel! to produce downloadable educational posters for schools to raise awareness of both breast and testicular cancer, as well as to a series of four new videos about testicular health by the British Fertility Society.

In the period Orchid Nurse Rob Cornes began a review of Orchid's information with view to attaining the PIF TICK which is the UK-wide Quality Mark for Health Information. Orchid also started work on the development of a new website to offer more accessible information about all three male cancers, collaborated with Ansar Projects and

CoppaFeel! on the development of testicular and breast cancer resources to support people with a learning disability to know their body, started making a film called *Take Three* which will tell the stories of people affected by each of the male cancers together with a booklet telling nine real life stories, and a film about advanced prostate cancer.

Orchid also worked in close collaboration with health and social care professionals, policy makers and other cancer charities to bring about positive change for men and their families. Examples include continuing to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the



UK, and with both Prostate Cancer Research and TACKLE Prostate Cancer on promoting the activities the different charities carry out.

Research is vital to understand why men develop prostate, testicular and penile cancers and to improve diagnosis and treatment. This is why Orchid continued to support world-class research by making a grant towards the Robert Lane Tissue Bank incorporating the Circulating Tumour Cells (CTCs) project. The work in the Tissue Bank is focused on the pathology and natural history of prostate, testicular and penile cancer, and on translating basic research into practical treatments for patients with novel tests and bespoke predictive treatments. Circulating Tumour Cells (CTCs) are held in the Tissue Bank for experimental research about cancer genetics and circulating biomarkers, including Circulating Tumour Cells.

Having previously reviewed training need, our small staff team undertook Diversity and Inclusion training, and two bespoke sessions on the use of our fundraising database.

A fold out 3 in 1 leaflet about all three male-specific cancers was launched

We continued to work in collaboration with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer



23,351



pieces of specialist information
requested by individuals, organisations
and healthcare professionals



4,821

people received
prostate cancer
information from
Orchid Community
Champions and
other experienced
volunteers




184,104

page views on the
Orchid website


3,693


men, women and healthcare
professionals had in-depth male
cancer support or information directly
from an Orchid Nurse / Male Cancer
Information Manager

24,096



pieces of
specialist
information
disseminated
through outreach
activities






5,400

sessions on *Your Privates* testicular cancer microsite

824,734

Organic reach of Orchid's social media platforms



people had the opportunity to learn about male cancer by attending an Orchid Roadshow



26

Number of peer reviewed papers to which Robert Lane Tissue Bank contributed



100

testicular and penile cancer counselling sessions delivered



2.

Fundraising

Significant growth in funds raised

Support for cancer research

Payroll giving a growing source of
unrestricted funds

Jonathan Freedland's Radio 4 Appeal
for Orchid

Fundraising

Working to save the lives of those diagnosed with prostate, testicular or penile cancer is only possible because of the generosity of our wonderful supporters, be they individuals, community groups, Trusts and Foundations or Companies.

Throughout a successful fundraising year, so many people gave donations because of having been touched in some way by male cancer and in memory of loved ones. The Orchid team cheered on supporters at large events such as the London Marathon and London Landmarks Half Marathon, as well as helped and encouraged the many individuals and groups who were busy fundraising across the UK through activities such as cake sales, the Twyford Beer Festival, running events, our new step challenge, and art events.

There were some significant grants during the year from Charitable Trusts and Companies restricted to developing innovative information resources, delivering Nurse-led services to support those affected, and reaching out to raise awareness in the heart of local communities. Considerable support was received to fund male cancer research, and a grant was received from the National Lottery Awards for All England to fund a project called "Trans women get prostate cancer too." Payroll giving continued to be a growing and valuable source of unrestricted income. Furthermore, two legacy payments made a remarkable contribution to income in the year.

A total of £841,808 was raised during the year which showed significant growth on £530,278 raised in the previous year. Each donation and grant given was a vital contribution, and Orchid would like to thank everyone who helped us in any way as income was regrown after the negative impact of COVID-19.

Incorporating learnings is important to Orchid. Throughout the year Orchid staff and Trustees continued to review our fundraising activities and sought to identify new opportunities to ensure we retain a diverse and cost-effective fundraising base to balance risk in the years ahead.

During the year we moved to the Fundraise Up platform to engage more supporters and improve the donor experience.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and

putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies.

Orchid operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received one complaint in relation to our fundraising activities which was resolved in line with our procedures. We remain committed to improving our practice, learning from supporter feedback.

Radio 4 Appeal

Orchid was delighted to be selected as a beneficiary of the weekly BBC Radio 4 Appeal. Furthermore, we were thrilled that leading broadcaster and journalist, Jonathan Freedland, was able to present Orchid's Appeal which went out on Easter Sunday 2022.

In the Appeal, Jonathan spoke very movingly of his own family experience of prostate cancer, telling listeners that his grandfather and father had both been diagnosed with this cancer which now affects over 52,000 men each year. He also shared the story of Orchid supporter, Glenn, who was stunned to be diagnosed with testicular cancer at the age of 55. Like many, Glenn had believed that testicular cancer only affected younger people. Jonathan

spoke about Glenn's relief at finding the support of Orchid's Male Cancer Nurse Specialist after he called our confidential Helpline. Jonathan also explained how speaking to an Orchid Nurse gave Glenn a better understanding of the potential impact of the cancer on his physical and mental health, which made him less fearful. The Appeal focused

on Orchid's Helpline which is run by Specialist Nurses. It also highlighted the continued need for donations to meet the demand by those seeking support and information about their prostate, testicular or penile cancer concerns. BBC Radio 4 listeners were generous in their support, and together they raised £16,109 towards Orchid's work.



Jonathan Freedland, journalist, author and broadcaster, who presented Orchid's Radio 4 Appeal on Easter Sunday 2022



3.

Our impact

Prostate cancer

Testicular cancer

Penile cancer

Research

Our impact

Prostate cancer

Over 52,000 people are diagnosed with prostate cancer in the UK annually, that's more than 140 people every day. Sadly, there are 11,855 deaths from prostate cancer each year with 10-year survival at around 78%. According to CRUK, one in six UK males will be diagnosed with prostate cancer in their lifetime.

With more and more men being diagnosed with prostate cancer it is becoming more essential to correctly identify those who may be at risk of disease progression and those with mild or inactive disease.

One of the interesting directions that this may take are so called liquid biopsies - the sampling of circulating cancer cells within the blood. Orchid has helped fund research into circulating tumour cells or CTCs and this method along with a more frequent use of MRI scans to identify potential areas of prostate cancer may improve medical assessment dramatically and reduce the side effects men may experience from cancer treatment.

In addition, those men with minimal risk of disease progression are likely to be managed by active surveillance. This is an option that is likely to increase dramatically over the next few years and one which Orchid has already created information about.

Some men who are put on active surveillance may take 6-months or more to adjust to the fact that their cancer does not require immediate treatment and Orchid has responded to the need for information and support to help them.

One of the greatest challenges around prostate cancer remains the unequal risk of this cancer among Black African and Black Caribbean men who are twice as likely to develop prostate cancer than Caucasian men. Creating awareness in this community and helping support Black men diagnosed with prostate cancer is crucial. Although there are over 95 prostate cancer support groups in the UK, the Black community remains underrepresented.

A need also exists to reach trans women and non-binary people assigned male at birth with prostate cancer messaging, as they too can be diagnosed with this cancer.



Overcoming the Barriers to Engaging with Prostate Cancer

May 2021 saw the start of a three-year project funded by The National Lottery Community Fund entitled *Overcoming the Barriers to Engaging with Prostate Cancer*. This work is led by Ali Orhan in his capacity as Project Director, alongside his role as Orchid CEO.

The project is running in Birmingham, Bradford, Bristol, Dudley, Leeds, Liverpool, Manchester, Newcastle, Nottingham and Wolverhampton, and was gaining real momentum as we entered the reporting year.

Throughout the 12-month period a growing number of Volunteer Community Champions were recruited and trained. Our team – which numbered 82 by the year

end – comprises community members, healthcare professionals and prisoners, and they cascade prostate cancer messages using the tool kit and leaflets developed by the Orchid project team, as they target those at risk within their own communities.

In the year, our Volunteer Community Champions reached 4,488 people with prostate cancer information. They had 1,114 in-depth conversations about this cancer, with evaluation showing the difference this made to the beneficiaries. 4,642 prostate cancer leaflets were disseminated, plus a further 3,503 leaflets signposting people to local services. The largest group reached were men, but women also were keen to gain knowledge for the men in their lives.

Our Champions used their own local knowledge to inform their choice of awareness raising activities. Some examples included: talking to and reaching people via information stands in libraries; health and other community events including festivals; on buses and trains; in markets, taxis,

and GP surgeries; by virtual talks; attending men's groups; the Amazon Distribution Centre in Newcastle; the Armed Forces Day in Wolverhampton; and via food banks.

Trained Community Champions also cascade prostate cancer in three prisons – HMP Dovegate, HMP Stafford and HMP Oakwood. Some of the training had been delayed because of COVID-19, but despite this, these Champions reached 337 men and had 109 in-depth conversations.

In Orchid's financial year 2022-2023, Orchid will be returning to the ten locations to meet with the teams of Volunteer Champions to celebrate their successes and to discuss the challenges, sharing regional learnings to all the Volunteer Community Champions. The Orchid team will be discussing the case studies reported by the Champions, as well as looking forward to determine how prostate cancer awareness can continue after the project ends in May 2024, and to ensure there is a positive project legacy in each location.



Our Volunteer Community Champions reached 4,488 people with prostate cancer information. The largest group reached were men, but women also were keen to gain knowledge for the men in their lives.

Our impact

Testicular cancer

Testicular cancer is rare with around 2,300–2,400 diagnoses each year in the UK. Around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of those diagnosed between the ages of 15–45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life. Treatment occurs quickly with men often being diagnosed and treated within a few weeks.

As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects, chemotherapy can increase the risk of cardiovascular disease in later life.

Challenges around testicular cancer involve supporting men in adjustment

to life following treatment. Many men will only realise the full implication of their cancer journey when treatment ends and may not be able to access either peer support or psychological support. Orchid has consistently supported the biggest testicular cancer support group in the UK, which is co-ordinated by the specialist nurse team at St Bartholomew's in London, both physically and virtually.

In addition, the creation of Orchid's telephone counselling service allows men to access psychological support without the necessity of waiting for extended periods of time.

Orchid also continues to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the UK.

Testicular cancer is the most common cancer in young men – many older men are not aware they remain at risk and may ignore potential symptoms.



Male Cancer Awareness Week 2022

Male Cancer Awareness Week unites individuals and organisations from around the UK to help raise awareness of prostate, testicular and penile cancer.

Every year the week highlights the importance of being aware of the risk factors and early signs or symptoms of these three cancers, and the importance of getting checked out by

your GP if concerned. The theme of the Awareness Week in 2022 was 'Older Men Get Testicular Cancer Too!'

Due to the period of National Mourning following the death of Her Majesty Queen Elizabeth II, Orchid delayed its Male Cancer Awareness Week which was planned for 12th to 18th September, until 26th September to 2nd October.

The messaging was delivered mainly digitally with a series of infographics delivered each day across Orchid's social media, and that of partners and supporters, as well as by targeted advertising. Testicular cancer is the most common cancer in young men and many older men are not aware they remain at risk and may ignore potential symptoms.

The infographics and accompanying text covered the risk factors, the potential signs and symptoms, and how men can check their testicles to understand what is normal and what may be a potential sign of this cancer. Our posts also highlighted the information available on the Orchid website, and that the Orchid Helpline run by experienced Male Cancer Nurse Specialists is there for anyone with a concern.

Through Orchid's own social media channels, we had an organic reach of over 6,500 with these important messages.

Paid social media advertising and radio coverage took the total number of opportunities to learn about testicular cancer to over 422,500.



Our impact

Penile cancer

Penile cancer is exceptionally rare in the UK with around 700 men being diagnosed each year. Around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.



Most men will never meet another man affected by penile cancer, so Orchid has focused on developing a telephone counselling service to support men and has created events to offer peer support.

Out of the three male-specific cancers, penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexual function.

Due to its intimate nature around 15-50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics.

Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease – many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its

rarity therefore missing out on invaluable peer support. In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral.

Orchid has therefore focused on the development of a telephone counselling service to support men and wherever possible has created events to offer peer support, as well as supporting and encouraging allied healthcare professionals in the creation of regional support groups.

With 83 cases a year, there is a higher incidence of penile cancer in Scotland in comparison to the rest of the UK, and those affected by penile cancer in Scotland are also being diagnosed at a younger age. A penile cancer diagnosis can be psychologically devastating, and treatment can be challenging especially if the diagnosis has been made at a late stage.

Orchid has significant experience of educating people about the signs and symptoms of penile cancer, as well as understanding the complex

issues involved in supporting penile cancer patients.

Whilst we do not as yet know why Scotland has a higher incidence proportionally than the rest of the UK, we do know that many people have not heard of penile cancer, let alone know what potential symptoms might be. This is why Orchid identified the need to deliver a project to put penile cancer on the agenda in Scotland, and whilst delivery of this specific piece of work is complete, many of the elements have now been brought into Orchid's core services.

Orchid's collaborative work

Orchid is pleased to continue its collaborative work with the European Reference Networks (eUROGEN) to improve the patient pathway for men with penile cancer across Europe. In addition, Rob Cornes is now a member of the EAU Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid.

In August 2022 Orchid Nurse Rob Cornes and two men with penile cancer, who have been supported and empowered by Orchid to act as Patient Representatives or ePAGs, gave a lecture at the European Association of Urology (EAU) Conference in

Amsterdam. This session highlighted the unmet needs of penile cancer patients and was based on a peer reviewed article written by Rob Cornes and published in the prestigious journal Seminars on Oncology Nursing.

Orchid is working collaboratively with eUrogen and is in the process of creating a suite of resources about penile cancer. These resources will consist of two humorous awareness videos, one aimed at the general public to raise awareness of penile cancer and the other to encourage GPs and primary care workers to refer men with any suspicious penile lesion urgently to a urologist. A further animated video is being scripted by Rob Cornes and created by the EAU

about penile cancer. With further funding a future video will be created dealing with management strategies for men living with the side effects of the disease. A patient experience booklet will also be created to provide guidance for health care professionals caring for penile cancer patients.

During the year Orchid also joined the Human Papilloma Virus Coalition, a consortium of numerous charities working in the field of HPV education, awareness and prevention. Regular meetings and collaboration will continue over the next few years. Around 50% of men diagnosed with penile cancer will have evidence of certain types of HPV infection which increase the risk of the disease.

Our impact

Research

Orchid was pleased to continue its support for the work of The Robert Lane Tissue Bank incorporating the Circulating Tumour Cells (CTC) project during the year.

Ongoing work includes:

- TAPG (the study with the Trans-Atlantic Cohort). Further papers are ongoing, with one in 'major revision at present' and another in preparation.
- Testis. Further collaborative work with Denmark continues, with 2/3 papers in preparation for 2023.
- A new collaboration looking closely at Sex cord stromal tumours of the testis has just been initiated. This International collaboration has support for 2023 from two international pathology organisations (The International Society of Urological Pathology (ISUP) and The Genitourinary Pathology Society (GUPS) for these challenging to treat tumours.
- STAMPEDE. Work is ongoing for publication in 2023/24. (STAMPEDE is a clinical trial looking at the best way of treating men with newly diagnosed advanced prostate cancer.)
- Review a manuscript on using CTCs for early detection of aggressive cancer: a synopsis has been submitted to Nature Review Clinical Oncology (Impact factor 62) and approved by the editors for full manuscript submit (to be submitted in January 2023).
- CTC clusters as prostate cancer prognostic biomarkers: a manuscript to be completed in 2023.

During the period, Orchid funded work has contributed to the following books:

- Chapter: Testicular Neoplasia. Sternberg's Diagnostic Surgical Pathology (2 Volume Set) 2022.
- Urinary and Male Genital Tumours. WHO Classification of Tumours, 5th Edition, Volume 8 WHO Classification of Tumours Editorial Board

A full list of papers for the period is available on request.

The Robert Lane Tissue Bank is headed by Professor Dan Berney, MB BChir, MA, FRCPath who is an Honorary Professor of Genito-urinary Pathology; Consultant Pathologist. Professor Berney has lectured throughout the world and is an internationally recognised pathology expert in the three male genito-urinary cancers.

Professor Yong-Jie Lu MBBS, MD, PhD, and Professor of Molecular Oncology, who leads the Circulating Tumour Cells Project, has worked on cancer genetics research for 30 years. Professor Lu has developed a number of novel cancer genetic analysis techniques and was first to identify the genetic difference in prostate cancer between the Chinese and Western population.

The Robert Lane Tissue Bank is an internationally significant resource for past and future research into all three male-specific cancers. Rather than collecting all tumours, it is a 'bespoke' bank often with long term clinical follow up and connected to clinical trial data. It holds tumours from nine separate clinical trials; over 600 penile cancer specimens, over 3,000 testicular cancer specimens, and over 6,000 prostate cancer specimens; and more than 1,200 blood samples collected and separated into Circulating Tumour Cells (CTCs), plasma, red blood cells,

white blood cells and platelets for separate storage and future research.

In 2022 The Robert Lane Tissue Bank contributed to 26 peer reviewed papers. This record-breaking number included 10 papers where, although the Tissue Bank had contributed data as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium, Professors Berney and Lu were not a named author, nor any other consortium member. This was changed as an Author correction to these papers in December 2022. The papers were published in 2020-2022 and have not previously been mentioned in Orchid's work. Many are now highly cited. This emphasises how the tissue collection has made a huge

contribution to international research. Abstracted work was presented at the United States and Canadian Academy of Pathology USCAP 2022 meeting in March on prostate cancer (accepted platform presentation) in Los Angeles, and at the European Congress of Pathology in September in Basel.

The Circulating Tumour Cell (CTC) and biomarker studies have shown that CTCs and gene expression analysis can predict prostate cancer patient response to the chemotherapy drug docetaxel with a manuscript accepted recently by Frontiers of Oncology. Blood samples (over 200) have been collected from prostate cancer patients, patients with suspected prostate cancer and

healthy volunteers, with CTCs isolated and other blood components separated and stored in -80°C freezer (over 1000 items) for future research.

Further CTC analysis confirmed that CTC positivity predicts prostate cancer aggressiveness and biopsy outcome. It also showed that CTC clusters (two or more CTC stick together in the blood) are associated with aggressive prostate cancer and a manuscript is in preparation.

CTC work as prostate cancer diagnostic and therapeutic biomarkers has been presented as invited talks at the 2021 UK National Cancer Research Institute Annual Meeting (November 2021); The BioTech Pharma Summit 2021 – Antibody Engineering Biomarkers Biobanking and Liquid Biopsy (Porto, November 2021); Prostate Cancer UK Spotlight on... webinar series – Spotlight on blood biomarkers (June 2022); Public Policy Exchange webinar series – Improving Cancer Screening in the UK (August 2022); 4th Annual Biomarker and Companion Diagnostics Conference (London, October 2022); 8th Taihu Chinese Urological Symposium and 8th Huishan Precision Medicine Summit (Wuxi, China, November 2022); and European Liquid Biopsy Society Circulating Tumour Cell technology workshop (December 2022).



Over 200 blood samples have been collected from prostate cancer patients and healthy volunteers, and stored for future research

4.

The year ahead

New film to start conversations about male cancer

Booklet to highlight nine real life encounters with cancer

Support for people with learning disabilities to know their body

New website to be launched

More Volunteer Community Champions to be recruited

The year ahead

The reporting year ended with the successful delivery of Orchid's fourteenth Male Cancer Awareness Week which, whilst highlighting all three male-specific cancers, had a particular focus on "Older men get testicular cancer too." Knowing that male cancer is easier to treat and cure if it is discovered early, raising awareness of male cancer risk factors, signs and symptoms remained a priority as we entered the new financial year.

Plans were in place to launch new educational resources in the early part of the year including two new films. *Take Three* will tell the story of three people affected by male cancers to start important conversations, and a film will help those diagnosed with advanced prostate cancer better understand their condition. Work will also start on another film which will be used to deliver targeted prostate cancer messages as well as providing information and support to those diagnosed.

Other resources to be launched early in the year include a booklet which will describe nine real life encounters with prostate, testicular and penile cancer. Again, its aim is to encourage

Plans are in place to launch new resources in the early part of the year which will start important conversations about male cancers



people to talk about these cancers and to learn what to look out for. Another addition to our portfolio will be a series of accessible resources developed with Ansar Projects and CoppaFeel! to support people with a learning disability to know their body. The resources will be the first of their kind and will include accessible testicular and breast cancer information packs, self-checking cards, testicular and breast cancer symptom guides, self-checking social stories and information on what to expect if you notice a change.

December will see the launch of the new Orchid website, with more accessible information and resources which will be available to order and download. The review of Orchid's information is ongoing with view to attaining the PIF TICK, the UK-wide Quality Mark for Health Information.

Community outreach will continue with Orchid's successful Male Cancer Information Roadshows run in targeted identified locations, delivered as funding is received. Alongside Roadshows, talks and presentations, Orchid plan to grow its Health at Work

programme. Plans are in place to recruit and train further Volunteer Community Champions through the National Lottery Community Fund project, Overcoming the Barriers to Engaging with Prostate Cancer. The project team are in regular contact with those who are already using their knowledge of their local communities to cascade prostate cancer information to support their outreach, and the learnings coming out of regionally based conferences planned for Spring 2023 will be shared widely.

Orchid's Male Cancer Awareness Week will take place between 11-17 September 2023, leading on to the third International Penile Cancer Awareness Day.

Supporting those affected by male cancer is also a high priority for the coming year. The Freephone National Male Cancer Helpline will continue to operate its increased hours for anyone worried about prostate, testicular or penile cancer. We also remain committed to delivering and co-facilitating peer support opportunities. In collaboration with the Maggie's Centre at the Christie Hospital in

Manchester, Orchid will help run a penile cancer support group every two months. A similar group had been set up prior to the pandemic as a direct result of an Orchid initiative. Now the group will reform in 2023 and working with the Christie penile cancer team Orchid will seek to further its contacts within this community. We will continue to offer a telephone counselling service to those affected by penile or testicular cancer.

Social media will be used to relay male cancer messages, promote our educational films and to drive followers to the Orchid website or to view, order or download resources. Posts will be developed incorporating the learnings of the last year when we found that the audience was more reactive to awareness and personal stories.

Orchid Nurse Rob Cornes works with healthcare professionals both in the UK and beyond to improve the patient journey for those with penile cancer. Orchid resources and services will be promoted throughout the year to healthcare professionals working in the relevant fields throughout the UK.

Through his work with the European Reference Networks (eUROGEN) Rob Cornes and the patient advocates Orchid identified will present a further session on communicating accurate medical information to patients for rare cancers at the European Association of Urology (EAU) conference in Milan in 2023. In addition, Rob Cornes, who is now a member of the EAU Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid, will provide two further talks at the upcoming EAU 2023 conference and take part in two panel discussions.

Orchid's roots are in male-cancer research. In recent years Orchid funded research has significantly advanced understanding of male cancers, and we will continue to invest in world-class male cancer research to benefit the well-being of current and future generations of men. Going into the year, Trustees agreed further funding for the Robert Lane Tissue Bank. The Tissue Bank is led by Professor Dan Berney MB B Chir, MA, FRCPath and is an internationally important resource for research into penile, testicular, and prostate cancer. Professor Berney is focused on translating basic research

into practical treatments for patients with novel tests and bespoke predictive treatments.

Donations have been received for the Orchid Research Innovation Fund. Trustees plan to award a significant grant from funds secured in the coming year.

Securing adequate funding at the best possible return on investment is essential to deliver our ambitious plans for the year ahead. After seeing income increase in 2021-2022, our fundraising strategy for 2022-2023 focusses on growing revenue further across all income streams.

The new year started with a wonderful team of runners fundraising for Orchid in the London Marathon, and 2023 will see both existing and new supporters taking part in a number of different running events, as well as in Orchid's unique Willy Waddles in London and Edinburgh. We are grateful to our supporters who are planning events such as a charity ball, a cycle ride and beard competitions, in addition to the annual and extremely successful Twyford Beer Festival.

We will continue to submit application to Charitable Trusts and

Social media will be used to relay male cancer messages and to drive followers to the Orchid website



Foundations on a rolling basis, and carry out research to identify new potential supporters. We will work with our corporate supporters to meet their needs as well as Orchid's and will explore corporate opportunities in the areas in which the Overcoming the Barriers to Engaging with Prostate Cancer project is running. We will also continue to explore other new income generating opportunities.

Looking after our supporters is paramount. We will continue to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and all the individuals and community groups who support us with donations and fundraise on our behalf.

Orchid recognises its responsibility to reduce its carbon and environmental footprint and will continue to monitor its activities in relation to our Environmental Policy.

Orchid's work is only possible because of the generosity of our supporters. We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead.

We will explore corporate opportunities in the areas in which our *Overcoming the Barriers to Engaging with Prostate Cancer* project is running





5.

Governance

Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK.

Objects, operating context and activities

Objects

Over 55,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly this number is increasing. Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers,

how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair's aim to maintain a balanced composition. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from office in rotation, in order of longevity of appointment and are eligible to be reappointed.

Throughout the COVID-19 pandemic Trustees met virtually and continued to do so in 2021-2022.

Trustee training and induction

On appointment, Trustees are offered a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Delegation and decision-making

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance Committee is responsible for the financial oversight of the Charity including budgeting, financial planning and monitoring as well as financial reporting and the creation and monitoring of internal controls and accounting policies. It presents a

report to the Board at each of its meetings. As at 30 September 2022, it comprised the Honorary Treasurer, Mr W Cohen, Mr C Osborne, Mr M Kibblewhite, Mr S Seymour and Mr S Harris.

- To improve efficiency, Sub-Committees have been reviewed, and the Fundraising Sub-Committee meets as required.
- At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept apprised of personnel, awareness, research programme and budgetary issues.

Public benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit including (PB2 Public Benefit: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept

fully informed of the organisation's strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the verification of outcomes, a Scientific Advisory

Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identifies risks under the following headings:

Governance and compliance
Operational
Financial
Research
Environmental/external
Quality assurance

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified. These are as follows:

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to

Mitigation

- An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and financial, are covered by suitably qualified professionals
- Training and support for Board of Trustees and Finance Committee
- Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
- Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

- Annual salary review to include benchmarking of compensation and benefits
- Staff development, training and succession planning programmes
- Communication programme to ensure staff are involved in the development of and progress towards Orchid's strategy and annual workplan

Financial

Economic pressures, impact of COVID-19, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

Mitigation

- Annual budgeting and ongoing management, reporting and monitoring of financial performance
- Diversification of income streams
- Ongoing consideration of market and consumer trends and regulations including GDPR

Research

Orchid's Research Programme fails to deliver results

Mitigation

- Scrutiny and approval of research funding applications by an expert Scientific Advisory Board
- Annual review of progress

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid's work

Mitigation

- Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
- Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
- Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid's strategy

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

- Services developed, delivered and evaluated in line with agreed protocol and standards
- Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)
- All information materials and content regularly reviewed and updated
- High-quality training for staff

6.

Financial review

Results for the year

Income for the year ended 30 September 2022 totalled £841,808 (2021: £530,278). After total expenditure of £740,252 (2021: £673,004), the year's activities show a net surplus of £101,556 (2021: deficit of £142,726). Total reserves at the end of the year amounted to £541,836 (2021: £440,280).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity's core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available free reserves net of tangible fixed assets are £162,113 (2021: £154,187). It is the Charity's policy to maintain free reserves of approximately 3-4 months of operating costs. At current levels of expenditure this equates to £160,000-£212,000.

Formal statements Statement of Trustees' responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiner's information

So far as each of the directors at the time the Trustees' report is approved is aware:

- a) there is no relevant information of which the examiner is unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees



C S Osborne
Chairman of Trustees
20/03/2023

Independent Examiner's Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since the Company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Moore Kingston Smith LLP.

James Saunders FCCA DChA

Date: **30 March 2023**

For and on behalf of
Moore Kingston Smith LLP
Chartered Accountants
6th Floor, 9 Appold Street,
London
EC2A 2AP

Statement of financial activities

(incorporating an income and expenditure account)

For the year ended 30 September 2022

	Note	Unrestricted Total £	Restricted Total £	Year ended 30 September 2022 £	Year ended 30 September 2021 £
Income from:					
Donations and Legacies	2	440,779	233,921	674,700	440,580
Charitable Activities	4	-	166,673	166,673	89,497
Trading Activities		309	-	309	177
Investment income		126	-	126	24
Total income		<u>441,214</u>	<u>400,594</u>	<u>841,808</u>	<u>530,278</u>
Expenditure on:					
Raising funds					
Fundraising					
(donations and grants)	5	185,431	-	185,431	185,083
Charitable Activities					
Education and Awareness	5	109,874	266,968	376,842	307,383
Research	5	127,859	50,120	177,979	180,538
Total expenditure		<u>423,164</u>	<u>317,088</u>	<u>740,252</u>	<u>673,004</u>
Net income / (expenditure) and net movement in funds	5,6	18,050	83,506	101,556	(142,726)
Reconciliation of funds					
Total funds brought forward		<u>278,966</u>	<u>161,314</u>	<u>440,280</u>	<u>583,006</u>
Total funds carried forward		<u>297,016</u>	<u>244,820</u>	<u>541,836</u>	<u>440,280</u>

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 13 to the financial statements.

Balance sheet

As at 30 September 2022

	Note	£	30 September 2022 £	£	30 September 2021 £
Fixed Assets					
Tangible Assets	10		3,891		2,971
Intangible fixed assets	11		9,204		-
Current Assets					
Cash at bank and in hand		590,444		508,854	
Debtors	12	108,806		77,325	
		699,250		586,179	
CREDITORS					
Amounts due within one year	13	(170,509)		(148,870)	
Net Current Assets					
			528,741		437,309
Total Assets less Current Liabilities					
	14		541,836		440,280
NET ASSETS					
			541,836		440,280
Represented by:					
	15				
General Unrestricted Funds		175,208		157,158	
Designated Funds		121,808		121,808	
			297,016		278,966
Restricted funds			244,820		161,314
			541,836		440,280

The company is limited by guarantee.

For the year ending 30 September 2022 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 20th March 2023 and signed on its behalf by:



Mr C S Osborne
Company number 3963360

Statement of cash flows

For the year ended 30 September 2022

	2022		2021	
	£	£	£	£
Cash flows from operating activities:				
Net income/(expenditure) for the year	101,556		(142,726)	
Adjustments for:				
Depreciation charges	1,944		1,486	
Interest	(126)		(24)	
(Increase)/Decrease in debtors	(31,481)		59,261	
Increase/(Decrease) in creditors	21,639		(132,517)	
Net cash provided by operating activities		93,532		(214,520)
Cash flows from investing activities:				
Interest	126		24	
Purchase of fixed asset	(12,068)		(4,091)	
Net cash used in investing activities		(11,942)		(4,067)
Change in cash and cash equivalents in the year		81,590		(218,587)
Cash and cash equivalents at the beginning of the year		508,854		727,441
Cash and cash equivalents at the end of the year		590,444		508,854
Analysis of cash and cash equivalents				
Cash at bank and in hand		590,444		508,854
		590,444		508,854

Notes to the financial statements

1. Accounting policies

For the year ended 30 September 2022

Basis of Preparation

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements and have considered the external economic environment on the charity's operations. In particular, the trustees have considered the charity's forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

Income for 2021-2022 showed considerable growth post the COVID-19 pandemic, and together with careful financial management the charity had stabilised. The accounts for the year show a surplus after a significant deficit in the previous year, leaving historic cash funds in place.

The project funded by the National Lottery Community Fund; Overcoming the Barrier to Engaging with Prostate Cancer will continue to run until May 2024, and there is a strong events and community fundraising pipeline after the disruption of the pandemic. The potential to grow income from Corporate Partnerships and Charitable Trusts and Foundations is recognised, and plans are in place to recruit more regular givers. Fundraising plans allow for income from different funding streams to spread risk. The National Lottery funded project along with continued support from loyal donors and supporters will enable Orchid to continue to as a going concern.

The trustees confirm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its financial statements.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a

purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment - 33 1/3% on written down value

Intangible fixed assets and Amortisation

Intangible fixed assets are included in the balance sheet at original cost less accumulated amortisation.

Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the number of years of expected use. Assets are amortised at the following rate:

Website - 20% on straight line value

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal.

The purpose and use of the Charity's restricted funds is set out in the notes to the financial statements.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity's objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity's objects.

Governance costs are those incurred in connection with the management of the Charity's assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension Scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year.

The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee's services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

2. Donations

Current year

	Restricted	Unrestricted	Year ended 30 September 2022 Total	Year ended 30 September 2021 Total
	£	£	£	£
Individuals	68,800	118,087	186,887	143,844
Legacies	-	100,000	100,000	-
Corporates	-	36,814	36,814	35,771
Trusts and Foundations	165,121	44,600	209,721	114,300
Fundraising Events	-	141,278	141,278	146,665
Total	233,921	440,779	674,700	440,580

Prior year

	Restricted	Unrestricted	Year ended 30 September 2021 Total
	£	£	£
Individuals	92,800	51,044	143,844
Corporates	-	35,771	35,771
Trusts and Foundations	97,250	17,050	114,300
Fundraising Events	-	146,665	146,665
Total	190,050	250,530	440,580

3. Fundraising events

Current year

	Restricted	Unrestricted	Year ended 30 September 2022 Total	Year ended 30 September 2021 Total
	£	£	£	£
Cycling events	-	658	658	11,257
Running events	-	68,646	68,646	56,100
Third party organised events	-	62,806	62,806	76,943
Other	-	9,168	9,168	2,365
Total	-	141,278	141,278	146,665

Prior year

	Restricted	Unrestricted	Year ended 30 September 2021 Total
	£	£	£
Cycling events	-	11,257	11,257
Running events	-	56,100	56,100
Third party organised events	-	76,943	76,943
Other	-	2,365	2,365
Total	-	146,665	146,665

4. Charitable activities

Current year

	Restricted	Unrestricted	Year ended 30 September 2022 Total	Year ended 30 September 2021 Total
	£	£	£	£
The National Lottery Community Fund RC England-wide	166,673	-	166,673	89,497
Total	166,673	-	166,673	89,497

Prior year

	Restricted	Unrestricted	Year ended 30 September 2021 Total
	£	£	£
The National Lottery Community Fund RC England-wide	89,497	-	89,497
Total	89,497	-	89,497

5. Total expenditure

Current year	Cost of raising funds £	Education and Awareness £	Research £	Year ended 30 September 2022 Total £	Year ended 30 September 2021 Total £
Grants	-	-	149,222	149,222	154,896
Staff costs	74,399	147,294	18,366	240,059	239,012
Fundraising expenses	68,941	-	-	68,941	51,935
Information materials	-	98,605	-	98,605	66,371
Direct costs	-	38,393	-	38,393	30,322
	143,340	284,292	167,588	595,220	542,536
<i>Support costs</i>					
Depreciation	558	1,248	138	1,944	1,486
Other	33,797	75,514	8,343	117,654	98,477
Governance - staff costs	5,869	11,618	1,449	18,936	24,628
Governance - examiners fees	1,867	4,170	461	6,498	5,877
	42,091	92,550	10,391	145,032	130,468
Total expenditure	185,431	376,842	177,979	740,252	673,004
Prior year	185,083	307,383	180,538	673,004	

6. Grants awarded

	Year ended 30 September 2022 Total £	Year ended 30 September 2021 Total £
Grant commitments brought forward	87,576	205,415
Institutional grants for medical research awarded during year/period		
Orchid Study and Travel Awards (2022: 2 individuals 2021: 0 individual)	2,000	-
Barts and London School of medicine	144,652	138,896
Payments made during period/year	(107,611)	(256,735)
Grant commitments carried forward	126,617	87,576
Payable less than one year	126,617	87,576
Payable two to five years	-	-

7. Net expenditure for the period

This is stated after charging:

	Year ended 30 September 2022	Year ended 30 September 2021
	Total	Total
	£	£
Depreciation	1,944	1,486
Examiners' remuneration: Examination	5,415	5,300
Payments made during period/year	-	-
Trustees' remuneration	-	-
Trustees' expenses		

8. Staff costs and numbers

Staff costs were as follows:

	Year ended 30 September 2022	Year ended 30 September 2021
	Total	Total
	£	£
Salaries and wages	205,290	182,602
Social security costs	16,414	13,020
Pension contributions	1,616	1,364
	223,320	196,986
Consultant costs	35,675	66,655
	258,995	263,641

During the year ended 30 September 2022 1 employee earned more than £60,000 (Year to 30 September 2021: 1). The pension contribution paid in respect of this employee totalled £Nil (2021: £Nil)

The key management personnel of the charity comprise the trustees and the chief executive.

The charity trustees do not receive remuneration. The total remuneration of the chief executive was £78,802 (year ended 30 September 2021: £66,494).

The average number of employees during the year was 7.5 (2021: 6.7)

The average number of employees during the year on a headcount basis was as follows:

	2022 No.	2021 No.
Fundraising	1.7	2.1
Education and Awareness	5.5	4.3
Grant support	0.3	0.3
Overall average	7.5	6.7

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Tangible fixed assets

Staff costs were as follows:

	Computer and office equipment	Year ended 30 September 2022 Total £	Year ended 30 September 2021 Total £
Cost	£	£	£
At the start of the period	7,315	7,315	3,224
Additions	2,864	2,864	4,091
At the end of the period	10,179	10,179	7,315
Depreciation			
At the start of the period	4,344	4,344	2,971
Charge for Period	1,944	1,944	1,486
At the end of the period	6,288	6,288	4,344
Net book value			
At the end of the period	3,891	3,891	2,971
At the start of the period	2,971	2,971	366

11. Intangible fixed assets

Staff costs were as follows:

	Website development	Year ended 30 September 2022 Total £	Year ended 30 September 2021 Total £
Cost	£	£	£
At the start of the period	-	-	-
Additions	9,204	9,204	-
At the end of the period	9,204	9,204	-
Depreciation			
At the start of the period	-	-	-
Charge for Period	-	-	-
At the end of the period	-	-	-
Net book value			
At the end of the period	9,204	9,204	-
At the start of the period	-	-	-

12. Debtors

	Year ended 30 September 2022	Year ended 30 September 2021
	Total £	Total £
Prepayments	10,071	45,594
Other debtors and accrued income	98,735	31,731
	108,806	77,325

13. Creditors: amounts due within one year

	Year ended 30 September 2022	Year ended 30 September 2021
	Total £	Total £
Grants Payable	126,617	87,576
Trade and Other Creditors	11,113	20,799
Accruals	32,779	40,495
	170,509	148,870

14. Movements in funds

	Brought forward £	Income £	Expenditure £	Carried forward £
Unrestricted				
General	157,158	441,214	(423,164)	175,208
Designated – Development	121,808	-	-	121,808
Total unrestricted	278,966	441,214	(423,164)	297,016
Restricted				
The National Lottery Community Fund - RC England-wide	32,445	166,673	(158,322)	40,796
Male Cancer Nurse Information Specialist - other funders	8,252	12,100	(16,752)	3,600
The Innovation Research Project	92,800	68,700	(7,320)	154,180
Penile Cancer Peer Support	-	8,500	(7,500)	1,000
Education and Awareness	5,000	58,950	(30,295)	33,655
Student Study and Travel Scholarships	6,729	-	(2,000)	4,729
Roadshows	2,860	42,871	(38,871)	6,860
Robert Lane Tissue Bank	-	42,800	(42,800)	-
Young Person's Testicular Cancer Project	3,228	-	(3,228)	-
City of London Corporation	10,000	-	(10,000)	-
Total restricted	161,314	400,594	(317,088)	244,820
Total funds	440,280	841,808	(740,252)	541,836

14. Movements in funds (continued)

Prior year	Brought forward £	Income £	Expenditure £	Carried forward £
Unrestricted				
General	135,382	250,731	(228,955)	157,158
Designated – Research	53,281	-	(53,281)	-
Designated – Development	121,808	-	-	121,808
Designated – Awareness	83,658	-	(83,658)	-
Total unrestricted	394,129	250,731	(365,894)	278,966
Restricted				
Testicular Cancer Counselling	-	3,000	(3,000)	-
The National Lottery Community Fund - RC England-wide	-	89,497	(57,052)	32,445
Male Cancer Nurse Information Specialist - other funders	56,974	6,000	(54,722)	8,252
The Innovation Research Project	16,200	92,800	(16,200)	92,800
Penile Cancer Peer Support	5,000	2,500	(7,500)	-
Education and Awareness	11,250	23,050	(29,300)	5,000
Student Study and Travel Scholarships	6,729	-	-	6,729
Roadshows	37,527	1,000	(35,667)	2,860
Robert Lane Tissue Bank	-	57,700	(57,700)	-
Young Person's Testicular Cancer Project	10,369	-	(7,141)	3,228
National Lottery Community Fund – Covid 19 Emergency	37,328	-	(37,328)	-
City of London Corporation	7,500	4,000	(1,500)	10,000
Total restricted	188,877	279,547	(307,110)	161,314
Total funds	583,006	530,278	(673,004)	440,280

General funds are unrestricted funds available for use at the Trustees' discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Research funds represent monies set aside at the Trustees' discretion to be used to help fund the costs of future research programmes.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

15. Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total funds at 30 September 2022 £
Fixed Assets	13,095	-	13,095
Current Assets	454,430	244,820	699,250
Creditors due within one year	(170,509)	-	(170,509)
Net assets at 30 September 2022	297,016	244,820	541,836
Prior year analysis of net assets between funds			
Fixed Assets	2,971	-	2,971
Current Assets	424,865	161,314	586,179
Creditors due within one year	(148,870)	-	(148,870)
Net assets at 30 September 2021	278,966	161,314	440,280

16. Related party transactions

Restricted donations of £52,500 were received from Professor RTD Oliver, trustee, in the year ended 30 September 2022. (Year to 30 September 2021: £80,000).

17. Financial commitments

For the year ended 30 September 2022, the charity was committed to making the following future payments under non cancellable operating leases.

	Year ended 30 September 2022 Total £	Year ended 30 September 2021 Total £
<i>Land and buildings</i>		
Expiring within one year	14,184	14,184
Expiring within two to five years	-	-
	14,184	14,184

18. Capital commitments

At the year ended 30 September 2022, the charity had capital commitments of £9,204 (2021: £Nil).


ORCHID CANCER APPEAL


England & Wales - Charity number 1080540

Accounts

Fighting male cancer

Orchid Cancer Appeal
Annual report and financial statements 2020–2021





Orchid Cancer Appeal, known as Orchid, is a small, influential charity solely dedicated to improving the lives of men of all ages who are at risk of, or affected by male cancer.

For over 25 years we have been working to save men's lives from prostate, testicular and penile cancer through a range of support services, education and awareness campaigns, and a world-class research programme.

Board of Trustees

Mr CS Osborne Chair
Mr W Cohen Treasurer
Mr D Badenoch
Mr PG Bracher
Mr S Harris
Mr M Kibblewhite
Professor RTD Oliver
Mr P Norman
Mr S Seymour
(resigned 1 January 2022)
Mr N Watkin
(resigned 7 December 2021)

Chief Executive

Mr A Orhan
(appointed interim
Chief Executive
24 Apr 2020 and as
Chief Executive
8 Jan 2021)

Independent Examiner

Moore Kingston Smith LLP
6th Floor, 9 Appold Street,
London EC2A 2AP

Accountants

JS2 Limited
1 Crown Square, Woking,
Surrey GU21 6HR

Legal advisors

Farrer & Co
66 Lincoln's Inn Fields,
London WC2A 3LH

Bankers

HSBC Plc
20 Electric Parade,
George Lane,
South Woodford,
London E18 2LX

Registered Office

60 Gray's Inn Road,
London WC1X 8AQ

Tel 020 3745 7310
www.orchid-cancer.co.uk

Registered in England with the
Charity Commission No.1080540

Company Limited by Guarantee
Registered in England
No. 3963360

Orchid Cancer Appeal

Annual report and financial statements

2020–2021

Welcome from our Chair	6
CEO's letter	7
The year in review	10
The year in numbers	12
Fundraising	14
Our impact	18
Prostate cancer	20
Testicular cancer	22
Penile cancer	24
Research	28
The year ahead	32
Governance	36
Objects, operating context and activities	36
Structure, Governance and Management	37
Financial review	40
Formal statements	40
Independent Examiner's information	41
Independent Examiner's Report	42
Statement of financial activities	43
Balance sheet	44
Statement of cash flows	45
Notes to the financial statements	46

Welcome from our Chair

The Trustees came together last year to look at new avenues of work while maintaining our focus, and I am pleased to report that our efforts have continued with tremendous success.

The Trustees advertised for a permanent CEO, and I am delighted to report that Ali Orhan who had been our Interim Chief Executive was appointed to the position.

I am very proud that our work in 2020 - 2021 was delivered with the same level of adaptability and resourcefulness that was shown in the previous year in response to the ongoing COVID-19 pandemic. We continued to work on raising awareness of prostate, testicular and penile cancers and supporting men with a diagnosis.

In September 2021 it was an honour to attend the renaming of the Orchid Research Tissue Bank which is now the Robert Lane Tissue Bank, renamed as tribute to the wonderful contribution Orchid's late Chair of Trustees, Robert Lane, made to the charity. The need to invest in research remains clear, so Orchid continued to support world-class research with our biggest grant being made to fund the Robert Lane Tissue Bank incorporating the Circulating Tumour Cells project.

Commencing with the recruitment of the staff team, Orchid has started on delivery of a substantial three-year programme of work entitled *Overcoming the Barriers to Engaging with Prostate Cancer*, funded by the National Lottery Community Fund. We thank the National Lottery for affording Orchid the opportunity to reach men at high risk and in some of the most deprived areas of the country.

In 2021 we said sad farewells to two long term and loyal supporters of Orchid, and I would like to pay tribute to them.

Roy Dickins passed away in August 2021 after a long illness. Together with his wife June, Roy was an avid Orchid fundraiser for many years. He was as well known for his quirky fund raising ideas as he was for his annual Christmas jumper. RIP Roy.

Roger Hunt MBE died in September 2021. Roger was a member of the 1966 World Cup winning England football team, and was a valued Ambassador for Orchid. RIP Roger.

I would like to thank the Orchid Trustees, CEO, and staff for continuing to deliver our services through these challenging times. Together I hope that we can continue to make Orchid successful and make further advancement in fighting the battle against cancer for men.

Colin Osborne MBE

CEO's letter

Educating people about male cancers and the benefits of an early diagnosis was a priority throughout 2020–2021, as Orchid was concerned that significant numbers of men were not presenting with cancer symptoms. With COVID-19 restrictions in place for much of the year, Orchid had to respond by adapting our support and practice once again. For this reason, technology and social media played a greater role in order to not only relay health messages, but also to deliver support through virtual sessions and online help, augmenting our face to face work.

With the team in place to deliver the National Lottery Community Fund programme Overcoming the Barriers to Engaging with Prostate Cancer, this work commenced in May. In September, our annual Male Cancer Awareness Week was once again delivered mostly digitally and had a particular focus on penile cancer for the first time. Two highlights from the Week were the launch of a new animated film called My Penile Cancer Journey, and the release of a moving video featuring photographs of male loved ones.

The Week led to the first International Penile Cancer Awareness Day and a global virtual conference on penile cancer which was developed in partnership with the Global Society of Rare Genitourinary Tumours and the Australian charity, Check Your Tackle.


In line with COVID-19 restrictions, our Community Engagement Team continued to take information directly to households in targeted areas and we provided opportunities for people to attend online sessions with an Orchid Nurse. As the external environment opened up, we were also able to deliver Male Cancer Information Roadshows in Bury, Croydon, Liverpool and Preston.

I believe that this blend of working virtually, using technology and delivering in person gives Orchid the opportunity to increase its reach and provide more information to a more diverse audience, and I am grateful for the dedication of Orchid's staff and volunteers, and the support of Trustees.

Ali Orhan, CEO

‘You go through life trying not to think about things like prostate cancer.

Then Orchid comes along and runs an awareness session in your community and you think: I’m so glad I do now actually understand a bit about the risks’



Opposite: A scene from the animated short film *My Penile Cancer Journey*, launched on social media during Male Cancer Awareness Week, September 2021

The year in review

2019-2020 had ended on a high note with the successful predominantly digital delivery of Orchid's Male Cancer Awareness Week. This was just one example that had showcased Orchid's ability to adapt its way of working to meet the challenges presented by COVID-19 and the changing external environment.

Work throughout 2020-2021 was delivered with that same level of adaptability in response to ongoing low male cancer awareness, the demand for information and support for those living with a male cancer diagnosis, and the need to invest in world-class research into the causes, potential prevention, and treatment of male cancers.

Orchid's Nurse-led services continued to be reviewed on an ongoing basis to ensure we could safely meet the needs of those living with or at risk of prostate, testicular or penile cancer.

Educating people about male cancer and the benefits of an early diagnosis if needed was a priority throughout the year, especially considering our concern that significant numbers of people were not presenting with cancer symptoms. Social media

played a greater role in the relaying of health messages with posts directing people to our website for information or to download or request resources, as well as to our Your Privates testicular cancer microsite. We were not surprised therefore to see increased traffic to both sites.

Reaching those at risk was a priority, and many of our awareness activities targeted individuals in areas of deprivation where people are often less likely to engage with traditional health services. In line with COVID-19 restrictions, our Community Engagement Team continued to take information directly to households in targeted areas, we promoted our services widely including via healthcare professionals, and provided opportunities for people to attend online sessions with an Orchid Nurse. Most male cancer talks were delivered virtually.

Delivery of a new project, *Overcoming the Barriers to Engaging with Prostate Cancer*, which is funded by The National Lottery Community Fund, began in May. Volunteer Community Champions will work in 10 locations across England to cascade prostate cancer messages in their local areas. September saw Orchid return to the heart of local communities to deliver



Male Cancer Information Roadshows in Bury, Croydon, Liverpool, and Preston, and where we were met with high demand for information.

The hours of Orchid's freephone National Male Cancer Helpline were increased in March 2020 and demand was such that this continued throughout 2020-2021. Both the number and duration of calls increased in comparison with the previous year. Most of the sessions of the peer support groups which Orchid helps facilitate were delivered online, although there was some demand (when COVID-19 restrictions permitted it) for meeting in person with social distancing in place. Orchid Nurse Rob Cornes continued to support the St Bartholomew's Testicular Cancer Support Group. In the reporting year he was also able to refer men affected by penile or testicular cancer to Orchid's telephone counselling service.

Orchid understands that talking to a GP about potential cancer symptoms, especially with virtual appointments, can be daunting for some men. Therefore, we created a checklist to help them start the conversation with their GP and to help them get the most out of their

appointment. Another new resource launched during the period was a PSHE Association accredited lesson plan to help schools educate their pupils about testicular health and testicular cancer.

September's annual Male Cancer Awareness Week was once again delivered mainly digitally, and had a particular focus on penile cancer for the first time. Two highlights of the Week were the launch of a new animated film called *My Penile Cancer Journey*, and the release of a moving video on the Rock Choir's social media channels featuring photographs of male loved ones. The Week led on to the first International Penile Cancer Awareness Day and a global virtual conference on penile cancer which was developed in partnership with the Global Society of Rare Genitourinary Tumours and the Australian charity, Check Your Tackle.

Alongside Nurse-led services, Orchid continued to support world-class research with our biggest grant being made to fund the Robert Lane Tissue Bank incorporating the Circulating Tumour Cells project. Our report on pages 28-30 shows that Orchid funded researchers had a productive year despite the impact of COVID-19.

The year in numbers



1,200

Downloads of the PSHE Association accredited lesson plan *What is testicular cancer?*



64,500

Pieces of Orchid's specialist information disseminated



350

New followers on social media




19%

increase in the number of Helpline calls answered by Orchid's Nurse Specialists compared to the previous year



10

Regional representatives recruited to the Task Force to support and help develop Orchid's new project *Overcoming the Barriers to Engaging with Prostate Cancer*



108,000

Reach of the animated film, *My Penile Cancer Journey*, launched on social media during Orchid's Male Cancer Awareness Week

1,609,920

Number of social media accounts reached with male cancer messaging



217,000

Page views on Orchid's website, an increase of 4% on previous year



50%

Increase in the average length of Helpline calls compared to the previous year

854



Number of people provided with in-depth support and information from a qualified Nurse

Orchid's work to save the lives of men from prostate, testicular and penile cancer during this reporting period was only possible because of the generosity of our wonderful supporters. Each and every contribution from individuals, community groups, Trusts and Foundations and companies helped us to make a difference, and we value all the support we received throughout what was another challenging year.

Fundraising

2019-2020 had seen a significant drop in income because of the impact of COVID-19. Whilst competition for funds remained high in 2020-2021 and the external environment was still uncertain, building relationships with existing and potential supporters continued to be a priority and Orchid's income stabilised and began to regrow. The year ended with a 32% increase in income on the previous year, and Orchid would like to thank everyone who helped us in any way.

Orchid was delighted to receive the support of The National Lottery Community Fund via the notification and then first payments of a 3-year grant to deliver a new prostate cancer programme across ten areas of England, alongside both restricted and unrestricted grants from Charitable Trusts and Foundations. Gifts from supporters were given in memory of loved ones and because of having been touched by male cancer. As COVID-19 restrictions lifted, our fundraising team

were pleased to be able to cheer and encourage supporters at events such as the London Landmarks Half Marathon in April, as well as supporting the many fundraising activities which individuals were organising across the UK. Significant support was received to fund male cancer research, and payroll giving continued to be a growing and valuable source of unrestricted income. Corporate support remained constant despite the challenges facing some of our supporters.

After the negative effect of the pandemic, our fundraising team and Trustees carried out a review of our activities to better understand the effect of COVID-19 on the different income streams. We used the learning from the previous year to help identify our fundraising strengths and new opportunities to ensure we retain a diverse and cost-effective fundraising base to balance risk in the years ahead.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises



Focus on Ian Wisdom

Ian Wisdom is one of Orchid's most committed supporters. For many years he has led his team comprising family and friends with great dedication to raise funds to help us fight male cancer. Ian is also passionate about raising awareness, to help people know who is at most risk and what to look out for. Thanks to Ian and his team, over £70,000 has been raised for Orchid, and thousands of people have gained important knowledge about male cancers.

The highlight of his fundraising year is the annual Twyford Beer Festival. After the disappointment of the cancellation of the 2020 event because of COVID-19, Ian and his team worked tirelessly and with great resilience to make the 11th Twyford Beer Festival in June 2021 a safe and successful event. Everyone working or performing at the festival gave their time for free so that they could raise as much as possible to help Orchid, and this year saw their previous fundraising record broken.

The 2021 Twyford Beer Festival raised the most incredible sum of £12,000 to help Orchid fight male cancer. Not only that, but two Male Cancer Information Nurses attended the event to help Ian's team raise awareness and to answer questions about prostate, testicular and penile cancer.

Orchid would like to thank Ian and all his team for their most wonderful dedication and support which is much valued, and which has been a significant contribution to Orchid's work to save men's lives from male cancer and to support those living with a diagnosis.

the importance of listening to and putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies.

Orchid operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves.

During the year we did not receive any complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.



**‘Having spoken with
you on the Orchid
Male Cancer Helpline
I now know so much
more about how to
go about supporting
my son’**

Our impact

Orchid is dedicated to improving the lives of men of all ages who are at risk of, or affected by male cancer. We work to save men's lives from prostate, testicular and penile cancer through a range of support services, education and awareness campaigns, and a world-class research programme:

Prostate cancer 20

Low awareness levels of this most common cancer in men in UK

Testicular cancer 22

Potentially most treatable cancer affects younger men

Penile cancer 24

Exceptionally rare but often psychologically damaging

Research 28

Our ongoing investment in future generations of men

Over the following pages, the names in the case studies have been changed and all photos are posed by models.



Our impact:

Prostate cancer

Over 52,000 men will be diagnosed with prostate cancer in the UK annually. Sadly, there are 11, 855 deaths from prostate cancer each year with 10-year survival at around 78%. According to CRUK, 1 in 6 UK males will be diagnosed with prostate cancer in their lifetime.

With more and more men being diagnosed with prostate cancer it is becoming more essential to correctly identify those men who may be at risk of disease progression and those with mild or inactive disease. One of the interesting directions that this may take are so called liquid biopsies – the sampling of circulating cancer cells within the blood. Orchid has helped fund research into circulating tumour cells or CTCs and this method along with a more frequent use of MRI scans to identify potential areas of prostate cancer may improve medical assessment dramatically and reduce the side effects men may experience from cancer treatment.

Orchid has a successful track record of working with the Black African and Black Caribbean community to raise awareness of Black men's increased incidence of prostate cancer, supported by the creation of relevant

resources. Building on that experience and reaching out to people from a wider range of identified communities, May 2021 saw the start of a new three-year project funded by The National Lottery Community Fund entitled Overcoming the Barriers to Engaging with Prostate Cancer. Through the project Orchid will recruit and train Volunteer Community Champions to help cascade prostate cancer messages to those at risk in Birmingham, Bradford, Bristol, Dudley, Leeds, Liverpool, Manchester, Newcastle, Nottingham, and Wolverhampton.

The project team has been recruited, and the initial months of the project were spent on development work, including the recruitment of a Task Force comprising of ten key community influencers who are helping to develop, implement and monitor key outputs and outcomes of the project. By the end of the reporting period resources such as the tool-kit (which will inform, guide and support the Volunteer Community Champions), policies, an evaluation framework and monitoring tools had been developed, and the recruitment of Volunteer Community Champions had begun.



Making the vital leap and reaching out to Orchid: Leford's story

When diagnosed with prostate cancer over 12 years ago at the age of 60, Leford was not displaying any of the classic symptoms of the disease but a friend urged him to get tested. Initial blood tests showed that his PSA levels were marginally high, but it was only a year later when he had further investigations that prostate cancer was diagnosed.

Despite being heartbroken by his diagnosis, Leford did not want to worry anyone else, particularly not his wife who is a retired Nurse. He told people that his regular trips to the hospital related to other health issues he had, his diabetes and high blood pressure, and Leford really thought he could deal with his cancer alone. He later realised that he had been wrong to think he could.

Leford underwent surgery to remove his prostate, which was followed by radiotherapy and then three-monthly hormone treatments. It was a

couple of years ago that he decided he needed to make the vital leap and contact Orchid who suggested he joined one of their prostate cancer support groups. He was part of both virtual and face-to-face groups and gained so much from them including the companionship with men who were experiencing similar emotions and had the same questions as he did.

Lockdown increased the isolation he felt at many times after his diagnosis, but the friends he made at the support group became his lifeline. He was also reassured by the knowledge that he could pick up the phone and speak to an Orchid Nurse, referring to them as his "Guardian Angels."

Leford shared his story with Orchid, and permission to use it to raise awareness to help others, in the knowledge that his condition was terminal. As a Black man he was at increased risk of prostate cancer, something he had not initially been aware of. Sadly, Leford passed away in late 2021.

Our impact:

Testicular cancer

Testicular cancer is rare with around 2,300 men being diagnosed each year in the UK. Sadly around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of men diagnosed between the ages of 15-45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life.

Treatment occurs quickly with men often being diagnosed and treated within a few weeks. As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects chemotherapy can increase the risk of cardiovascular disease in later life.

Challenges around testicular cancer involve supporting men in adjustment to life following treatment. Many will only realise the full implication of their cancer journey when treatment ends and may

not be able to access either peer support or psychological support.

Demand for information about testicular cancer has been high over the year, and there was a 16% increase of sessions on Orchid's testicular cancer microsite Your Privates compared to sessions in the previous year.

Orchid has consistently supported the biggest testicular cancer support group in the UK, which is co-ordinated by the specialist nurse team at St Bartholomew's Hospital in London, both physically and virtually.

In addition, Orchid's telephone counselling service allows men affected by testicular cancer to access psychological support without the necessity of waiting for extended periods of time.

Orchid has also been working with the Thera Group, an organisation supporting people with learning disabilities, along with the breast cancer charity Coppafeel. The aim is to produce an informative awareness leaflet on breast and testicular cancer with a target launch date of summer of 2022.



Finding comfort in knowing what the future might hold: Jack's story

When Jack was diagnosed with testicular cancer in 2018 he was 55 years old and had always thought this cancer only affected younger men. Indeed, testicular cancer is more common cancer in young men, and incidence rates for testicular cancer in the UK are highest in males aged 30 to 34, but older men can be affected too, as Jack discovered.

Jack had not thought he had anything to worry about, so was in complete shock when given a testicular cancer diagnosis. He found it a huge challenge to adjust to the diagnosis.

Following surgery, blood tests, x-ray and a CT scan, his cancer cells had metastasised to his abdominal lymph nodes. He had a cycle of chemotherapy to destroy the remaining cancer cells, and fortunately, after one cycle, he was told

that the treatment had been successful.

Jack knew he needed support to help him come to terms with his diagnosis and what it might mean for the future. He contacted Orchid's confidential Male Cancer Helpline, and later contacted Orchid in person. He was comforted by the support he received, but it also gave Jack an insight into what he could expect in the future – such as how it would affect both his physical and mental health.

Jack feels he can now be positive about the future. He knows that he can always talk to a Specialist Nurse on Orchid's Helpline, and that despite the potential challenges and issues he may face, he knows that there is support available from Orchid.

Our impact:

Penile cancer

Penile cancer is exceptionally rare in the UK with around 700 men being diagnosed each year. Sadly around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.

Out of all the male-specific cancers penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexual function. Due to its intimate nature up to 50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics. Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease - many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its rarity therefore missing out on invaluable peer support. In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral.

In response to the lack of awareness of this rare cancer, Male Cancer Awareness Week in September 2021 had a particular focus on penile cancer for the first time ever. Orchid also created the first International Penile Cancer Awareness Day (September 20th) and held a virtual conference for health care professionals and survivors.

In September 2021 Orchid facilitated and hosted a meeting of like-minded individuals, penile cancer survivors and those working within the field of penile cancer, in London. The result of this was the formation of The Orchid Penile Cancer Steering Group. The aim of this group is to foster links with anyone throughout the world who actively provides psychological, medical and peer support in order to create a global resource and support network. The manifesto for this group, entitled The Way Forward, is currently being created by Orchid with the aim of disseminating its existence globally throughout 2022.

Support for those affected is needed, and Orchid continues to run its telephone counselling service to support men going through a diagnosis of penile cancer as well as providing online peer support opportunities.

With the support of two penile cancer patient advocates, Orchid have continued to work with eUrogen/Eurodis (The European Network for Rare Urogenital Diseases), a network of European urologists and institutions whose aim is to improve the treatment of rare urological diseases including penile cancer in Europe. Orchid have helped produce a patient journey document which will be adopted by the European network and used to illustrate the needs of penile cancer patients.



One of the most significant conversations of his life: Ted's story

Like so many men, when Ted was diagnosed with penile cancer five years ago at the age of 58, he had never heard of this rare cancer.

His medical treatment for the disease made him feel anxious and confused, and he was completely surprised by the psychological impact of his diagnosis. He didn't know anyone else who had been affected by penile cancer and felt he needed to know if what he was experiencing was what also happened to other men.

Ted called Orchid's Freephone Male Cancer Helpline and his call was answered by Rob Cornes, Orchid's lead Male Cancer Information Nurse Specialist. Rob empathised with his situation, provided really important practical advice, and importantly, Rob completely understood how he was feeling. Ted later described his first call to Orchid as "one of

the most crucial and significant conversations I have ever had."

The Helpline is just one of the ways in which Orchid is able to help those affected by penile cancer. As well as dealing with the immediate issues, Rob suggested that Ted join an online support group which he facilitates. This provided Ted with the opportunity to meet others affected by penile cancer, and he was able to share his experience and gain mutual support from others in the group.

Rob also offered Ted the opportunity to be referred to Orchid's telephone counselling service for men diagnosed either with penile cancer or testicular cancer which he accepted. "The counselling service has proved invaluable in allowing me to address long standing issues which I hadn't realised remained unresolved."

**‘I hadn’t realised
that trans women and
non-binary people
can also be at risk of
these cancers’**





Orchid's research programme is an investment in the well-being of current and future generations. If we understand the three male-specific cancers, how they work and how to treat them, we can offer a better and brighter outlook for our loved ones, their children and grandchildren.

Our impact: research

In September 2021 the Orchid Research Tissue Bank was renamed in recognition of the most wonderful contribution made to Orchid by our former Chair, Robert Lane CBE, who died unexpectedly in February 2020.

Despite the impact of COVID-19, 2020-2021 was another productive year for the researchers in the Robert Lane Tissue Bank. There was a significant build-up of research capacity, important research findings and numerous publications in leading international journals.

The Tissue Bank has now collected over 13,000 specimens in total, representing an internationally significant resource for past and future research into all three male-specific cancers. Rather than collecting all tumours, this is a 'bespoke' bank often with long term clinical follow up and connected to clinical trial data, making it an invaluable resource for the future. Specifically, it holds:

- Tumours from nine separate clinical trials.
- Over 600 penile cancer specimens.
- Over 3,000 testicular cancer specimens.
- Over 6,000 prostate cancer specimens.
- Over 1,200 blood samples collected and separated into Circulating Tumour Cells (CTCs), plasma, red blood cells, white blood cells and platelets for separate storage and future research.

While the development of new drugs and therapies prolongs patients' survival period, advanced cancers are still rarely cured, yet cancers diagnosed at early stage are mostly curable by a number of treatments. However, detection of cancer at an early stage is still

challenging for many cancer types, including prostate cancer. Currently, cancer diagnosis is based on tissue biopsy. In their previous work, the researchers investigated a blood test in prostate cancer detection using a platform, Parsortix made by ANGLE plc, to efficiently detect cancer cells spread into the blood circulation (CTCs). This showed that the detection of cancer cells in the blood predict the prostate cancer tissue biopsy outcome with high accuracy, which not only distinguishes cancer from benign, but also indolent from aggressive cancers. In the aim to change the paradigm of prostate cancer diagnosis and also guide the treatment of cancer patients by monitoring cancer aggressiveness and progression by a blood test, they have started the validation study locally (Barts Hospital) and have set up the national network for a multiple centre validation study including QMUL (Barts and Whipps Cross Hospitals), University College of London (UCL)(UCL Hospitals), Imperial College (Hammersmith and Charing Cross Hospitals), University of Cambridge (Addenbrooke Hospital) and University of Newcastle (Newcastle upon Tyne Hospitals NHS Foundation Trust), a critical step to move this prostate cancer blood test into clinical use.

The CTC detection method used previously is time-consuming. In collaboration with ANGLE plc, researchers investigated faster CTC isolation methods and evaluated their efficiency in CTC detection in comparison with the previously established method. In collaboration with ANGLE plc, they have also established a method of using a method called, HyZip, which can simultaneously analyse a large number of CTC RNAs (ribonucleic acid) to further increase the

accuracy of detecting clinically significant prostate cancer. All these will facilitate the planned multiple-centre clinical study and the clinical implementation of detecting CTCs for prostate cancer diagnosis.

In collaboration with researchers at Pacific Northwest National Laboratories in USA, the team has also developed a proteomics technology (analysis of thousands of proteins simultaneously), applicable for CTC analysis.

CTCs clustered together are able to survive the immune cell attack in the blood circulation better than isolated single CTCs, therefore, they may form cancer metastasis easier than single CTCs. The team found that CTC clusters were found significantly more and larger (more CTCs per cluster) in patients with metastasis than non-metastatic prostate cancer. In non-metastatic cancer patients, more CTC clusters were found in aggressive than latent cases.

The researchers have also started to investigate the potential of using other materials/products that cancer cells released into the blood circulation. They have detected in peripheral blood certain prostate cancer cell released molecules, which are used by cancer cells to communicate with other body cells for cancer growth and metastasis, and their appearance is associated with the development of hormone therapy resistance of prostate cancer. The work has been published in *Frontiers in Cell and Developmental Biology*. The team has now identified by the advanced genetic sequencing technology that these molecules differentially presented in blood samples between prostate cancer and non-cancer patients.

Not all prostate cancers diagnosed at early stage are life threatening, so while the aim is to treat aggressive prostate cancer efficiently to cure the cancer, reducing side effects of treatment such as impotence and incontinence by avoiding unnecessary therapies for non-significant prostate cancer is equally important. Currently, cancer pathology grade, clinical stage and blood PSA (prostate-specific antigen) level have been used to decide who requires treatment and who can be safely 'observed' with routine follow up. Further molecular biomarkers are required to improve the treatment stratification, which is the team's long-term research focus. The team continued the study with the Trans-Atlantic Cohort, now with over 3,000 cases, and have validated that the biomarkers they identified are able to determine the aggressiveness of prostate cancer). Following their previous findings of using the protein Ki67 as aggressive cancer biomarker at prostate cancer diagnosis, the team further analysed Ki67 in advancing/metastatic prostate cancer samples from the largest prostate cancer national clinical study investigating drug treatment efficacy. They found that Ki67 may be a powerful prognostic and even predictive marker in advanced prostate cancer, helping to determine treatment.

Following the previous success in applying artificial intelligence, the team published the finding that intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists in Modern Pathology. As an international leading pathologist in urological cancers, Professor Berney published four more papers in the past year about improving the pathological diagnosis of prostate cancer.


Prevention is a more efficient approach than therapies to reduce death from cancer. The team have been involved in a prostate cancer prevention clinical study (PROVENT phase 1), aiming to use aspirin and vitamin D to prevent indolent cancer from progressing into aggressive cancer. The pilot study has recently been successfully completed. Patient samples are stored in the Robert Lane Tissue Bank under a Human Tissue Authority license awaiting further ethical approval for use in future research.

The genetic changes in cancer cells determines cancer development, behaviour and the treatment responses. Therefore, the team have continued the collaborative work with the international consortiums in prostate cancer genetic risk and somatic genetic abnormality studies, which led to high profile publications in the top scientific journals, Nature Genetics and Nature Communications. These findings are landmarks for our understanding of human cancer genetic alterations and will promote the development of new approaches in cancer diagnosis and treatment.

For testicular cancer, there have been publications in relation to using tumour node metastasis staging system as predictors for non-seminomatous germ cell tumours and management of patients at late stage after chemotherapy as well as a study carried out in UK with 216 patients for the efficacy of the use of a drug in metastatic seminoma. In addition, an overview of the impact on treatment decision making on testicular cancer has been done by the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). These studies all have the aim of appropriate and refined targeting of chemotherapy: to make sure it is

administered to those men who need it, and sparing the toxic side effects for those who do not. It is hoped these papers will become a mainstay of pathological information to guide treatment for both localised and advanced germ cell tumours. As well as publications, first prize was awarded at the National Germ Cell Group (NGCG) for a poster for review of pathology and outcome on Primary Somatic Transformation of Testicular Germ Cell Tumours.

The Tissue Bank team continued to collect penile cancer samples from St George's Hospital for future utilisation.



As a teacher I am so glad to have proper testicular cancer resources from Orchid and accredited by the PSHE Association as they tackle a potentially difficult subject in an engaging way

The reporting year ended with the successful delivery of Orchid's thirteenth Male Cancer Awareness Week which highlighted all three male-specific cancers, with a particular focus on the rare penile cancer.

The year ahead

Raising awareness of male cancer risk factors, signs and symptoms remained a priority as we entered the new financial year. To ensure this is supported by the best possible resources and information, Orchid Nurse Rob Cornes has committed to undertake a review of Orchid's information with view to attaining the PIF TICK which is the UK-wide Quality Mark for Health Information. Alongside that, three new resources are planned, including a z card about all three male cancers which will be used at Roadshows in particular, a film about advanced prostate cancer, and a series of posters.

In September 2021 we had returned to delivering Male Cancer Information Roadshows in the heart of local communities, and whilst we will monitor the external environment, we plan to run these throughout the coming year as funding becomes available. Roadshow locations have been identified for the first three months of the year and delivery planned. Orchid's Health at Work programme will be grown, and initial bookings for the year suggest there is a real appetite for Orchid's Male Cancer Information Nurse Specialists to talk to workforces, both virtually and in person. Orchid has been working with Tesco to help colleagues learn about male cancer, and staff will be delivering tailored Roadshows for Tesco in the year ahead.

Our plan is to further increase the reach of our social media activity and population type approaches. Case studies are being gathered as there is evidence to show that sharing the stories of people affected by male cancer is an effective way to raise awareness and to highlight the ways Orchid's Nurse-led services

can help. These case studies will also be used to support our fundraising activities.

In 2020-2021 the staff team had been recruited and work begun on our new project called Overcoming the Barriers to Engaging with Prostate Cancer, funded by The National Lottery Community Fund. The year ahead will see the recruitment and training of a large team of Volunteer Community Champions who will cascade prostate cancer health messages to targeted groups in the ten identified areas in which the project is being delivered.

Orchid's Male Cancer Awareness Week will take place between 12-18 September 2022 and have a particular focus on older men and testicular cancer. Testicular cancer tends to affect a younger age group than most other cancers, but Orchid has identified a need to highlight the fact that older men can be affected too, and to develop support aimed specifically at this older age group. The second International Penile Cancer Awareness Day will take place on 20 September.

Supporting those affected or concerned is a high priority for the coming year. The Freephone National Male Cancer Helpline will continue to operate with its increased hours, and if funding can be secured, the hours will be increased further to reduce the number of calls missed. We remain committed to offering peer support opportunities, and those currently delivered through the Penile Cancer Support Service in Scotland will be brought into our core services. We will continue to offer a telephone counselling service to those affected by penile or testicular cancer. Regarding penile cancer, Orchid has created a steering group, made up of survivors and healthcare

professionals, who are developing a programme of ongoing initiatives, called The Way Forward. Through this, Orchid will work on a global level to improve the patient journey for those with penile cancer.

Orchid's roots are in male cancer research, and we will continue to invest in world-class innovative male cancer research to benefit the well-being of current and future generations of men. Going into the year, Trustees identified two areas funds would be directed towards.

One is The Robert Lane Tissue Bank incorporating the Circulating Tumour Cell project, which is led by Professors Dan Berney and Yong-Jie Lu. Collection and validation of tissue from male cancers from high quality clinical trials and cohorts will advance our understanding of male cancers, creating better prognostic and predictive targets for treatment and diagnosis. Furthermore, the project will also increase understanding of the molecular mechanisms of prostate cancer development, progression and response to therapies and develop biomarkers for the diagnosis, prognosis and treatment response prediction of prostate cancer as well as testicular and penile cancers. The other male cancer research area Orchid will be focussing on is to award a significant grant from funds secured for the Orchid Research Innovation Fund.

Securing adequate funding at the best possible return on investment is paramount to delivering our ambitious plans for the year ahead. Having reviewed all fundraising activities and seen our income stabilised, our fundraising strategy for 2021-2022 focusses on continuing to grow revenue across all income streams.

The first day of the year ahead saw our wonderful team of runners fundraising in the London Marathon, and the charity is receiving interest in events throughout the year now that external events are being planned after so many were postponed because of COVID-19. We are excited that Orchid will be the recipient of a Radio 4 Appeal in April 2022, and September 2022 will see the return of the successful fundraising event, Orchid's Willy Waddle. Digital fundraising is a new area for the charity, and a Christmas appeal will be launched on Facebook. To make giving easier for our supporters, we will be looking at a new fundraising platform.

We will also continue to explore other new income generating opportunities, and to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, The National Lottery Community Fund and the individuals and community groups who support us with donations and fundraise on our behalf.

Having reviewed training need, we will invest in training for our small staff team, with the first priorities being Equality, Diversity, Equity and Inclusion, and the use of our fundraising database. Orchid also recognises its responsibility to reduce its carbon and environmental footprint and will continue to monitor its activities in relation to our Environmental Policy.

Orchid's work would not be possible without the generosity of our supporters, and the charity is grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the coming year.



**‘Contacting the
helpline was the most
important call of my
life. For the first time
here was someone
who understood and
could reassure me
that I was not alone’**

Governance

Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK

Objects, operating context and activities

Objects

Over 55,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly this number is increasing. Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair's aim to maintain a balanced composition. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from office in rotation, in order of longevity of appointment and are eligible to be reappointed. Throughout the COVID-19 pandemic Trustees met virtually.

Trustee training and induction

On appointment, Trustees receive a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Delegation and decision-making

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance Committee is responsible for the financial oversight of the Charity including budgeting, financial planning and monitoring as well as financial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at 30 September 2021, it comprised the Honorary Treasurer, Mr W Cohen, Mr C Osborne, Mr M Kibblewhite, Mr S Seymour and Mr S Harris.
- To improve efficiency, Sub-Committees have been reviewed, and the Fundraising Sub-Committee meets as required.
- At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept apprised of personnel, awareness, research programme and budgetary issues.

Public benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit including (PB2 Public Benefit: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation's strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the verification of outcomes, a Scientific Advisory Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identifies risks under the following headings:

Governance and compliance

Operational

Financial

Environmental/external

Research

Quality assurance

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified. These are shown in the table on the next page.

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to.

Mitigation

- An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and financial, are covered by suitably qualified professionals
- Training and support for Board of Trustees and Finance Committee
- Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
- Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

- Annual salary review to include benchmarking of compensation and benefits
- Staff development, training and succession planning programmes
- Communication programme to ensure staff are involved in the development of and progress towards Orchid's strategy and annual workplan

Financial

Economic pressures, impact of COVID-19, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

Mitigation

- Annual budgeting and ongoing management, reporting and monitoring of financial performance
- Diversification of income streams
- Ongoing consideration of market and consumer trends and regulations including GDPR

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid's work

Mitigation

- Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
- Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
- Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid's strategy

Research

Orchid's Research Programme fails to deliver results

Mitigation

- Scrutiny and approval of research funding applications by an expert Scientific Advisory Board
- Annual review of progress

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

- Services developed, delivered and evaluated in line with agreed protocol and standards
- Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)
- All information materials and content regularly reviewed and updated
- High-quality training for staff

Financial review

Results for the year

Income for the year ended 30 September 2021 totalled £530,278 (2020: £401,181). After total expenditure of £673,004 (2020: £756,577), the year's activities show a net deficit of £142,726 (2020: deficit of £355,396). Total reserves at the end of the year amounted to £440,280 (2020: £583,006).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity's core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available free reserves net of tangible fixed assets are £150,886 (2020: £139,396). It is the Charity's policy

to maintain free reserves of approximately 3-4 months of operating costs. At current levels of expenditure this equates to £145,000-£192,000.

Formal statements

Statement of Trustees' responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiner's information

So far as each of the directors at the time the Trustees' report is approved is aware:

- a) there is no relevant information of which the examiner is unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees



C S Osborne
Chairman of Trustees
14/06/2022

Independent Examiner's Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since the Company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or

4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Moore Kingston Smith LLP

James Saunders FCCA DChA
16/06/2022

For and on behalf of

Moore Kingston Smith LLP
Chartered Accountants
6th Floor, 9 Appold Street,
London EC2A 2AP

Statement of financial activities

(incorporating an income and expenditure account)

For the year ended 30 September 2021

	Note	Unrestricted Total £	Restricted Total £	Year ended 30 September 2021 £	Year ended 30 September 2020 £
Income from:					
Donations and Legacies	2	250,530	190,050	440,580	350,828
Charitable Activities	4	-	89,497	89,497	47,571
Trading Activities		177	-	177	534
Investment income		24	-	24	2,248
Total income		<u>250,731</u>	<u>279,547</u>	<u>530,278</u>	<u>401,181</u>
Expenditure on:					
Raising funds					
Fundraising (donations and grants)	5	185,083	-	185,083	187,210
Charitable Activities					
Education and Awareness	5	74,173	233,210	307,383	426,471
Research	5	106,638	73,900	180,538	142,896
Total expenditure		<u>365,894</u>	<u>307,110</u>	<u>673,004</u>	<u>756,577</u>
Net income / (expenditure) and net movement in funds	5,6	(115,163)	(27,563)	(142,726)	(355,396)
Reconciliation of funds					
Total funds brought forward		<u>394,129</u>	<u>188,877</u>	<u>583,006</u>	<u>938,402</u>
Total funds carried forward		<u><u>278,966</u></u>	<u><u>161,314</u></u>	<u><u>440,280</u></u>	<u><u>583,006</u></u>

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 13 to the financial statements.

Balance sheet

As at 30 September 2021

		30 September 2021	30 September 2020
	Note	£	£
Fixed Assets			
Tangible Assets	10	<u>2,971</u>	<u>366</u>
Current Assets			
Cash at bank and in hand		508,854	727,441
Debtors	11	<u>77,325</u>	<u>136,586</u>
		586,179	864,027
CREDITORS			
Amounts due within one year	12	<u>(148,870)</u>	<u>(281,387)</u>
Net Current Assets		<u>437,309</u>	<u>582,640</u>
Total Assets less Current Liabilities	13	<u>440,280</u>	<u>583,006</u>
NET ASSETS		<u>440,280</u>	<u>583,006</u>
Represented by:	14		
General Unrestricted Funds		157,158	135,382
Designated Funds		<u>121,808</u>	<u>258,747</u>
		278,966	394,129
Restricted funds		<u>161,314</u>	<u>188,877</u>
		<u>440,280</u>	<u>583,006</u>

The company is limited by guarantee.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 9 June 2022 and signed on its behalf by:



Mr C S Osborne

Company number 3963360

Statement of cash flows

For the year ended 30 September 2021

	2021		2020
	£	£	£
Cash flows from operating activities:			
Net expenditure for the year	(142,726)		(355,396)
Adjustments for:			
Depreciation charges	1,486		729
Interest	(24)		(2,248)
Decrease in debtors	59,261		50,460
(Decrease) in creditors	(132,517)		(25,980)
Net cash provided by operating activities		(214,520)	(332,435)
Cash flows from investing activities:			
Interest	24		2,248
Disposal of fixed assets	-		(1,091)
Purchase of fixed asset	(4,091)		-
Disposals of investments	-		912,297
Net cash used in investing activities		(4,067)	913,454
Change in cash and cash equivalents in the year		(218,587)	581,019
Cash and cash equivalents at the beginning of the year		727,441	146,422
Cash and cash equivalents at the end of the year		508,854	727,441
Analysis of cash and cash equivalents			
Cash at bank and in hand		508,854	727,441
		508,854	727,441

Notes to the financial statements

1. Accounting policies

Basis of Preparation

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements and have considered the impact of the coronavirus pandemic on the charity's operations. In particular the trustees have considered the charity's forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2021/22; however, there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

The charity has secured a 3-year project funded by The National Lottery Community Fund: Overcoming the Barriers to Engaging with Prostate Cancer. The aim is to work in targeted locations across England and focus on supporting individuals from identified communities to overcoming barriers to engaging with prostate cancer. This will enable Orchid to continue its valued work. Many fundraising events have been postponed from 2020 and as a result Orchid has an all-time number of runners signed up for events in the Summer of 2021. Whilst there is still some risk around fundraising events being held in the Summer, Orchid is hopeful that the relaxation of Covid-19 restrictions will enable these events to take place. The National Lottery project along with continued support from loyal donors and will enable Orchid to continue to as a going concern.

The trustees confirm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its financial statements.

Functional currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised. Computer and Office Equipment - 33 1/3% on written down value.

Funds accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal. The purpose and use of the Charity's restricted funds is set out in the notes to the financial statements.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/ distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity's objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity's objects.

Governance costs are those incurred in connection with the management of the Charity's assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee's services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

Notes to the financial statements

2. Donations

Current year

			Year ended 30 September 2021 Total £	Year ended 30 September 2020 Total £
	Restricted £	Unrestricted £		
Individuals	92,800	51,044	143,844	85,501
Legacies	-	-	-	17,000
Corporates	-	35,771	35,771	22,434
Trusts and Foundations	97,250	17,050	114,300	99,365
Fundraising Events	-	146,665	146,665	114,545
Total	190,050	250,530	440,580	338,845

Prior year

			Year ended 30 September 2020 Total £
	Restricted £	Unrestricted £	
Individuals	16,200	69,301	85,501
Legacies	-	17,000	17,000
Corporates	5,000	17,434	22,434
Trusts and Foundations	88,115	11,250	99,365
Fundraising Events	-	114,545	114,545
Total	109,315	229,530	338,845

Notes to the financial statements

3. Fundraising events

Current year

			Year ended 30 September 2021	Year ended 30 September 2020
	Restricted	Unrestricted	Total	Total
	£	£	£	£
Cycling events	-	11,257	11,257	3,249
Running events	-	56,100	56,100	39,017
Third party organised events	-	76,943	76,943	64,346
Other	-	2,365	2,365	7,933
Total	-	146,665	146,665	114,545

Prior year

			Year ended 30 September 2020
	Restricted	Unrestricted	Total
	£	£	£
Cycling events	-	3,249	3,249
Running events	-	39,017	39,017
Third party organised events	-	64,346	64,346
Other	-	7,933	7,933
Total	-	114,545	114,545

Notes to the financial statements

4. Charitable activities

Current year

	Restricted	Unrestricted	Year ended 30 September 2021 Total £	Year ended 30 September 2020 Total £
	£	£	£	£
Grants - National Lottery Community Fund				
Covid 19 Emergency Funding	-	-	-	47,571
The National Lottery Community Fund - RC England-wide	89,497	-	89,497	-
Total	89,497	-	89,497	47,571

Prior year

	Restricted	Unrestricted	Year ended 30 September 2020 Total £
	£	£	£
Grants - National Lottery Community Fund			
Covid 19 Emergency Funding	47,571	-	47,571
Total	47,571	-	47,571

Notes to the financial statements

5. Total expenditure

Current year				Year ended 30 September 2021 Total £	Year ended 30 September 2020 Total £
	Cost of raising funds £	Education and awareness £	Research £		
Grants	-	-	154,896	154,896	112,876
Staff costs	88,500	133,468	17,044	239,012	339,143
Fundraising expenses	51,935	-	-	51,935	26,277
Information materials	-	66,371	-	66,371	72,185
Direct costs	-	30,322	-	30,322	79,807
	<u>140,435</u>	<u>230,161</u>	<u>171,940</u>	542,536	<u>630,288</u>
Support costs					
Depreciation	499	891	96	1,486	729
Other	33,057	59,054	6,366	98,477	105,333
Governance - staff costs	9,119	13,753	1,756	24,628	8,717
Governance - examiner's fees	1,973	3,524	380	5,877	11,510
	<u>44,648</u>	<u>77,222</u>	<u>8,598</u>	130,468	<u>126,289</u>
Total expenditure	<u>185,083</u>	<u>307,383</u>	<u>180,538</u>	673,004	<u>756,578</u>
Prior year	<u>187,210</u>	<u>426,471</u>	<u>142,896</u>	756,578	

Notes to the financial statements

6. Grants awarded

	Year ended 30 September 2021 £	Year ended 30 September 2020 £
Grant commitments brought forward	205,415	199,002
Institutional grants for medical research awarded during year: Barts and London School of Medicine	138,896	112,876
Payments made during period/year	(291,459)	(106,463)
Grant commitments carried forward	<u>52,852</u>	<u>205,415</u>
Payable less than one year	52,852	205,415
Payable two to five years	-	-

Notes to the financial statements

7. Net expenditure for the year

This is stated after charging:

	Year ended 30 September 2021 £	Year ended 30 September 2020 £
Depreciation	1,486	729
Examiner's remuneration: Examination	5,300	-
Auditor's remuneration: Audit	-	9,592
Trustees' remuneration	-	-
Trustees' expenses	-	-

Notes to the financial statements

8. Staff costs and numbers

Staff cost were as follows:

	Year ended 30 September 2021 £	Year ended 30 September 2020 £
Salaries and wages	182,602	241,235
Social security costs	13,020	20,787
Pension contributions	1,364	2,442
	196,986	264,464
Consultants' costs	66,655	83,397
	263,641	347,861

During the year ended 30 September 2021 one employee earned more than £60,000 (Year to 30 September 2020: one). The pension contribution paid in respect of this employee totalled £Nil (2020: £Nil)

The key management personnel of the Charity comprise the Trustees and the Chief Executive.

The charity trustees do not receive remuneration.

The total remuneration of the chief executive was £66,494 (year ended 30 September 2020: £80,177).

The average number of employees during the year was 6.7 (2020: 5.8)

The average number of employees during the year on a headcount basis was as follows:

	2021 No.	2020 No.
Fundraising	2.1	1.7
Education and awareness	4.3	5.1
Grant support	0.3	0.2
	6.7	7

Notes to the financial statements

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

Notes to the financial statements

10. Tangible fixed assets

	Computer and office equipment Total £	30 September 2021 Total £	30 September 2020 Total £
Cost			
At the start of the period	3,224	3,224	2,674
Additions	4,091	4,091	2,187
Disposals	-	-	(1,637)
At the end of the period	7,315	7,315	3,224
Depreciation			
At the start of the period	2,858	2,858	2,674
Charge for the period	1,486	1,486	729
Disposals	-	-	(545)
At the end of the period	4,344	4,344	2,858
Net book value			
At the end of the period	2,971	2,971	366
At the start of the period	366	366	-

Notes to the financial statements

11. Debtors

	Year ended 30 September 2021 £	Year ended 30 September 2020 £
Prepayments	45,594	83,777
Other debtors and accrued income	31,731	52,809
	<u>77,325</u>	<u>136,586</u>

Notes to the financial statements

12. Creditors: amounts due within one year

	Year ended 30 September 2021 £	Year ended 30 September 2020 £
Grants payable	87,576	205,415
Trade and other creditors	20,799	34,691
Taxation and Social Security	-	5,530
Accruals	40,495	35,754
	<u>148,870</u>	<u>281,390</u>

Notes to the financial statements

13. Movements in funds

Current year	Brought forward	Income	Expenditure	Carried forward
	£	£	£	£
Unrestricted				
General	135,382	250,731	(228,955)	157,158
Designated – Research	53,281	-	(53,281)	-
Designated – Development	121,808	-	-	121,808
Designated – Awareness	83,658	-	(83,658)	-
Total unrestricted	394,129	250,731	(365,894)	278,966
Restricted				
Testicular Cancer Counselling	-	3,000	(3,000)	-
The National Lottery Community Fund – RC England-wide	-	89,497	(57,052)	32,445
Male Cancer Nurse Information Specialist – other funders	56,974	6,000	(54,722)	8,252
The Innovation Research Project	16,200	92,800	(16,200)	92,800
Penile Cancer Peer Support	5,000	2,500	(7,500)	-
Education and Awareness	11,250	23,050	(29,300)	5,000
Student Study and Travel Scholarships	6,729	-	-	6,729
Roadshows	37,527	1,000	(35,667)	2,860
Robert Lane Tissue Bank	-	57,700	(57,700)	-
Young Person's Testicular Cancer Project	10,369	-	(7,141)	3,228
National Lottery Community Fund – Covid 19 Emergency	37,328	-	(37,328)	-
City of London Corporation	7,500	4,000	(1,500)	10,000
Total restricted	188,877	279,547	(307,110)	161,314
Total funds	583,006	530,278	(673,004)	440,280

Notes to the financial statements

13. Movements in funds (continued)

Prior year	Brought forward	Income	Expenditure	Carried forward
	£	£	£	£
Unrestricted				
General	334,804	244,295	(443,717)	135,382
Designated – Research	166,157	-	(112,876)	53,281
Designated – Development	121,808	-	-	121,808
Designated – Awareness	83,658	-	-	83,658
Total unrestricted	706,427	244,295	(556,593)	394,129
Restricted				
Testicular Cancer Counselling	16,247	-	(16,247)	-
Big Lottery Reaching Communities Fund	51,469	-	(51,469)	-
Male Cancer Nurse Information Specialist - other funders	76,706	-	(19,732)	56,974
The Innovation Research Project	0	16,200	-	16,200
Penile Cancer Peer Support	4,492	5,000	(4,492)	5,000
Education and Awareness	-	33,250	(22,000)	11,250
Student Study and Travel Scholarships	6,729	-	-	6,729
Roadshows	30,926	33,415	(26,814)	37,527
Tissue Bank	-	13,750	(13,750)	-
Young Person's Testicular Cancer Project	10,369	-	-	10,369
National Lottery Community Fund – Covid 19 Emergency	-	47,571	(10,243)	37,328
City of London Corporation	-	7,500	-	7,500
Services	-	200	(200)	-
North East London Cancer Network	35,037	-	(35,037)	-
Total restricted	231,975	156,886	(199,984)	188,877
Total funds	938,402	401,181	(756,577)	583,006

General funds are unrestricted funds available for use at the Trustees' discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Research funds represent monies set aside at the Trustees' discretion to be used to help fund the costs of future research programmes.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

Notes to the financial statements

14. Analysis of net assets between funds

Current year	Unrestricted funds £	Restricted funds £	Total funds at 30 September 2021 £
Fixed assets	2,971		2,971
Current assets	424,865	161,314	586,179
Creditors due within one year	(148,870)		(148,870)
Net assets at 30 September 2021	278,966	161,314	440,280
Prior year	Unrestricted funds £	Restricted funds £	Total funds at 30 September 2020 £
Fixed assets	366		366
Current assets	613,437	250,590	864,027
Creditors due within one year	(281,387)		(281,387)
Net assets at 30 September 2020	332,416	250,590	583,006

Notes to the financial statements

15. Related party transactions

Aggregate donations of £80,000 were received from trustees in the year ended 30 September 2021. (Year to 30 September 2020: none)

Notes to the financial statements

16. Financial commitments

For the year ended 30 September 2021, the charity was committed to making the following future payments under non cancellable operating leases.

	Year ended 30 September 2021 £	Year ended 30 September 2020 £
<i>Land and buildings</i>	-	-
Expiring within one year	14,184	14,184
	<u>14,184</u>	<u>14,184</u>

ORCHID CANCER APPEAL

England & Wales - Charity number 1080540

Accounts



ORCHID CANCER APPEAL

**annual report and
financial statements**
2019–2020

About Orchid Cancer Appeal

Orchid Cancer Appeal, known as Orchid, is a small, influential charity, solely dedicated to improving the lives of men of all ages who are at risk of, or affected by male cancer.

For over 20 years we have been working to save men's lives from prostate, testicular and penile cancer through a range of support services, education and awareness campaigns, and a world-class research programme.

Registered office
60 Gray's Inn Road
London WC1X 8AQ

Tel 020 3745 7310
www.orchid-cancer.co.uk

Registered in England with the
Charity Commission No.1080540

Company Limited by Guarantee
Registered in England No.
3963360



Report designed by
Andrassy Media

Registered Office	60 Gray's Inn Road London WC1X 8AQ
Board of Trustees	Mr R Lane CBE Chair (deceased 8 February 2020) Mr CS Osborne Chair (appointed 10 March 2020) Mr W Cohen Treasurer (appointed 1 January 2020) Mr K Cook Treasurer (resigned 3 March 2020) Mr D Badenoch Mr PG Bracher Mr S Harris Mr M Kibblewhite (appointed 10 March 2020) Professor RTD Oliver Mr P Norman Mr S Seymour Mr N Watkin
Chief Executive	Miss RI Porta (resigned 23 April 2020) Mr A Orhan (appointed interim Chief Executive 24 April 2020 and as Chief Executive 8 January 2021)
Auditor	Moore Kingston Smith LLP Devonshire House 60 Goswell Road London EC1M 7AD
Accountants	JS2 Limited 1 Crown Square Woking Surrey GU21 6HR
Legal advisors	Farrer & Co 66 Lincoln's Inn Fields London WC2A 3LH
Bankers	HSBC Plc 20 Electric Parade George Lane South Woodford London E18 2LX

Contents

Welcome from our Chair	4
CEO's letter	5
The year in review	6
The year in numbers	10
Fundraising	12
Our impact	16
Prostate cancer	18
Testicular cancer	22
Penile cancer	26
Research	30
The year ahead	32
Governance	36
Objects, operating context and activities	36
Structure, Governance and Management	37
Financial review	40
Formal statements	41
Auditor's Report	45
Statement of financial activities	45
Balance sheet	46
Statement of cash flows	47
Notes to the financial statements	48

Welcome from our Chair

With the advent of the COVID-19 pandemic, and changes in senior personnel, this year was one of rapid, and unexpected change for Orchid to work through.

In February 2020, the whole organisation was deeply saddened by the sudden passing of our Chair, Robert Lane CBE. Robert had been with Orchid for twelve years, the last six as Chair, leading the organisation with his characteristic warmth and strength.

In March, I was asked to step into the role of Chair and Orchid were delighted to welcome back Mark Kibblewhite as a Trustee. The Board of Trustees came together to identify and explore new avenues and existing areas of business to help in our fight to help educate men and save lives, and I would like to thank them for their dedication and leadership this year.

Shortly after the UK entered full lockdown due to the pandemic, our CEO Rebecca Porta left for a new position after nine years of service to the organisation. This led the Board to appoint Ali Orhan as interim CEO from April 2020. Ali had been working with Orchid since 2017 and we felt his extensive knowledge of public health – with specialisms in cancer and sexual health – together with his senior management experience was exactly what Orchid required.

The Trustees worked closely with the new CEO to restructure Orchid and make the necessary changes to secure our future going forward. I would like to thank all our wonderful staff, volunteers, grant givers and supporters for their enduring support to Orchid at this time.

Colin Osborne MBE

CEO's letter

In April 2020, I was honoured to be appointed as the interim CEO at Orchid. I knew at the time it would be a huge challenge as the UK was in full lockdown due to the pandemic.

In the COVID-19 environment there were critical decisions to be made and actions to be taken from a very basic level of operation such as reassessing contracts with service providers, to ensuring the safety of staff and supporters by changing the way we did business, to making strategic fundraising decisions and applying for vital grants to ensure Orchid's survival.

I am pleased to say that the whole of the organisation responded to this testing time with creativity and positivity and there were many highlights including:

- Changing the London Marathon into a virtual marathon team, raising £10,000
- Rapidly adapting our outreach work in communities to be COVID-19 safe, so that information packs were in sealed packs and letter box drops were carried out to avoid any virus transmission
- Progressing on a substantial National Lottery Community Fund grant application which gives us optimism for next year.

In addition, I am extremely proud to say that Orchid's short film on prostate cancer and its impact, Uncle Mike, won awards at Thundr Short Film Showcase in August 2020, as well as numerous mentions and commendations at other international film festivals such as the Baltimore International Black Film Festival, London City Film Awards and the Edinburgh Independent Film Awards. This is a testament to the quality of the film and the story, and enables Orchid's messages to reach an international audience.

Reaching wider and more diverse audiences is something that I am passionate about, and I will be working tirelessly to make sure Orchid's information and support becomes more inclusive and reaches new audiences. Not only will this help to promote our brand and protect more men, but it will also bring in new supporters and funders to perpetuate our work.

I would like to thank the Board of Trustees, staff and volunteers for their support and understanding as we navigated numerous challenges and demands whilst still keeping to our mission and plans

Ali Orhan, CEO

The year in review



This page, left to right:
Our **Dare A Dad** sponsorship campaign was one innovative response to fundraising activity moving online; **One in Four** was a creative way of raising prostate cancer awareness from the pre-COVID-19 part of the year; while **Each One Teach One** – a virtual way of offering support, prompted by the pandemic – proved very popular with men

For almost the first six months of the year, Orchid responded to low levels of male cancer awareness by reaching out into the heart of local communities to educate people about the signs, symptoms and risk factors of testicular, penile and prostate cancer.


We gave talks in workplaces and in prison, had information stands in libraries and at community events, showed films to community groups with question-and-answer sessions, and delivered Male Cancer Roadshows in locations such as Bristol, Luton and Blackburn. We particularly targeted men in areas of deprivation where men are often less likely to engage with traditional health services.

When the COVID-19 pandemic hit, Orchid's immediate response was to pause community outreach in line with Government guidance. At

the same time, we realised that our colleagues in the NHS may not be available to answer as many patient queries as normal regarding male cancer concerns, so we increased the hours of our freephone National Male Cancer Helpline. As we had expected, calls did increase, both in number and duration. The complexity of calls to the Helpline also increased at this point as it became difficult for some people to access healthcare services.

We were concerned by reports of people not presenting to healthcare professionals with potential cancer symptoms, and our Nurse led services were reviewed and adapted in light of the changing external landscape so we could reach men safely with male cancer messages and offer support.

The peer support groups which Orchid help



Above: We launched our award-winning short film **Uncle Mike** which tells the story of a young man and his mentor, and the impact of prostate cancer on their relationship
 Above right: **Check.Check.Check.** was our social media-based campaign for Male Cancer Awareness Week


to facilitate moved to meet virtually. This proved popular with those attending, and the first online penile cancer forum delivered via Zoom attracted men from as far afield as Nottingham, Birmingham, London and Scotland.

Our social media activity also increased. Our annual Male Cancer Awareness Week in September was at the height of the pandemic, so the decision to deliver a predominantly digital campaign proved timely. The campaign delivered a series of daily messages via social media about seeking medical advice if potential male cancer symptoms were present, with a call to action for men to “Check.Check.Check.”

Unable to give talks and presentations face to face, we developed a presentation about each of the male-specific cancers which could be delivered virtually. As our staff worked from home for much

of the second part of the year and were not always able to respond as quickly as we would like to requests for information, we also improved the information found on our website. This included making sure that all of our information was easily downloadable to avoid any delay for people who wanted our specialist information.

Working in partnership has remained a key objective despite COVID-19, and we have continued to work with other groups to improve patient outcomes. We were particularly delighted to be invited to take part in the European Reference Network (eUROGEN) and European Patient Advocacy Groups (ePAG) meetings, to improve the patient pathway for men with penile cancer across Europe. This has included the recruitment and empowerment of two men with penile cancer, who have been supported by Orchid to become patient



Above, left to right: We launched **Active Surveillance**, our film describing the benefits of this treatment involving regular blood tests, physical examinations and MRI biopsies; an emergency grant from **National Lottery Community Fund** was a much needed boost for the charity as the pandemic started to take its toll.


representatives for ePAG in an ongoing programme which includes Orchid Nurse Rob Cornes.

A documentary about Orchid supporter Richard Stamp's experience of living with penile cancer aired on Channel 5 in August 2020, with a potential viewing audience of 6 million. The documentary, in which both Orchid and our Nurse Rob Cornes were represented, did so much to raise the profile of penile cancer. A subsequent interview on ITV's This Morning had a potential audience of 500,000, while a youtube clip of this video has been viewed by over 30,000 people. There was also coverage in the national press.

Orchid has also continued to work closely with the St Bartholomew's Testicular Cancer Support Group with Orchid Nurse Rob Cornes helping facilitate virtual online meetings.

Alongside our Nurse-led services, Orchid continues to support world-class research. During 2019-20 we were pleased to support the work of the Orchid Research Tissue Bank and the Circulating Tumour Cells project, and more on this work can be found on page 30 of this report.

**‘Contacting
the Orchid
helpline was
the most
important
call of my
life’**



The year in numbers

With the challenges of the Coronavirus pandemic Orchid needed to find new and innovative ways of connecting with men. Consequently, many of the most significant numbers during the year have been a result of the organisation's online activities...

125%

Increase in Instagram followers

2

Orchid launched two new films during the reported year: *Active Surveillance* and *Uncle Mike*

334,027

Total reach of Male Cancer Awareness Week campaign 2020

5,451 prostate

3,081 testis

639 penile

Number of patient samples stored at the Orchid Tissue Bank

48,281

Resources disseminated and shared

1,270

**Number of Circulating Tumour Cells
at the Orchid Tissue Bank**

260,778

**Facebook reach (number of unique accounts that
have seen any of Orchid's posts)**

350

**Number of individuals who signed up
to Hands On Payroll Giving**

91,814

**Number of
impressions on
Twitter (number of
people who saw
Orchid's tweets)**

**National Male Cancer
Helpline: number of
helpline hours
provided**

As a result of the pandemic, fundraising in all areas became increasingly competitive. We were therefore delighted to receive a grant from the National Lottery Community Fund's COVID-19 emergency funding programme, as well as grants from other supporters including Janssen, to help us through a difficult time.

Fundraising

Throughout the period our fundraising team remained resilient and continued to build relationships with existing and potential supporters

Orchid worked tirelessly throughout the year to save the lives of men from prostate, testicular or penile cancer, and we could not have done this without our supporters. We really appreciate every donation or grant given in what has been a challenging year and would like to thank everyone who has supported us.

There had been a promising start to the year in all areas of fundraising. However, the COVID-19 pandemic brought new and unknown challenges for our small fundraising team, including the postponement and cancellation of both externally organised events and Orchid's own established fundraising events. Furthermore, there was a change in the giving criteria for some Charitable Trusts as a number supported only causes directly COVID-19 related, and others postponed meetings whilst giving was reviewed.

Fundraising in all areas became increasingly competitive. We were therefore delighted to receive a grant from the National Lottery Community Fund's COVID-19 emergency funding programme, as well as grants from other supporters including Janssen, to help us through a difficult time. Throughout the period our fundraising team remained resilient and continued to build relationships with existing and potential supporters.

Some of the priorities for the year were further developing areas such as payroll giving which produces long term sustainable income, working with funders to seek permission to delay the start of projects or to seek permission to deliver activities differently, and carefully stewarding those who had signed up to or were interested in postponed or cancelled events



which resulted in strong teams for the virtual London Marathon as well as for future events. We truly are indebted to the many supporters, friends and volunteers who have supported Orchid during this testing year.

Orchid recognises the importance of listening to and putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies.

Orchid operates a clear and stringent complaints handling procedure that is reported

to the Senior Management team and the Board of Trustees. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the Charity.

We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received one complaint in relation to our fundraising activities which was addressed in line with our policy. We remain committed to improving our practice, learning from supporter feedback.

Above: social media campaigns like Orchid's Virtual Challenges sought innovative ways to fundraise when existing channels were interrupted by COVID-19



**We truly are
indebted to the
many supporters,
friends and
volunteers who
have supported
Orchid during this
testing year**

Our impact

Orchid is dedicated to improving the lives of men of all ages who are at risk of, or affected by male cancer. We work to save men's lives from prostate, testicular and penile cancer through a range of support services, education and awareness campaigns, and a world-class research programme:

Prostate cancer

Low awareness levels of this most common cancer in men in UK 18

Testicular cancer

Potentially most treatable cancer affects younger men 22

Penile cancer

Exceptionally rare but often psychologically damaging 26

Research

Our ongoing investment in future generations of men 30



Our impact: Prostate cancer

Although there are over 95 prostate cancer support groups in the UK, the black community remains under represented

Prostate cancer is the most common cancer in men in the UK. Around 49,000 men will be diagnosed each year while 11,500 will die from the disease. Survival at 10 years is high at around 68%.

One of the biggest changes over the last few years has been the utilisation of a treatment called active surveillance. As more men are diagnosed with early prostate cancer which may remain indolent for some time, sometimes for years, there is a greater benefit from close monitoring of patients with regular PSA (prostate-specific antigen) blood tests, physical examinations and MRI guided biopsies. This means that treatment, which will inevitably have an effect on sexual function and continence, can be avoided until such time that there is obvious progression of disease. Research has also indicated that even some men with more severe disease may also benefit from active surveillance and this is likely to become one of the biggest treatment options for men in the next 10 years. Research also shows that it may take some men 6-months or more to adjust to the fact that their cancer does not require immediate treatment, and initial

support for these men is essential to help them come to terms with their treatment. As more accurate biomarkers evolve, identifying men who will have significant or non-significant disease, surveillance is likely to become much more widely used.

One of the greatest challenges around prostate cancer remains the unequal risk of prostate cancer among black African and black Caribbean men who are twice as likely to develop prostate cancer than Caucasian men. Creating awareness in this community and helping support black men diagnosed with prostate cancer is crucial. Although there are over 95 prostate cancer support groups in the UK, the black community remains underrepresented.



Successful completion of a three-year prostate cancer project delivered in targeted London Boroughs

January 2020 saw the end of the successful three-year 'Changing lives: engaging with Black African and Black Caribbean men at risk of, or affected by, prostate cancer' project which had been funded by the Big Lottery Fund (now the National Lottery Community Fund) in partnership with the charity Cancer Black Care.

The project had been developed in response to low levels of awareness amongst black African and black Caribbean men about prostate cancer and their increased risk which meant many were presenting late to healthcare professionals with possible signs and symptoms. One in four black men will develop prostate cancer in their lifetime, compared to a risk of one in eight among other men.

Using culturally appropriate print and film resources developed as part of the project, Orchid reached out to the black community in seven London boroughs to increase awareness and understanding of prostate cancer. We also encouraged black men to discuss their prostate cancer risk with healthcare professionals, as well as empowering them with the necessary information to seek help for any potential signs and symptoms as soon as possible. Treatment is more likely to be successful if a cancer is diagnosed at an early stage.

The project also provided support opportunities for black

men living with and beyond a diagnosis of prostate cancer to increase their confidence about engaging with treatment and aftercare, and to reduce the isolation many men may feel through the provision of peer support opportunities. In addition, the project team offered specialist training and support to healthcare professionals to increase their confidence and competence to discuss prostate cancer with black men at risk and post-diagnosis and to provide appropriate support.

Throughout the project, our team carried out outreach activities working with community groups, faith groups, barber shops and in other targeted locations. Over the three years of the project, more than 1,600 culturally appropriate posters, 42,000 prostate cancer z-cards and 26,000 Helpline cards were distributed in the target boroughs.

Independent evaluation shows the success of the project. Through the 'Changing Lives' project Orchid engaged with over 8,000 black men at risk of prostate cancer, over 200 black men who were living with prostate cancer, and over 400 healthcare professionals.

Orchid is keen to share the project learnings, and the full evaluation report showing the outcomes is available to download via the Orchid website.



**‘To me, the leaflet
was saying, don’t
leave it too late!
I had no idea
about the signs.
I showed it to
my friends and
they didn’t
know either’**

Our impact: Testicular cancer

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35

Testicular cancer is rare with around 2,300-2,400 men being diagnosed each year in the UK. Around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of men diagnosed between the ages of 15-45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life. Treatment occurs quickly with men often being diagnosed and treated within a few weeks. As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects chemotherapy can increase the risk of cardiovascular disease in later life.

Challenges around testicular cancer involve supporting men in adjustment to life following treatment. Many men will only realise the full implication of their cancer journey when treatment ends and may not be able to access

either peer support or psychological support. Orchid has consistently supported the biggest testicular cancer support group in the UK, which is co-ordinated by the specialist nurse team at St Bartholomew's in London, both physically and virtually. In addition, the creation of Orchid's telephone counselling service will allow men to access psychological support without the necessity of waiting for extended periods of time. Orchid also continues to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the UK.



‘Your Privates’ microsite: a one stop shop for information about testicular cancer

Since the launch of Orchid’s ‘Your Privates’ microsite in 2013, men and their loved ones have regularly accessed this unique resource to find out about the signs and symptoms of testicular cancer, its diagnosis, what life is like after testicular cancer, and where they can seek support if they need it. People have also used the site to contact an Orchid Nurse to get answers to their testicular health questions and concerns.

During the year 2,900 people accessed the ‘Your Privates’ site, an increase of 2.5% on the previous year. The videos embedded in the site were particularly popular with over 33,000 views of the video showing how to carry out testicular self-examination, and 15,000 views of ‘what’s not testicular cancer’ which we know can help allay men’s fears. Feedback about these videos includes: “Best calm explanation video” and “Thanks for this! The last thing saved me! I had this cyst on the

top of my balls that was exactly how you explained it, and I was so scared it was testicular cancer (I’m 14) thanks for clarifying!”

With an early diagnosis for testicular cancer being so important, Orchid also knows we must reach out to those at risk. We particularly want to increase young people’s understanding of testicular cancer and their confidence in seeking help and support if they need it. We continued work on resources to be used in schools through the development of a teachers’ lesson plan, activities, and a summary video to be delivered during personal, social, health and economic education (PSHE) lessons. The resources outline possible risk factors, signs and symptoms, and highlight the importance of self-examination, and are now an important part of the microsite. We are delighted to report that the lesson plan has recently been both accredited and promoted by the PSHE Association.



**‘You’ve saved me!
I had this cyst on
the top of my balls
that was exactly as
you explained it,
and I had been so
scared it was
testicular cancer
(I’m 14). Thanks for
clarifying!’**

Our impact: Penile cancer

Most men will never meet another man affected by penile cancer due to its rarity therefore missing out on invaluable peer support

Penile cancer is exceptionally rare in the UK with around 670 men being diagnosed each year. Around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.

Out of all the male specific cancers penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexuality.

Due to its intimate nature around 15-50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics. Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease - many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its rarity therefore missing out on invaluable peer support.

In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral. Orchid has therefore focused on the development of a telephone counselling service to support men and wherever possible has created events to offer peer support, as well as supporting and encouraging allied healthcare professionals in the creation of regional support groups.



Putting penile cancer on the agenda in Scotland

With 83 cases a year, there is a higher incidence of penile cancer in Scotland in comparison to the rest of the UK, and those affected by penile cancer in Scotland are also being diagnosed at a younger age. A penile cancer diagnosis can be psychologically devastating, and treatment can be challenging especially if the diagnosis has been made at a late stage.

Orchid has significant experience of educating people about the signs and symptoms of penile cancer, as well as understanding the complex issues involved in supporting penile cancer patients. Whilst we do not as yet know why Scotland has a higher incidence proportionally than the rest of the UK, we do know that many people have not heard of penile cancer, let alone know what potential symptoms might be. Orchid therefore identified the need to develop a project to put penile cancer on the agenda in Scotland.

With the support of two retired Nurses, delivery of the Penile Cancer Support Service began with a series of Penile Cancer Information Roadshows run in non-medical settings in targeted locations across the country, using Scotland specific resources developed for the project. Our team engaged local people in penile cancer conversations, and the

retired Nurses also gave talks to healthcare professionals and patient groups.

We were delighted to recruit to the post of Penile Cancer Information Manager – Scotland in December 2019. Based in Glasgow and sharing Orchid's literature and knowledge, they have been leading and developing the project to raise awareness of signs and symptoms amongst the Scottish population, and to encourage those with concerns to seek immediate help.

They have also been providing support to those living with a diagnosis, working with the Orchid Male Cancer Nurse and referring patients to the Orchid National Male Cancer Helpline for specialist information when needed. Collaborative working and a flexible approach during the COVID-19 pandemic have been key to the success of the project, and the Information Manager has been working to introduce Orchid's specialist penile cancer materials and services to healthcare professionals across the country. Our Information Manager also sits on the Cross-Party Group on Cancer and had the opportunity to contribute to the development of Scotland's Cancer Recovery Plan.

**Orchid's research
programme is
investing in the
wellbeing of
current and future
generations
of men**



Our impact: Research

Orchid's research programme is an investment in the wellbeing of current and future generations of men. If we understand the three male-specific cancers, how they work and how to treat them, we can offer a better and brighter outlook for our loved ones, their children and grandchildren.

The Orchid Research Tissue Bank

– *Professor Daniel Berney*

The Circulating Tumour Cell project

– *Professor Yong-Jie Lu*

Despite the impact of COVID-19, it was a productive year with important research findings and publications in leading international journals.


While the development of new drugs and therapies prolongs patients' survival period, advanced cancers are still rarely cured, yet cancers diagnosed at early stage are mostly curable. Detection of cancer at an early stage is still challenging for many cancer types, including prostate cancer. Currently cancer diagnosis is based on tissue biopsy.

Professor Lu's team have been investigating a blood test in prostate cancer detection for several years using a platform, Parsortix made by ANGLE plc, to efficiently detect cancer cells spread into the blood circulation. Their research shows the detection of cancer cells in the blood and their gene expression predict the prostate cancer tissue biopsy outcome with high accuracy, which not only distinguishes cancer from benign, but also indolent from aggressive

cancers. This has the potential to change the paradigm of prostate cancer diagnosis and guide the treatment of cancer patients by monitoring cancer aggressiveness and progression by a blood test. The team now want to perform a multiple centre validation study, a critical step to move this prostate cancer blood test into clinical use.

They have also started to investigate the potential of using other materials/products that cancer cells release into the blood circulation. They have detected in peripheral blood certain prostate cancer cell released molecules, which are used by cancer cells to communicate with other body cells for cancer growth and metastasis, and their appearance is associated with the development of hormone therapy resistance of prostate cancer. These cancer cell molecules may also have potential in prostate cancer early detection, which is in their future research plan.

Not all prostate cancers diagnosed at early stage are life threatening, so while the aim is to treat aggressive prostate cancer efficiently to cure the cancer, reducing side effects of treatment such as impotence and incontinence by avoiding unnecessary therapies for



Adapted from Xu et al. Clin Cancer Res. 2017; 23:5112-5122 (<https://clincancerres.aacrjournals.org/content/23/17/5112>)

non-significant prostate cancer is equally important. Currently, cancer pathology grade, clinical stage and blood PSA level have been used to decide who requires treatment and who can be safely 'observed' with routine follow up. Further molecular biomarkers are required to improve the treatment stratification, which is long-term research focus.

The research team have also been actively involved in the application of artificial intelligence in assisting pathological grade of prostate cancer. Artificial intelligence assisted pathological grading saves pathologist time in cancer diagnosis and reduces human errors/variation in cancer grading such as individual grading variation. Therefore, artificial intelligence assisted pathological grading has the potential to resolve the pathological diagnosis of cancers. As an international leading pathologist in urological cancers, Professor Berney has published papers in improving pathological diagnosis standards and promoting diagnostic communications.

The genetic changes in cancer cells determines cancer development, behaviour and the treatment responses. Therefore, the team has continued collaboration work with the international

consortiums in prostate cancer genetic risk and somatic genetic abnormality studies, which led to high profile publications in the top scientific journal Nature and its sister journals. These findings are landmarks for understanding of human cancer genetics alterations and will promote the development of new approaches in cancer diagnosis and treatment.

For testis cancer the team are researching the appropriate and refined targeting of chemotherapy, to make sure it is administered to those men who need it and sparing the toxic side effects for those who do not. It is hoped a suite of papers about testis cancers with pathological review jointly with the University of Denmark will become a mainstay of pathological information to guide treatment for both localised and advanced germ cell tumours.

For penile cancer, the team have reviewed the current stage of research and their understanding of the molecular pathogenesis of penile carcinoma.

A full list of publications for the period is available on request.

Above: Circulating tumour cells (CTCs) detected in the blood of prostate cancer patients. In panel A, CTCs were visualised using a cell painting method called immunofluorescence staining, which stains specific proteins in cells. The proteins specific to cancer cells are VIM (yellow) and CK (green), while the protein CD45 (red) is specific to blood cells. Cell nuclei were stained using a dye called DAPI. Photos of each colour can be taken separately as well as all together (merged). In this image three types of CTCs (arrowed) can be seen, 1. painted green (top row arrowed); 2. both green and yellow (middle row) and 3. yellow (bottom row), while blood cells were painted red. In panel B, on the same CTC the scientists detected the genetic changes using a method called fluorescence in-situ hybridisation (FISH), proving that the cell is cancerous.

The year ahead

The reporting year ended with Male Cancer Awareness Week where we reached 334,027 people via our digital ‘Check.Check.Check.’ campaign, complemented by the taking of COVID-19 safe male cancer information packs to 10,000 households in targeted areas.

Raising awareness of male cancer risk factors, signs and symptoms remained a priority as we entered the new financial year. Still unable to work face to face in the community and deliver Male Cancer Information Roadshows, talks and presentations, we are developing an alternative programme of increased social media activity to reach men in targeted locations, as well as offering virtual male cancer talks. We will continue to review our activities and use the learnings from COVID-19 to inform the development of plans to return to working in the community when it is safe to do so. In addition, we are increasing the promotion of our Nurse-led services via GP practices and e-bulletins to healthcare professionals.

We will also be developing and expanding our Health at Work programme, working with Wellbeing Teams within businesses to empower employees with the information they need to know about male cancer and when and where to seek help if needed.

The evaluation of our ‘Changing Lives’ project highlighted the need for more work in the heart of communities to help overcome the barriers to engaging with prostate cancer, and we will work to secure funding to do this.

We will seek accreditation from PSHE Association for our new testicular cancer lesson plan for use in schools. This

outlines possible risk factors, signs and symptoms, and highlights the importance of self-examination, and we are planning to work further with the PSHE Association to promote this new resource. We will continue to review all our male cancer materials, and to develop new materials as necessary.

With access to GPs difficult in many areas, yet an ongoing need for men to discuss potential male cancer symptoms, we plan to develop a check card to help men prepare for appointments. This resource will enable men to give a clear and concise account of what they are experiencing and will support men to feel comfortable when sharing intimate details which will make their first appointment more effective.

Funded with a grant from Janssen we will be launching a new film ‘Living with prostate cancer’ in the year ahead to encourage men and loved ones to talk about the impact of this cancer. We will also be developing a film on living with advanced prostate cancer. The project will offer those living with advanced prostate cancer practical solutions to improve their quality of life.

Supporting men living with male cancer (and their loved ones) will remain a priority for Orchid in the coming year. The hours of the National Male Cancer Helpline were increased due to the COVID-19 pandemic, and we are planning to pilot an out-of-hours service with the aim of being there for more men who need us.

The embarrassment men with male cancers may feel about using public toilets can be a barrier to leaving home, and to help overcome this we are exploring the possibility of providing radar keys for men with penile cancer in Scotland as

part of the Penile Cancer Support Service. Having a radar key would enable men to access the privacy of locked disabled toilets. We will explore the offer of radar keys more widely.

The peer support opportunities which we facilitate will continue to be delivered virtually or online as appropriate. We will be launching a unique telephone counselling service for men affected by testicular and penile cancer. This will allow up to 30 men, over twelve months, access to a professional counsellor who can offer up to six free counselling sessions. The telephone service can be utilised by men anywhere within the UK and is being co-ordinated with the guidance of Dr Peter Branney, senior psychologist at the University of Bradford. It will be evaluated, and the information obtained will be used to create a bespoke service for the future.

We evaluate all our activities to measure success and impact, and we will carry out independent evaluation of the Penile Cancer Support Service in Scotland in the coming year.

We will continue to invest in world class male cancer research to benefit the well-being of current and future generations of men. The focus of our research in the year ahead will be the Orchid Research Tissue Bank incorporating the Circulating Tumour Cell project. This project is led by Professors Dan Berney and Yong-Jie Lu.

Collection and validation of tissue from male cancers from high quality clinical trials and cohorts will advance our understanding of male cancers, creating better prognostic and predictive targets for treatment and diagnosis, and the project will also increase understanding of the molecular

mechanisms of prostate cancer development, progression and response to therapies and develop biomarkers for the diagnosis, prognosis and treatment response prediction of prostate cancer as well as testicular and penile cancers.

Securing funding for our plans is a priority. As a small charity we were able to adapt to the COVID-19 environment and develop a flexible approach to delivering services to meet the needs of men. We were also able to adapt our fundraising to the changing landscape. Having reviewed our income streams and stabilised, our fundraising strategy now focusses on developing and re-growing our income. We will continue to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and the individuals and community groups who support us with donations and fundraise on our behalf. Alongside that, our fundraising plans also include exploring new opportunities and developing areas where we will secure the best return on investment.

Orchid is grateful to everyone who has supported us in the last year, and those who will support us in the coming year. Our work would not be possible without you.

**Our Health at Work
programme will
empower employees
so they know when
and where to to
seek help**

Governance

Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK

Objects, operating context and activities

Objects

Over 50,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly these numbers are increasing. Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair's aim to maintain a balanced composition. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from office in rotation, in order of longevity of appointment and are eligible to be reappointed. During the Coronavirus pandemic Trustees met virtually.

Trustee training and induction

On appointment, Trustees receive a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Structure, delegation and decision-making

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance Committee is responsible for the financial oversight of the Charity including budgeting, financial planning and monitoring as well as financial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at 30 September 2020, it comprised the Honorary Treasurer, Mr W Cohen, Mr C Osborne, Mr S Seymour and Mr S Harris.
- To improve efficiency, Sub-Committees have been reviewed, and the Fundraising Sub-Committee meets as required.
- At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept apprised of personnel, awareness, research programme and budgetary issues.

Public benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit including (PB2 Public Benefit: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation's strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the verification of outcomes, the Scientific Advisory Board (SAB) provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals.

Following Charity Commission recommendations the risk register identifies risks under the following headings:

Governance and compliance

Operational

Financial

Environmental/external

Research

Quality assurance

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified. These are shown in the table on the next page.

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to.

Mitigation

- An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and financial, are covered by suitably qualified professionals
- Training and support for Board of Trustees and Finance Committee
- Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
- Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

- Annual salary review to include benchmarking of compensation and benefits
- Staff development, training and succession planning programmes
- Communication programme to ensure staff are involved in the development of and progress towards Orchid's strategy and annual workplan

Financial

Economic pressures, impact of COVID-19, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

Mitigation

- Annual budgeting and ongoing management, reporting and monitoring of financial performance
- Diversification of income streams
- Ongoing consideration of market and consumer trends and regulations including GDPR

Environmental/external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid's work

Mitigation

- Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
- Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
- Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid's strategy

Research

Orchid's Research Programme fails to deliver results

Mitigation

- Scrutiny and approval of research funding applications by an expert committee, Orchid Scientific Advisory Board
- Annual review of progress

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

- Services developed, delivered and evaluated in line with agreed protocol and standards
- Nurse Specialists are members of the Royal College of Nursing (RCN)
- All information materials and content regularly reviewed and updated
- High-quality training for staff

Financial review

Results for the year

Income for the year ended 30 September 2020 totalled £401,181 (2019: £846,169). After total expenditure of £756,577 (2019: £918,939), the year's activities show a net deficit of £355,396 (2019: deficit of £72,770). Total reserves at the end of the year amounted to £583,006 (2019: £938,402).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £53,281 towards future research grant awards. In addition £121,808 has been designated to help fund the costs of increased organisational capacity with the Charity and a further £83,658 designated to help fund specific awareness activities.

Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity's core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available free reserves net of tangible fixed assets are £139,396 (2019: £334,804). It is the Charity's policy to maintain free reserves of approximately 3-4 months of operating costs. At current levels of expenditure this equates to £152,000-£203,000.

Formal statements

Statement of Trustees' responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Auditor's information

So far as each of the directors at the time the Trustees' report is approved is aware:

- a) there is no relevant information of which the auditors are unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The auditor, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed auditor for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees



C S Osborne
Chairman of Trustees
15 June 2021

Independent Auditor's Report to the Members of Orchid Cancer Appeal

Opinion

We have audited the financial statements of Orchid Cancer Appeal ('the company') for the year ended 30 September 2020 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 30 September 2020 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or

- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit, or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Strategic Report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 19, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion.

Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of this report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Moore Kingston Smith LLP.

James Saunders FCCA DChA

for and on behalf of Moore Kingston Smith LLP,
Statutory Auditor

Devonshire House
60 Goswell Road
London
EC1M 7AD

16 June 2021

Statement of financial activities

(incorporating an income and expenditure account)

For the year ended 30 September 2020

	Note	Unrestricted Total £	Restricted Total £	Year ended 30 September 2020 £	Year ended 30 September 2019 £
Income from:					
Donations and Legacies	2	241,513	109,315	350,828	650,135
Charitable Activities	4	-	47,571	47,571	185,526
Trading Activities		534	-	534	527
Investments		2,248	-	2,248	9,981
Total income		<u>244,295</u>	<u>156,886</u>	<u>401,181</u>	<u>846,169</u>
Expenditure on:					
Raising funds					
Fundraising (donations and grants)	5	187,210	-	187,210	247,885
Charitable Activities					
Education and Awareness	5	240,237	186,234	426,471	594,359
Research	5	129,146	13,750	142,896	76,695
Total expenditure		<u>556,593</u>	<u>199,984</u>	<u>756,577</u>	<u>918,939</u>
Net income / (expenditure) and net movement in funds	5,6	(312,298)	(43,098)	(355,396)	(72,770)
Reconciliation of funds					
Total funds brought forward adjusted		<u>706,427</u>	<u>231,975</u>	<u>938,402</u>	<u>870,730</u>
Prior Year Adjustment		-	-	-	140,442
Total funds brought forward as restated		<u>706,427</u>	<u>231,975</u>	<u>938,402</u>	<u>1,011,172</u>
Total funds carried forward		<u><u>394,129</u></u>	<u><u>188,877</u></u>	<u><u>583,006</u></u>	<u><u>938,402</u></u>

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 13 to the financial statements.

Balance sheet

As at 30 September 2020

	Note	£	30 September 2020 £	£	30 September 2019 £
Fixed Assets					
Tangible Assets	10		<u>366</u>		<u>-</u>
Current Assets					
Cash at bank and in hand		727,441		84,979	
Investments – cash deposits		-		973,744	
Debtors	11	136,586		187,046	
			<u>864,027</u>	<u>1,245,769</u>	
CREDITORS					
Amounts due within one year	12	(281,387)		(307,367)	
Net Current Assets			<u>582,640</u>		<u>938,402</u>
Total Assets less Current Liabilities	13		<u>583,006</u>		<u>938,402</u>
NET ASSETS			<u>583,006</u>		<u>938,402</u>
Represented by:	14				
General Unrestricted Funds		135,382		334,804	
Designated Funds		258,747		371,623	
			394,129		706,427
Restricted funds			<u>188,877</u>		<u>231,975</u>
			<u>583,006</u>		<u>938,402</u>

The company is limited by guarantee.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 15 June 2021 and signed on its behalf by:



Mr C S Osborne

Company number 3963360

Statement of cash flows

For the year ended 30 September 2020

	2020		2019
	£	£	£
Cash flows from operating activities:			
Net expenditure for the year	(355,396)		(72,770)
Adjustments for:			
Depreciation charges	729		-
Interest	(2,248)		(9,981)
Decrease/(increase) in debtors	50,460		(57,457)
(Decrease) in creditors	(25,980)		(75,553)
Net cash provided by operating activities		(332,435)	(215,761)
Cash flows from investing activities:			
Interest	2,248		9,981
Disposal of fixed assets	(1,091)		-
Disposals of investments	912,297		143,440
Net cash used in investing activities		913,454	153,421
Change in cash and cash equivalents in the year		581,019	(62,340)
Cash and cash equivalents at the beginning of the year		146,422	208,762
Cash and cash equivalents at the end of the year		727,441	146,422
Analysis of cash and cash equivalents			
Cash at bank and in hand		727,441	84,979
Notice deposits of less than 3 months		-	61,443
		727,441	146,422

Notes to the financial statements

1. Accounting policies

Basis of Preparation

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements and have considered the impact of the coronavirus pandemic on the charity's operations. In particular the trustees have considered the charity's forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2020/21; however, there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

The charity has secured a 3-year project funded by The National Lottery Community Fund: Overcoming the Barrier to Engaging with Prostate Cancer. The aim is to work in targeted locations across England and focus on supporting individuals from identified communities to overcome barriers to engaging with prostate cancer. This will enable Orchid to continue its valued work. Many fundraising events have been postponed from 2020 and as a result Orchid has an all-time high number of runners signed up for events in the Summer of 2021. Whilst there is still some risk around fundraising events being held in the Summer, Orchid is hopeful that the relaxation of COVID-19 restrictions will enable these events to take place. The National Lottery project along with continued support from loyal donors will enable Orchid to continue to as a going concern.

The trustees confirm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its financial statements.

Functional currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the Charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised. Computer and Office Equipment - 33 1/3% on written down value.

Funds accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal. The purpose and use of the Charity's restricted funds is set out in the notes to the financial statements.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/ distributed. The values attributable to gifts in kind are an

estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity's objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity's objects.

Governance costs are those incurred in connection with the management of the Charity's assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee's services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

Notes to the financial statements

2. Donations**Current year**

			Year ended 30 September 2020 Total £	Year ended 30 September 2019 Total £
	Restricted £	Unrestricted £		
Individuals	16,200	69,301	85,501	56,468
Legacies	-	17,000	17,000	-
Corporates	5,000	17,434	22,434	120,076
Trusts and Foundations	88,115	11,250	99,365	161,065
Fundraising Events	-	114,545	114,545	312,526
Total	109,315	229,530	338,845	650,135

Prior year

			Year ended 30 September 2019 Total £
	Restricted £	Unrestricted £	
Individuals	-	56,468	56,468
Legacies	-	-	-
Corporates	29,000	91,076	120,076
Trusts and Foundations	151,515	9,550	161,065
Fundraising Events	-	312,526	312,526
Total	180,515	469,620	650,135

Notes to the financial statements

3. Fundraising events

Current year

			Year ended 30 September 2020 Total £	Year ended 30 September 2019 Total £
	Restricted £	Unrestricted £		
Cycling events	-	3,249	3,249	9,478
Running events	-	39,017	39,017	117,694
Third party organised events	-	64,346	64,346	159,279
Trek	-	-	-	-
Other	-	7,933	7,933	26,075
Total	-	114,545	114,545	312,526

Prior year

			Year ended 30 September 2019 Total £
	Restricted £	Unrestricted £	
Cycling events	-	9,478	9,478
Running events	-	117,694	117,694
Third party organised events	-	159,279	159,279
Trek	-	-	-
Other	-	26,075	26,075
Total	-	312,526	312,526

Notes to the financial statements

4. Charitable activities**Current year**

			Year ended 30 September 2020 Total £	Year ended 30 September 2019 Total £
	Restricted £	Unrestricted £		
Grants - National Lottery Community Fund				
Covid 19 Emergency Funding	47,571	-	47,571	-
Big Lottery Reaching Communities Fund	-	-	-	132,526
North East London Cancer Network	-	-	-	50,000
Other	-	-	-	3,000
Total	47,571	-	47,571	185,526

Prior year

			Year ended 30 September 2019 Total £
	Restricted £	Unrestricted £	
Grants - Big Lottery Reaching Communities Fund	132,526	-	132,526
North East London Cancer Network	50,000	-	50,000
Other	3,000	-	3,000
Total	185,526	-	185,526

Notes to the financial statements

5. Total expenditure

				Year ended 30 September 2020	Year ended 30 September 2019
	Cost of raising funds	Education and awareness	Research	Total	Total
	£	£	£	£	£
Grants	-	-	112,876	112,876	41,454
Staff costs	118,013	199,116	22,014	339,143	373,753
Fundraising expenses	26,277	-	-	26,277	107,362
Information materials	-	72,185	-	72,185	131,634
Direct costs	-	79,807	-	79,807	93,154
	<u>144,290</u>	<u>351,108</u>	<u>134,890</u>	<u>630,288</u>	<u>747,357</u>
<i>Support costs</i>					
Depreciation	247	436	46	729	-
Other	35,735	62,932	6,666	105,333	151,090
Governance - staff costs	3,033	5,118	566	8,717	11,060
Governance - audit fees	3,905	6,877	728	11,510	9,432
	<u>42,920</u>	<u>75,363</u>	<u>8,006</u>	<u>126,289</u>	<u>171,582</u>
Total expenditure	<u>187,210</u>	<u>426,471</u>	<u>142,896</u>	<u>756,578</u>	<u>918,939</u>
Prior year	<u>247,885</u>	<u>594,359</u>	<u>76,695</u>	<u>918,939</u>	

Notes to the financial statements

6. Grants awarded

	Year ended 30 September 2020 £	Year ended 30 September 2019 £
Grant commitments brought forward	199,002	249,616
Institutional grants for medical research awarded during year:		
Orchid Study and Travel awards (2019: 1 individual)	-	970
Barts and London School of Medicine	112,876	83,843
Write off	-	(43,360)
Payments made during period/year	(106,463)	(92,067)
Grant commitments carried forward	<u>205,415</u>	<u>199,002</u>
Payable less than one year	205,415	199,002
Payable two to five years	<u>-</u>	<u>-</u>

Notes to the financial statements

7. Net expenditure for the year**This is stated after charging:**

	Year ended 30 September 2020 £	Year ended 30 September 2019 £
Depreciation	729	-
Auditor's remuneration:		
Audit	9,592	9,432
Prior year under accrual		
Trustees' remuneration	Nil	Nil
Trustees' expenses	<u>Nil</u>	<u>Nil</u>

Notes to the financial statements

8. Staff costs and numbers

Staff cost were as follows:

	Year ended 30 September 2020 £	Year ended 30 September 2019 £
Salaries and wages	241,235	222,273
Social security costs	20,787	21,968
Pension contributions	2,442	2,174
	<u>264,464</u>	<u>246,415</u>
Consultants' costs	83,397	138,398
	<u>347,861</u>	<u>384,813</u>

During the year ended 30 September 2020 no employee earned more than £60,000; one employee earned £80,000-£89,999. The pension contribution paid in respect of this employee totalled £Nil (2019: £2,014)

The key management personnel of the Charity comprise the Trustees and the Chief Executive.

The charity trustees do not receive remuneration. The total remuneration of the chief executive was £80,177 (year ended 30 September 2019: £92,476). This includes amounts payable to a staff member covering the position in the absence of a permanent Chief Executive.

The average number of employees during the year was 5.8 (2019: 4.6)

The average number of employees during the year on a headcount basis was as follows:

	FTE 2020 No.	FTE 2019 No.
Fundraising	1.3	0.8
Education and awareness	4.2	3.5
Grant support	0.3	0.3
	<u>5.8</u>	<u>4.6</u>

Notes to the financial statements

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

Notes to the financial statements

10. Tangible fixed assets

	Computer and office equipment Total £	30 September 2020 Total £	30 September 2019 Total £
Cost			
At the start of the period	2,674	2,674	25,678
Additions	2,187	2,187	-
Disposals	(1,637)	(1,637)	(23,003)
At the end of the period	<u>3,224</u>	<u>3,224</u>	<u>2,674</u>
Depreciation			
At the start of the period	2,674	2,674	25,678
Charge for the period	729	729	-
Disposals	(545)	(545)	(23,003)
At the end of the period	<u>2,858</u>	<u>2,858</u>	<u>2,674</u>
Net book value			
At the end of the period	<u>366</u>	<u>366</u>	<u>-</u>
At the start of the period	<u>-</u>	<u>-</u>	<u>-</u>

Notes to the financial statements

11. Debtors

	Year ended 30 September 2020 £	Year ended 30 September 2019 £
Prepayments	83,777	35,060
Other debtors and accrued income	52,809	151,986
	<u>136,586</u>	<u>187,046</u>

Notes to the financial statements

12. Creditors: amounts due within one year

	Year ended 30 September 2020 £	Year ended 30 September 2019 £
Grants payable	205,415	199,002
Trade and other creditors	34,691	61,885
Taxation and Social Security	5,530	6,311
Accruals	35,754	40,169
	<u>281,390</u>	<u>307,367</u>

Notes to the financial statements

13. Movements in funds

Current year	Brought forward	Income	Expenditure	Carried forward
	£	£	£	£
Unrestricted				
General	334,804	244,295	(443,717)	135,382
Designated – Research	166,157	-	(112,876)	53,281
Designated – Development	121,808	-	-	121,808
Designated – Awareness	83,658	-	-	83,658
Total unrestricted	706,427	244,295	(556,593)	394,129
Restricted				
Testicular Cancer Counselling	16,247	-	(16,247)	-
Big Lottery Reaching Communities Fund	51,469	-	(51,469)	-
Male Cancer Nurse Information Specialist	76,706	-	(19,732)	52,870
The Innovation Research Project		16,200	-	16,200
Penile Cancer Peer Support	4,492	5,000	(4,492)	5,000
Education and Awareness	-	33,250	(22,000)	11,250
Student Study and Travel Scholarships	6,729	-	-	6,729
Roadshows	30,926	33,415	(26,814)	37,527
Tissue Bank	-	13,750	(13,750)	-
Young Person's Testicular Cancer Project	10,369	-	-	10,369
National Lottery Community Fund – Covid 19 Emergency	-	47,571	(10,243)	37,328
City of London Corporation	-	7,500	-	7,500
Services	-	200	(200)	-
North East London Cancer Network	35,037	-	(35,037)	-
Total restricted	231,975	156,886	(199,984)	188,877
Total funds	938,402	401,181	(756,577)	583,006

Notes to the financial statements

13. Movements in funds (continued)

Prior year	Brought forward	Income	Expenditure	Carried forward
	£	£	£	£
Unrestricted				
General	303,777	480,128	(449,101)	334,804
Designated – Research	250,000	-	(83,843)	166,157
Designated – Development	121,808	-	-	121,808
Designated – Awareness	83,658	-	-	83,658
Total unrestricted	759,243	480,128	(532,944)	706,427
Restricted				
Testicular Cancer Awareness	-	-	-	-
Testicular Cancer Counselling	19,226	-	(2,979)	16,247
Big Lottery Reaching Communities Fund	69,664	135,526	(153,721)	51,469
Male Cancer Nurse Information Specialist Awareness	88,499	3,000	(14,793)	76,706
	242	19,750	(19,992)	
Penile Cancer Peer Support	9,960	5,000	(10,468)	4,492
Prostate Cancer Nurse	10,000	-	(10,000)	-
Student Study and Travel Scholarships	7,700	-	(971)	6,729
Roadshows	25,057	81,815	(75,946)	30,926
Tissue Bank	-	38,950	(38,950)	-
Young Person's Testicular Cancer Project	12,381	-	(2,012)	10,369
Prostate Cancer Awareness	9,200	29,000	(38,200)	-
Services	-	3,000	(3,000)	-
North East London Cancer Network	-	50,000	(14,963)	35,037
Total restricted	251,929	366,041	(385,995)	231,975
Total funds	1,011,172	846,169	(918,939)	938,402

General funds are unrestricted funds available for use at the Trustees' discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Research funds represent monies set aside at the Trustees' discretion to be used to help fund the costs of future research programmes.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

Notes to the financial statements

14. Analysis of net assets between funds

Current year	Unrestricted funds £	Restricted funds £	Total funds at 30 September 2020 £
Fixed assets	367		367
Current assets	952,583	250,590	1,203,173
Creditors due within one year	(281,390)		(281,390)
Net assets at 30 September 2020	671,560	250,590	922,150

Prior year analysis of net assets between funds	Unrestricted funds £	Restricted funds £	Total funds at 30 September 2020 £
Fixed assets	-		-
Current assets	1,013,794	231,975	1,245,769
Creditors due within one year	(307,367)		(307,367)
Net assets at 30 September 2019	706,427	231,975	938,402

Notes to the financial statements

15. Related party transactions

There were no related party transactions during the year (Year to 30 September 2019: none)

Notes to the financial statements

16. Financial commitments

For the year ended 30 September 2020, the charity was committed to making the following future payments under non cancellable operating leases:

	Year ended 30 September 2020 £	Year ended 30 September 2019 £
<i>Land and buildings</i>	-	-
Expiring within one year	14,184	18,300
	14,184	18,300

ORCHID
FIGHTING MALE CANCER

